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Abstract 
Angie Cooper 
Long-chain fatty acids and endoplasmic reticulum stress in pancreatic 
beta-cells: the role of Protein Kinase R (PKR) 
 
 
Type 2 diabetes (T2D) is a growing health-care and economic burden.  Obesity 
is a risk factor for developing T2D, but the underlying molecular mechanisms are 
not well understood.  However, mechanisms such as lipotoxicity, endoplasmic 
reticulum stress and inflammation are becoming increasingly well-recognised in 
obesity, and may underlie the development and progression of T2D.  A central 
player in these mechanisms is Protein Kinase R (PKR), proposed to have a role 
within nutrient- and pathogen-sensing pathways, and is activated by ER stress 
and lipotoxicity.   
 
A small molecule inhibitor Compound-16, adenoviral vectors and RNAi 
techniques in BRIN-BD11 rodent pancreatic β-cells, were used to demonstrate 
that PKR knockdown affords significant protection against palmitate-induced cell 
death.  Furthermore, PKR knockdown potentiates palmitoleate cytoprotection 
during lipotoxicity, suggesting the cytotoxic and cytoprotective actions of long-
chain fatty acid species may function via the PKR signalling pathway.   
 
The use of a novel 1.1B4 human pancreatic β-cell line has shown that important 
differences exist between human and rodent cell responses to fatty acids in vitro.  
In 1.1B4 cells, long-chain saturated and monounsaturated fatty acids do not 
provide increasing protection as their chain-length increases, in contrast to rodent 
cell models.  Furthermore, methyl-saturated fatty acid species are well tolerated, 
and methyl-monounsaturated fatty acids are cytoprotective to 1.1B4 β-cells.   
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TXNIP overexpression in an INS-TXNIP β-cell model has a proapoptotic role in 
conditions of glucotoxicity, but not glucolipotoxicity.  Furthermore, in this cell 
model, succinate is cytoprotective against glucotoxicity, but not glucolipotoxicity.  
By contrast in 1.1B4 β-cells, succinate significantly protects against apoptosis 
induced by both glucotoxic and glucolipotoxic conditions.   
 
Chronic inflammation has been implicated in the development and progression 
of T2D. At the centre of this response is the pro-inflammatory cytokine IL-1β.  The 
cellular origin of IL-1β is unclear, but IL-1β secretion has been linked to activation 
of the NLRP3 inflammasome, recently implicated in pancreatic β-cell death in 
T2D.  Results suggest that IL-1β is secreted by INS-TXNIP and 1.1B4 pancreatic 
β-cells under lipotoxic conditions, thus offering a potential role for targeted IL-1β 
therapy in T2D.   
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Structure of thesis 
The objective of this work was to investigate whether lipotoxicity-induced 
pancreatic β-cell death is mediated by activation of an ER stress response, 
centred on alterations to PKR activity.  The availability of a newly developed 
human pancreatic β-cell line 1.1B4 extended the main objective, to include 
investigations which characterised responses to FA species in this cell model.  
Additional studies considered the role of TXNIP as a proapoptotic factor during 
lipotoxic conditions in a TET-induced TXNIP overexpression INS-1 cell model.  A 
role for succinate as a cytoprotective agent in glucotoxic and glucolipotoxic 
conditions was also investigated in this cell model.  Mediators of inflammation 
and inflammasome activation, and the effect of endogenous pro-inflammatory 
cytokines in pancreatic β-cells were investigated during glucotoxic and 
glucolipotoxic conditions, in 1.1B4 cells and INS-TXNIP cells.  
 
Chapter 1  
This introduction chapter covers an overview of T2D within the scope of this study, 
including the link between obesity and T2D; mechanisms of lipotoxicity; FA 
effects on β-cell function; ER stress; and PKR as a mediator of apoptosis.  The 
introduction also considers the role of inflammation in obesity and T2D, 
specifically inflammasome activation and the involvement of IL-1β as an 
underlying apoptotic mediator in T2D.  To conclude, this section considers the 
historical limitations of human pancreatic β-cells for in vitro use, and introduces a 
new human pancreatic β-cell line 1.1B4.  
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Chapter 2  
This chapter details an overview of the general methods adopted throughout the 
study, the materials used and the protocols followed in each chapter. 
 
Chapter 3  
PKR has been identified as a potential mediator of pro-apoptotic responses in 
pancreatic β-cells exposed to lipotoxicity.  A small molecule inhibitor, DN 
adenoviral vectors and shRNA methods were used in this chapter to target PKR 
in rodent BRIN-BD11 pancreatic β-cells, to determine how altered kinase activity 
affected cell viability and markers of ER stress in response to FA species.  
 
Chapter 4  
The timely publication reporting a novel human pancreatic β-cell 1.1B4, allowed 
the opportunity to conduct functional studies to investigate the cytotoxic or 
cytoprotective effects of various FA species.  This chapter focussed on viability 
studies to investigate 1.1B4 in vitro responses to FAs, to consider the suitability 
of this cell model for the study of β-cell dysfunction during lipotoxicity.  
 
Chapter 5  
This chapter considered the role of TXNIP as a proapoptotic factor in conditions 
of glucotoxicity and glucolipotoxicity, using an INS-1 cell line with a TET-inducible 
stable-INS-1 TXNIP overexpression vector.  We investigated the cytoprotective 
role of succinate on TXNIP overexpression, and considered mediators of 
inflammasome activation in the INS-1 TXNIP cell line and human 1.1B4 cells 
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during lipotoxic and pro-inflammatory conditions.  This chapter also considered 
the effect of endogenous pro-inflammatory cytokines on 1.1B4 β-cell viability.   
 
Chapter 6 
This final section provides a brief overview of each chapter, the key findings in 
terms of novel results, limitations of the studies undertaken and areas for future 
work. 
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Chapter 1 Introduction 
1.1 Diabetes mellitus  
In 2011 the World Health Organisation (WHO) estimated that 346 million people 
worldwide had diabetes mellitus (DM).  Diabetes mellitus is defined as a 
metabolic disorder characterised by chronic hyperglycaemia.  There are now 
several recognised categories of DM, but the two main forms are known as type 
1 diabetes (T1D) and type 2 diabetes (T2D).  Both types of diabetes are a major 
cause of morbidity and mortality with the cost of treating these diseases and their 
associated complications representing an ever-escalating economic and health-
care burden (Ryan, 2009).   
 
Type 1 diabetes accounts for approximately 10% of all diagnosed DM cases, and 
is caused by an autoimmune-mediated mechanism of unknown pathoaetiology.  
This disease involves a process known as insulitis (Gepts, 1965): recent work 
investigating insulitis has more clearly defined the cellular profile of the 
inflammatory infiltrate of the islets of Langerhans (IoL) within the pancreas.  
These cells have been found to be predominantly cytotoxic T-cells and 
macrophages, although there are also a smaller number of other immune cells 
present.  Insulitis leads to pancreatic beta-cell (β-cell) destruction and complete 
loss of insulin secretion (Gepts, 1965; Willcox et al., 2009).  Type 1 diabetes 
typically develops in children and juveniles, and requires daily exogenous insulin 
therapy (Zhong et al., 2012).   
 
The majority of DM cases globally have T2D, and there has been an alarming 
rise in the number of diagnosed cases in recent decades.  This is suggested to 
be attributable to the increasing prevalence of obesity due to the widespread 
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adoption of Westernised diets high in saturated-fat, combined with a more 
sedentary lifestyle (Hu, 2011).  Being chronically overweight or obese can cause 
adverse metabolic effects such as increased circulating cholesterol and 
triglyceride (TG) levels.  These effects result in elevated plasma lipid 
concentrations which are suggested to underlie insulin deficiency (decreased 
insulin secretion by the β-cells), or a reduced physiological response to insulin 
secretion (insulin resistance), or indeed a combination of both mechanisms.  
These mechanisms collectively result in diminished utilisation of glucose within 
peripheral tissues, greatly increasing the risk of the development of DM (Cunha 
et al., 2008; Cnop et al., 2007; Leibowitz et al., 2011).   
 
Type 2 diabetes has historically been considered a ‘late-onset’ disease.  However, 
in the past couple of decades, there has been a clear reduction in the mean age 
of diagnosis (52.0 to 46.0 years, p=<0.05), and a tendency towards higher 
frequency of diagnosed cases among children and younger adults (Peterson et 
al., 2007; Koopman et al., 2005; Cree-Green et al., 2013).  Furthermore, racial or 
ethnic groups that had a higher risk of developing T2D compared to Caucasian 
populations, now no longer show an ethnic or race difference in risk (Koopman 
et al., 2005; Ford et al., 1997).   
 
1.2 The link between obesity and T2D 
Obesity occurs when there is a long-term excess of nutrient intake, to the extent 
that health and well-being are affected.  In particular, obesity is associated with 
increased risk of hypertension, hyperinsulinaemia, glucose intolerance, some 
common cancers and cardiovascular disease (Vernochet et al., 2009).  
Importantly, there is a clear link between chronic obesity and an increased risk of 
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developing T2D (Ford et al., 1997; Gwiazda et al., 2009).  Obesity is now 
considered the predominant metabolic ‘disease’ globally (Golay and Ybarra, 
2005).  A WHO consultation on obesity defined pre-obesity (overweight) as a 
body mass index (BMI) of ≥ 25, obesity (class 1) as a BMI ≥ 30, class 2 obesity 
as a BMI of ≥ 35 and class 3 obesity as a BMI ≥ 40 (Barlow and Dietz, 1998).  
Studies linking obesity and T2D collectively suggest that between 60 – 90% of 
patients with T2D have a BMI greater than 23.0 kg/m2 (Wannamethee and Shaper, 
1999; Golay and Ybarra, 2005; Haslam, 2010).  It has also been suggested that 
for every kilogramme of body weight gained, the risk of developing T2D increases 
between 4.5 - 9% (Ford et al., 1997).  This risk is further increased when there is 
an established family history of DM, gestational diabetes or weight gain 
particularly in childhood (Wannamethee and Shaper, 1999; Haslam, 2010).  
Recent change in lifestyle habit, particularly less exercise and increased intake 
of energy-dense foods, as seen more commonly in Westernised or rapidly-
developing third world countries, leads directly to increased adipose tissue 
deposition, which if persistent, may eventually cause metabolic dysfunction 
(Vernochet et al., 2009).   
 
A primary purpose of adipose tissue is to store energy in the form of TG within 
lipid droplets, which can be easily utilised by activation of lipolysis depending on 
the energy requirements of other tissues and organs.  Adipose tissue can secrete 
proteins, such as leptin and adiponectin that impact on energy homeostasis 
(Vernochet et al., 2009; Ravussin and Smith, 2002).  Dysregulation of these 
processes is suggested to trigger reduced insulin sensitivity (Despres and 
Lemieux, 2006).  Furthermore, large adipocytes within subcutaneous deposits 
are less insulin responsive than smaller adipocytes (Lafontan, 2012).  In addition, 
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it has been suggested that adipocytes present in larger adipose mass are subject 
to elevated stress, possibly as a result of mechanisms such as hypoxia, 
lipotoxicity and low-grade chronic inflammation (Gregor and Hotamisligil, 2007), 
therefore suggesting a mechanism between obesity and the progression of T2D.   
 
1.3 Lipotoxicity  
Obesity has been shown to create an altered plasma lipid profile, specifically 
elevated concentrations of plasma free fatty acids (FFAs).  Free fatty acids, such 
as palmitate or palmitoleate, are derived from TG and circulate in the plasma 
bound to albumin.  They are recognised to be the vehicle by which TG is 
transported from storage within adipose tissue, to target sites for utilisation (Karpe 
et al., 2011).  If an elevated FFA profile persists in a chronic state, it is thought to 
underlie the progression of insulin resistance and subsequent insulin deficiency, 
resulting in reduced glucose utilisation within peripheral tissues (Eizirik et al., 
2008; Cnop et al., 2005; Maedler, 2008).  Chronically elevated plasma FFAs 
concentrations are proposed to exert a deleterious effect on both β-cell function 
and survival via a mechanism termed ‘lipotoxicity’ (Newsholme et al., 2007; Wei 
et al., 2006).  Lipotoxicity as observed in vivo, is defined as an excess of fatty 
acids (FAs) in non-adipose tissue (such as the pancreas), over and above their 
metabolic requirement.  This has a detrimental effect on the cells resulting in 
metabolic dysregulation, rather than specific cellular insult such as radiation or 
infection (Schaffer, 2003; Bergman and Ader, 2000; Eitel et al., 2003; El-Assaad 
et al., 2003; Moffitt et al., 2005).  It is this process of metabolic dysregulation 
within the pancreas that is suggested to underlie the long-term reduction in β-cell 
mass seen in T2D (Butler et al., 2003).  Interestingly, several groups propose that 
lipotoxicity is unlikely to adversely affect β-cell viability unless chronic 
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hyperglycaemia is already established.  This suggests that β-cell loss may be 
induced by a combination of both chronic hyperglycaemia and lipotoxicity, via a 
mechanism perhaps more aptly termed ‘glucolipotoxicity’ (Fig. 1.1) (El-Assaad et 
al., 2003; Poitout and Robertson, 2008).   
 
1.3.1 Mechanisms of lipotoxicity 
Many mechanisms have been suggested to explain the underlying molecular 
pathway that drives lipotoxicity, however, to date this process is still to be fully 
elucidated.  What is clear is that there are differences between in vivo and in vitro 
responses to FA: for example, the acute reduction of FFAs in vivo leads to a drop 
in insulin response to glucose (Boden et al., 1998).  Conversely, in vitro studies 
have shown that the acute reduction of FFAs may result in exceptionally high 
levels of GSIS (Straub and Sharp, 2004).  Furthermore, the loss of β-cell viability 
occurs much more quickly in in vitro models than when compared to in vivo 
models (Diakogiannaki et al., 2007; Dhayal et al., 2008).  Nonetheless, the varied 
responses observed in β-cells during chronic exposure to saturated fatty acids 
(SFAs) and monounsaturated fatty acids (MUFAs), suggest that different FA 
species may exert their effects via different mechanisms (Welters et al., 2004; 
Eitel et al., 2003; Dhayal et al., 2008; Diakogiannaki et al., 2007; Diakogiannaki 
et al., 2008; Morgan et al., 2008).  There have been several hypotheses proposed 
to explain why this may be the case which are outlined below.   
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Fig. 1.1 Suggested model for the development of T2D  
A sedentary lifestyle and being obese can lead to insulin resistance resulting in 
the increased production of glucose in the liver, decreased glucose utilisation in 
peripheral tissues and increased lipolysis and TG deposition in adipose tissue. 
Pancreatic β-cells initially secrete more insulin to compensate for insulin 
resistance and maintain normoglycaemia, however, eventually β-cells will be 
unable to continue with this compensatory mechanism and glucose intolerance 
occurs. Hyperglycaemia and increased lipolysis drive lipotoxicity and 
glucolipotoxicity in β-cells, causing decreased β-cell mass and eventual 
progression to overt T2D (schematic adapted from Yang and Trevillyan, 2008).  
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1.3.2 Mechanisms of lipotoxicity: ceramide formation 
Palmitate, as one of the predominant FFA species present in human serum, is 
readily accessible to pancreatic β-cells in vivo.  Furthermore, palmitate has been 
identified as one of the main precursors required for de novo ceramide synthesis 
(Orrenius, 2004).  It has been suggested that the abundant availability of 
palmitate as a preferentially-metabolised SFA species may drive increased 
ceramide production (Wei et al., 2006; Kelpe et al., 2003; Maedler et al., 2001).  
Ceramide has an important role as a second signalling molecule, but is also 
known to be a potent apoptotic mediator in response to diverse stress stimuli, 
such as nutrient overload or withdrawal (Ruvolo et al., 2001).  Therefore, 
increased ceramide formation is suggested to initiate apoptosis in pancreatic β-
cells subjected to nutrient overload as seen in obesity.  Shimabukuro and 
colleagues (1998) proposed that in part, an increased rate of de novo ceramide 
synthesis was responsible for SFA-induced pancreatic β-cell death seen in fa/fa 
Zucker Diabetic fatty (ZDF) rats.   
 
However, other groups have countered this hypothesis, and shown that in a liver 
cell model, SFAs significantly increased cell death; however, this was observed 
independently of ceramide production (Wei et al., 2006).  Furthermore, Hardy and 
colleagues (2003), from their studies in a breast cancer cell line, argued that de 
novo ceramide synthesis was not the mechanism by which palmitate induced β-
cell apoptosis.  Their use of a specific ceramide-synthesis inhibitor, fumonisin B1, 
prevented palmitate-induced ceramide synthesis in these cells, but did not 
prevent apoptosis.  This inhibitory effect using fumonisin B1 has also been 
observed in rat and human islets (Maedler et al., 2001; Shimbukuro et al., 1998).  
In other studies, fumonisin B1 did not prevent palmitate-induced caspase-3 
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activity or palmitate-induced cell death.  This suggests that the formation or 
increased production of ceramide, cannot be the sole mechanism responsible for 
cytotoxic effects seen during palmitate exposure (Beeharry et al., 2004; Hardy et 
al., 2003; Welters et al., 2004).  The exact mechanism whereby changes in 
ceramide levels may trigger cell death are still unclear and require further 
investigation (Newsholme et al., 2007).   
 
1.3.3 Mechanisms of lipotoxicity: TG formation 
Free fatty acids are transported into cells by membrane-associated fatty-acid 
binding proteins, such as CD36 (Schwenk et al., 2010).  Once inside the 
cytoplasm, FFAs are activated by acyl-CoA synthetase to form acyl-CoA; this can 
then be transported into the mitochondria or peroxisomes by carnitine acyl 
transferase for β-oxidation to release ATP.  Alternatively, it may be stored as TG 
in lipid droplets.  Importantly, the metabolism of long-chain acyl-CoA (LC-CoA) 
from SFA is less efficient than from MUFA, suggested to lead to an accumulation 
of ceramide, and diacylglycerols (DAGs) (another second messenger molecule), 
(Shimabukuro et al., 1998; Nolan and Larter, 2009; Schaffer, 2003).  Some 
groups have shown that blocking β-oxidation using the FA oxidative inhibitor 
etomoxir, (which specifically blocks carnitine palmitoyltranferase-1, a 
mitochondrial enzyme that mediates the transport of LC-FAs across the 
membrane), markedly enhanced palmitate-induced cytotoxicity in rodent β-cells 
and human islets (El-Assaad et al., 2003; Hardy et al., 2003; Cnop et al., 2001).  
However, results using this inhibitor to block β-oxidation are conflicting as 
heightened palmitate-induced cytotoxicity is not universally observed (Busch et 
al., 2005; Welters et al., 2004).   
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One hypothesis is that the process of TG accumulation may function as a defence 
mechanism and might therefore be beneficial to β-cell survival, by sequestration 
of excess FFAs that would otherwise have toxic effects (Nolan and Larter, 2009; 
Ricchi et al., 2009; Cnop et al., 2001; Cnop et al., 2002).  Conversely, others 
suggest that TG formation due to elevated levels of FFAs is detrimental to β-cells 
through physiochemical disruption of cells as observed in vitro using INS-1 cells 
(Moffitt et al., 2005).  Elevated SFA incorporation within the cell is suggested to 
impact on cell membrane rigidity and fluidity due to altered lipid deposition.  It is 
this physical action which may ultimately have a detrimental effect on 
mechanisms such as cell signalling, the secretion and trafficking of insulin 
granules, protein processing within the ER and disrupted secretory granule fusion 
during exocytosis.   
 
Diakogiannaki and colleagues (2007) showed that remodelling and increased TG 
formation occurs in β-cells incubated with SFAs.  However, the use of methyl-
palmitoleate in the presence or absence of palmitate, failed to increase TG or to 
modify the amount of TG formation seen in the β-cells treated with palmitate, 
suggesting TG formation is unlikely to be the cause of cytotoxicity.  The addition 
of a methyl group on the functional FA carboxyl group blocks the initial 
esterification step in the β-oxidation pathway, and as such, FA methyl-esters 
prevent FA oxidation.  Methyl-palmitoleate did however, display cytoprotective 
effects, suggesting that cytoprotection is not via altered TG formation or 
composition.   
 
Moffitt and colleagues (2005) stated that using a single SFA species within an in 
vitro system affects TG storage resulting in disruption of normal cell morphology, 
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in a manner that may not typically occur in vivo, where equal concentrations of 
unsaturated FAs would also be present.  On this basis, they argue that lipotoxicity 
is an in vitro artefact observed when culturing β-cells with exogenous FAs, and 
suggested that this presents limitations when using cell models to investigate the 
effects of SFAs.   
 
While it is probably accepted that in vitro models may not be completely 
representative of in vivo conditions, it is also acknowledged that in vitro findings 
are likely to be reflective of in vivo pancreatic β-cell responses to circulating FFAs.  
This suggests that the prevailing ratio of plasma FFA species within the 
pancreatic β-cell environment at any time is a relevant and important factor with 
regard to long-term β-cell survival.  Consequently, in vitro models may still offer 
critical information regarding the pathological mechanisms underlying lipotoxicity 
(Newsholme et al., 2007).   
 
1.4 Fatty acid effects on β-cell function 
Key observations regarding the molecular mechanisms underlying the effects of 
FA have been gleaned using in vitro culture of pancreatic β-cell lines (Newsholme 
et al., 2007; Welters et al., 2004; Eitel et al., 2003; Dhayal et al., 2008; 
Diakogiannaki et al., 2007; Diakogiannaki et al., 2008; Morgan et al., 2008).  What 
is clear from these studies is that not all FA species exert similar effects on β-
cells during chronic exposure.  The degree of toxicity observed in BRIN-BD11 
and INS-1 β-cells varies markedly according to the carbon chain length, degree 
of saturation and configuration of FA species (Table 1.1).   
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Long-chain SFA (LC-SFAs) such as palmitate (C16:0) or stearate (C18:0) exert 
a detrimental effect on cell viability, whereas medium-chain and/or shorter-chain 
SFAs (C14:0 or less) are well-tolerated and do not affect cell viability (Welters et 
al., 2004; Eitel et al., 2003; Dhayal et al., 2008).  Long-chain monounsaturated 
fatty acids (LC-MUFAs) such as palmitoleate (C16:1) or oleate (C18:1) are also 
well-tolerated by rodent β-cells.  However, most importantly, the in vitro co-
incubation of LC-MUFAs with LC-SFAs effectively attenuates the cytotoxic effects 
seen when β-cells are incubated with LC-SFAs alone (Karaskov et al., 2006; 
Welters et al., 2004).  It has been demonstrated that this protective effect of LC-
MUFAs is also observed when rodent β-cells are exposed to pro-inflammatory 
cytokines, or when the cells are subjected to serum withdrawal (Welters et al., 
2004).  Palmitoleate was able to ameliorate cytotoxic effects in BRIN-BD11 cells 
when it was added up to 10 h after cells were initially incubated with the SFA 
palmitate.  This suggests that the protective actions of LC-MUFAs are exerted 
rapidly, as cytotoxicity due to palmitate-induced toxicity would already have been 
initiated.   
 
The configuration of the FA species also impacts on the cytoprotective action of 
LC-MUFAs.  Again using BRIN-BD11 and INS-1 β-cells, it has been 
demonstrated that LC-MUFAs in the cis configuration effectively protect cells 
against the cytotoxic effects of LC-SFAs.  However, substituting a cis double bond 
with a trans double bond results in significantly reduced cytoprotective potency 
(Dhayal et al., 2008).   
 
It has been suggested that the SFA palmitate must be metabolised to LC-CoA to 
exert a cytotoxic effect, as studies using a non-metabolisable palmitate analog, 
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2-bromopalmitate, did not promote cell death, nor evoked such a cytotoxic 
response as palmitate (Diakogiannaki et al., 2007; Hardy et al., 2003; El-Assaad 
et al., 2003; Gwiazda et al., 2009).  However, it has also been proposed that 
altered lipid-partitioning (when lipid is stored in areas other than sub-cutaneous 
tissue) (Weiss, 2007), not β-oxidation, enhances the proapoptotic effects of 
palmitate.  Poorly-metabolised methyl-FA derivatives such as 2-bromopalmitate, 
have also been used to demonstrate that the cytoprotection afforded by the 
addition of LC-MUFA species is not via their metabolism, prompting suggestions 
that the cytoprotective action may be mediated by a FA receptor (Diakogiannaki 
et al., 2007).  However, while there has been great interest in the relatively newly 
discovered class of lipid-responsive G-protein-coupled receptors with regard to 
mechanisms of FA action, there is no clear consensus about a single receptor 
that may satisfactorily explain the cytotoxic or cytoprotective effects of individual 
FFAs (Morgan and Dhayal, 2009; Morgan, 2009).  
 
1.5 The ER: function and implications of FFA-mediated stress 
Whilst the exact molecular mechanisms that may mediate the proapoptotic or 
protective effects of FFAs in β-cells are still unclear, the last few years has seen 
increased interest in the possibility that the decline in β-cell numbers observed 
during the progression of T2D may be attributable to ER stress (Qu et al., 2009; 
Breckenridge et al., 2003; Laybutt et al., 2007).  The ER is a highly dynamic 
organelle that plays a key role in the routing of secretory proteins through 
eukaryotic cells (Schröder, 2008).  It is a primary site for synthesis, folding and 
post-translational modification of secretory and membrane proteins and is also 
the location where disulphide bonds are formed.  In addition, the ER has a central 
role in lipid, sterol and protein synthesis and is involved in the storage and 
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regulation of intracellular calcium (Ca2+) (Qu et al., 2009; Eizirik et al., 2008; 
Scheuner and Kaufman, 2008; Schröder, 2008).  Another important ER function 
is its strict quality control role, whereby slowly-folding or folding-incompetent 
proteins are retained and subsequently targeted for proteolytic degradation via 
the ER-associated protein degradation (ERAD) pathway (Schröder, 2008).  
Appropriate Ca2+ concentrations ([Ca2+]) and a suitable redox state within the ER 
lumen are essential factors for competent protein folding and chaperone function.  
Imbalances can lead to an accumulation of misfolded proteins, triggering an ER 
stress response (ERS), which in turn triggers an unfolded protein response (UPR) 
to re-establish homeostasis (refer to Section 1.8 for more detail).  It has been 
proposed that some metabolic disease states can impair ER equilibrium, initiating 
ER stress, a subsequent UPR and eventual apoptosis (Xu et al., 2005; Lindholm 
et al., 2006; Kin et al., 2008).  One mechanism suggested to mediate this process 
is a depletion of ER Ca2+ concentration (rather than increased [Ca2+]cyt) due to 
activation of the UPR, leading to dysfunctional processing of luminal proteins and 
apoptosis (Eizirik et al., 2008; Gwiazda et al., 2009; Michalak et al., 2002; Nakano 
et al., 2006).   
 
Some groups have shown that palmitate causes a marked increase in cell death, 
due to upregulation of certain ERS proteins such as p-eIF2α, ATF4 and CHOP10 
(known as the p-eIF2α/ATF4/CHOP10 apoptotic pathway) (Eizirik et al., 2008; 
Özcan et al., 2004).  This establishes a link between underlying 
pathophysiological perturbations observed in obesity such as increased plasma 
FFA, and the progression of T2D via β-cell ER stress-mediated apoptosis 
(Laybutt et al., 2007; Karaskov et al., 2006; Breckenridge et al., 2003; Wei et al., 
2009).  However, it is interesting that Karaskov and colleagues (2006) found no 
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change in the level of the ER chaperone protein GRP78/BiP expressed in INS-1 
cells that had been treated with palmitate, which would be reasonably expected 
in response to an ERS.   
 
1.6 The pancreas: cells and function 
The pancreas functions as both an endocrine and exocrine organ.  The majority 
of the pancreas consists of acinar cells: these are found clustered around small 
ducts that ultimately coalesce to form the single large pancreatic duct.  The acinar 
cells have an important role in digestion and metabolism as the enzymes 
secreted from these cells, such as carbohydrases, lipases and proteases within 
pancreatic juice, are responsible for the digestion of all the major food groups.  
The endocrine cells of the pancreas are spread around the entire organ, in small 
clusters known as IoL.  The islets consist of distinct endocrine cell types that 
secrete different hormones with various functions.  The β-cells secrete insulin, 
while the alpha-cells (α-cells) secrete glucagon.  These two cell types are 
predominantly responsible for glucose homeostasis: in simple terms, insulin 
decreases blood glucose levels (BGL) whereas glucagon increases BGL.  The 
delta-cells (δ-cells) secrete somatostatin which inhibits the secretion of both 
insulin and glucagon; the gamma cells (also known as PP-cells) secrete 
pancreatic polypeptide which has an appetite-suppressing role.  Finally, the 
epsilon cells (ε-cells) secrete ghrelin, which is implicated in increasing appetite 
(Fig. 1.2) (Hohmeier and Newgard, 2004).   
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Fig. 1.2 Cell anatomy and function of the pancreas   
The pancreas consists predominantly of acinar cells which secrete digestive 
enzymes. The IoL are interspersed throughout the pancreas, and consist of 
insulin secreting β-cells (~70%), glucagon secreting α-cells (~20%), 
somatostatin secreting δ-cells (~5%) and smaller numbers of pancreatic 
polypeptide secreting PP-cells and ghrelin secreting ε-cells (schematic 
adapted from Efrat and Russ, 2012).  
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1.6.1 β-cells and susceptibility to ER stress 
One of the primary functions of the pancreatic β-cell is the synthesis and secretion 
of insulin in response to glucose, thereby maintaining normoglycaemia.  Beta-
cells have a highly developed ER with high secretory capacity necessary to 
handle insulin secretion load.  This is estimated to take up approximately 70% of 
all protein synthesis within the cell.  It is this high secretory load which is believed 
to be responsible for the particular vulnerability to homeostatic change (Cnop et 
al., 2007; Cardozo et al., 2005).  The ER stress response (ERS) is suggested to 
have evolved to allow temporal and physiological variations in ER load to be more 
effectively managed (Butler et al., 2003), making the ERS a critical adaptive 
signalling response necessary for optimal β-cell function (Cnop et al., 2008; 
Laybutt et al., 2007; Araki et al., 2003).  The growth of a glucose-responsive β-
cell phenotype within the pancreas during foetal development is typically subject 
to strict regulation, as the risk of uncontrolled insulin secretion could lead to 
severe or persistent hypoglycaemia, for example as seen in persistent 
hyperinsulinaemic hypoglycaemia of infancy (PHHI) (Aynsley-Green, 1981).  In 
addition to tight regulation of function and mass, it is suggested the β-cell 
phenotype has developed especially sensitive apoptotic susceptibility during 
developmental differentiation (Mandrup-Poulsen, 2003; Laybutt et al., 2007).  It 
is known that ER stress-susceptibility varies according to cell type, so it is relevant 
given the aforementioned points, that β-cells are highly susceptible to ER stress 
which may be regarded as an adaptive ‘failsafe’ mechanism to eliminate 
compromised cells (Araki et al., 2003).   
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1.7 The role of ERS in obesity and T2D 
Evidence points strongly towards a role for the ER in cell survival and apoptotic 
responses, particularly when associated with lipotoxic conditions in individuals 
with T2D (Mathias et al., 1998; Cnop et al., 2001).  Beta-cell ERS occurs as a 
result of perturbations in normal ER balance due to pathological or physiological 
insults such as infection, nutrient deprivation or nutrient overload, ER luminal 
Ca2+ depletion, accumulation of misfolded proteins, impaired protein trafficking or 
inflammatory cytokines.  Any of these insults may lead to altered ER functionality 
resulting in the accumulation of unfolded or misfolded proteins within the ER 
lumen (Ito et al., 1999; Özcan et al., 2004; Qu et al., 2009; Schröder and Kaufman, 
2006; Araki et al., 2003; Lee et al., 2007; Hotamisligil, 2005).   
 
It has already been mentioned that the hyperlipidaemic state accompanying 
obesity results in an altered circulating lipid profile, which has been shown to be 
cytotoxic to β-cells under both normal physiological conditions and in obesity-
induced diabetes models (Herbert, 2007; Lai et al., 2008; Araki et al., 2003; Cnop 
et al., 2007; Shimbukuro et al., 1998).  This is supported by studies that show 
heightened expression of certain ER stress marker proteins such as activating 
transcription factor 4 (ATF-4) and the proapoptotic transcription factor C/EPB 
[CCAAT/enhancer-binding protein]-homologous protein 10 (CHOP10) (Laybutt et 
al., 2007).  In vitro rodent cell and mouse model studies have also shown that 
elevated plasma FFA concentrations contribute to insulin resistance and impaired 
insulin secretion, a prerequisite for the development of T2D (Diagkogiannaki and 
Morgan, 2008; Cunha et al., 2008).  Furthermore, the initiation of the β-cell ERS 
by exposure to LC-SFAs is reported to be necessary for β-cell lipoapoptosis 
(Araki et al., 2003; Eitel et al., 2003).  Taken together, these data suggest that 
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the persistently high plasma concentrations of FFAs commonly seen in obese 
individuals may drive a prolonged decline in β-cell mass and the gradual 
progression to T2D, consequently implicating the ERS in this mechanism.  This 
further implies that, for the long-term survival of β-cells in a lipotoxic environment, 
the mammalian ERS is critical to alleviate cytotoxic effects by inhibiting global 
protein synthesis, thus allowing the opportunity for recovery from ER stress and 
restoration to normal ER homeostasis (Diakogiannaki et al., 2008).   
 
1.8 The ERS pathway 
The ERS triggers the initiation of a group of signal transduction pathways 
collectively called the UPR, which attempt to reduce ER burden and restore 
homeostasis.  These collective stress responses are initiated and mediated by 
three specific transducer proteins, whose role are to collectively transmit stress 
signals from the ER to the nucleus, under the activated UPR pathways that 
mediate adaptive cell survival responses (Qu et al., 2009; Fonseca et al., 2009; 
Cnop et al., 2008; Araki et al., 2003; Herbert, 2007).  The three ER-membrane 
localised components are the α-subunit of inositol requiring ER-to-nucleus signal 
kinase (IRE-1), activating transcription factor 6 (ATF-6) and the double-stranded 
ribonucleic acid (dsRNA)-dependent protein kinase R (PKR)-like ER kinase 
(PERK).   
 
1.8.1 The UPR 
To date, there are four known functionally co-ordinated and distinct transcriptional 
and translational responses associated with the ERS (Fig. 1.3).  The first 
response to disrupted ER function is the initiation of a molecular chaperone 
system, through upregulation of ER chaperone genes encoding GRP78 (also 
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known as the immunoglobulin heavy-chain binding protein, BiP) and GRP94, 
thereby preventing protein agglutination and also enhancing protein folding 
capacity within the ER (Araki et al., 2003).  Secondly, attenuation of protein 
translation is mediated by the phosphorylation of a key serine residue (Ser51) on 
the α-subunit of eukaryotic initiation factor 2 (eIF2).  This prevents the exchange 
of eIF2-GDP for eIF2-GTP required to bind and deliver the initiator met-tRNA to 
the translation machinery.  This reduces synthesis of new proteins and prevents 
additional protein overload in the already compromised ER (Raven and 
Koromilas, 2008).  Thirdly, increased proteasomal degradation via the ERAD 
pathway facilitates the removal of folding-incompetent or slowly-folding proteins, 
also helping to relieve protein overload in the ER (Eizirik et al., 2008; 
Breckenridge et al., 2003; Laybutt et al., 2007; Araki et al., 2003).  Finally, a 
paradox of the UPR is that if prolonged or persistent ER stress continues 
unabated in cells and cannot be relieved by other compensatory UPR 
mechanisms, the initiation of apoptosis occurs (Qu et al., 2009; Fonseca et al., 
2009; Scheuner and Kaufman, 2008).  Apoptotic cell death is induced via 
transcription factors (TFs) that include activating transcription factor-6 (ATF-6), 
ATF-4, ATF-3 and their downstream target CHOP10 (explained more fully in 
Section 1.9).  These TFs elude the effects of translation inhibition imposed by 
eIF2α phosphorylation as they are further downstream in the signalling pathway 
(Scheuner and Kaufman, 2008; Okada et al., 2002).  Despite evidence clearly 
implicating a role for ER stress within β-cells in the pathogenesis of T2D, it is still 
unclear which of the activated ERS pathways are most critical in β-cell death, 
specifically with regard to β-cell exposure to LC-SFAs such as palmitate.   
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Fig. 1.3 The ERS pathway  
The ERS consists of three ER-localised proteins that mediate stress 
responses: IRE-1, ATF-6 and PERK. All three proteins typically associate with 
the chaperone GRP78 under non-stress conditions, and are located within the 
ER lumen. However, during cell stress GRP78 dissociates from the ER lumen 
and interacts with intralumenal unfolded proteins, initiating downstream 
signalling cascades. ATF-6 facilitates upregulation of the GRP78/GRP94 
chaperone system, which prevents a build-up of misfolded proteins and 
enhances folding capacity. ATF-6 also enhances the TF XBP-1 mRNA 
expression and directs degradation of misfolded proteins via the ERAD.  IRE-
1 principally cleaves XBP-1 which directs gene expression involved in protein 
folding, helping to reduce ER protein load. PERK auto-phosphorylation in turn 
phosphorylates eIF2α, inhibiting mRNA and thereby protein translation. PERK 
also regulates the TFs ATF-4 and ATF-3 that can eventually trigger apoptosis 
during persistent stress conditions (schematic adapted from Breckenridge et 
al., 2003).  
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1.8.2 Key players of the UPR 
The IRE-1α protein is expressed constitutively in most cells, with particularly high 
levels of expression in pancreatic tissue.  Once activated, IRE-1α acts as an 
endoribonuclease, cleaving the mRNA encoding X-box binding protein 1 (XBP-
1), generating a spliced XBP-1 variant termed XBP-1s.  XBP-1s is a potent TF 
for genes that are involved in ER protein maturation, folding and export, and 
targeted mRNA degradation, all of which contribute to reduced protein load in the 
ER (Breckenridge et al., 2003; Cnop et al., 2008).  ATF-6 is an ER-bound, 
constitutively expressed basic leucine zipper (bZIP) type II transmembrane 
protein, involved in the upregulation of the GRP78/GRP94 chaperone system and 
also acts to augment XBP-1 mRNA expression (Eizirik et al., 2008; Wek et al., 
2006).  PERK is an ER-resident type I transmembrane kinase protein (Butler et 
al., 2003) that recognises misfolded proteins in the ER, triggering its own 
activation via trans-autophosphorylation under stress conditions, and is proposed 
to upregulate in sequence: ATF-4, ATF-3 and CHOP10 (Lee et al., 2007; Boyce 
and Yuan, 2006).  Under non-stress conditions, each ER stress protein remains 
in an inactive state, bound and associated to GRP78 located within the ER lumen.  
However, GRP78 dissociates from the ER membrane to bind unfolded 
intralumenal proteins during cellular stress, thereby releasing the transducer 
proteins and consequently activating downstream ER signalling cascades (Cnop 
et al., 2008; Qu et al., 2009).   
 
1.9 ERS apoptotic pathways 
The exact mechanism whereby persistent ER stress eventually triggers β-cell 
death apoptosis is unclear, although so far there have been several individual 
apoptotic signalling pathways identified during ER stress conditions (Lee et al., 
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2007).  These involve the PERK/eIF2α-dependent induction of CHOP10, Ca2+ 
release from the ER, IRE1α-mediated activation of the cJUN NH2-terminal kinase 
(JNK) pathway and cleavage and activation of caspase 12.  Typically, CHOP10 
is barely detectable under normal physiological conditions.  It is strongly induced 
under prolonged stress conditions however, where translocation to the nucleus 
initiates proapoptotic factors that ultimately lead to the death of the cell (Scheuner 
and Kaufman, 2008).  Targeted disruption or knockout of the CHOP10 gene can 
protect against ER stress conditions in both mice and β-cell models, by improving 
β-cell function and promoting cell survival (Song et al., 2008; Zinszner et al., 1998; 
Jiang and Wek, 2005; Marciniak et al., 2004; Oyadomari and Mori, 2003).   
 
Transcriptional activation of CHOP10 is mediated by the three upstream ERS 
proteins: IRE1α, PERK and ATF6, although at present there is little known 
regarding potential downstream targets of CHOP10 in apoptosis.  The JNK family 
is comprised of signal transduction proteins that regulate not only gene 
expression, but also survival or apoptotic responses in cells.  The activated IRE1α 
subunit recruits both tumour necrosis factor (TNF) receptor-associated factor 
(TRAF) 2 and apoptosis signal-regulating kinase (ASK) 1 proteins, forming an 
IRE1α/TRAF2/ASK1 complex that triggers JNK activation.  Caspase 12 activation 
has been demonstrated during ER stress in mice, and although it is also 
expressed in humans, its exact role is not yet clear.  This third apoptotic pathway 
needs further research to clarify the associated molecular mechanisms, although 
it does not appear to involve either death receptor-mediated or mitochondria-
targeted apoptotic signals (Araki et al., 2003).  Additionally, research shows that 
FFA induce activation of both JNK and Caspase 12 (Cunha et al., 2008), however, 
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it is not yet clear which of these pathways or molecular mechanisms is the most 
important response under lipotoxic conditions (Lee et al., 2007).   
 
1.10 PERK: function and role in ER stress 
The PERK protein has been extensively studied and is known to play a critical 
role in the proliferation and differentiation of pancreatic β-cells, as evidenced by 
PERK knockout mice (Herbert, 2007).  PERK’s role links ER stress to arrest of 
ER translation.  It is a serine/threonine kinase that has long been proposed to 
directly phosphorylate eIF2α under ER stress conditions (Kapoor and Sanyal, 
2009), thus inhibiting global protein synthesis via regulation of selected mRNAs.  
Somewhat paradoxically, certain mRNAs such as ATF-4 (whose downstream 
targets include ATF-3 and CHOP10) continue to be translated when eIF2α is 
phosphorylated (Kapoor and Sanyal, 2009; Wek et al., 2006).  PERK is typically 
held docked on the ER membrane via interaction with GRP78.  It recognises 
misfolded proteins within the ER and inhibits protein translocation into the ER 
lumen, collectively reducing ER protein load during stress conditions (Butler et 
al., 2003; Scheuner and Kaufman, 2008).  ER stress stimuli trigger the release of 
PERK from its interaction with GRP78, allowing activation of the kinase via 
autophosphorylation (Lee et al., 2007; Harding et al., 2000; Ron, 2002).   
 
A critical early step and one of the arms of the ERS, is the arrest of bulk protein 
synthesis, mediated by the phosphorylation of eIF2α, thereby preventing 
additional protein overload in the already compromised ER.  Exposure of SFA to 
pancreatic β-cell lines has been shown to result in augmentation of eIF2α 
phosphorylation, followed by a marked increase in ATF-4 and subsequently 
CHOP10, both consistent with activation of this arm of the ER stress signalling 
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cascade (Diakogiannaki and Morgan, 2008; Diakogiannaki et al., 2008; Eizirik et 
al., 2008; Ito et al., 1999; Qu et al., 2009; Harding et al., 2000; Herbert, 2007).  
Induced CHOP10 expression in certain pancreatic β-cell lines during palmitate 
exposure is also associated with apoptotic progression under the PERK-
dependent arm of ER stress, as cited by many groups (Diakogiannaki and 
Morgan, 2008; Diakogiannaki et al., 2008; Cnop et al., 2008; Morgan et al., 2008; 
Scheuner and Kaufman, 2008; Laybutt et al., 2007; Song et al., 2008).  As such, 
activation of the PERK signalling cascade has been well established under ER 
stress conditions and to date, it has been generally accepted that the PERK 
protein is responsible for this eIF2α phosphorylation step (Cunha et al., 2008; 
Eizirik et al., 2008; Qu et al., 2009; Harding et al., 2000; Herbert, 2007).  However, 
new research now questions whether PERK is the sole factor underlying the 
progression to T2D as studies investigating PERK’s involvement have produced 
somewhat conflicting results (Morgan, 2009; Lee et al., 2007).   
 
Diakogiannaki and colleagues (2008) was unable to observe consistent or full 
activation of PERK in β-cells exposed to palmitate, and although others have 
cited evidence of PERK activation in response to SFA, the extent of this activation 
is rather moderate (Laybutt et al., 2007).  Furthermore, others have noted that 
GRP78 levels remain unaltered during palmitate exposure: an unusual result 
given that upregulation of GRP78 transcription normally occurs as part of the 
collective ERS (Diakogiannaki et al., 2008; Karaskov et al., 2006; Diakogiannaki 
and Morgan, 2008).  Studies have also suggested that GRP78 over-expression, 
which in theory should attenuate palmitate-induced ER stress, has a limited effect 
at best, or in some cases, has proven to be completely ineffective (Laybutt et al., 
2007; Morgan, 2009; Lai et al., 2008).  All considered, these results suggest that 
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PERK may have a less significant role in ER stress-mediated apoptosis than was 
previously thought.   
 
1.11 PKR: structure and function 
Protein kinase R (PKR) is a soluble serine/threonine kinase that is ubiquitously 
expressed and constitutively active at low levels in most cell types.  Around 80% 
of PKR is distributed within the cytoplasm and mostly associated with ribosomes 
(Clemens, 1997).  PKR has been implicated in many cellular processes such as 
signal transduction, apoptosis, tumour suppression and regulation of growth and 
differentiation (Patel and Sen, 1998), as well as ascribed functions in certain 
disease processes (Cole, 2007; Clemens, 1997; Lee et al., 2007; Lemaire et al., 
2005; Sadler and Williams, 2007).   
 
Both PKR and PERK belong to a small family of protein kinases, which respond 
to a variety of environmental stressors via phosphorylation of eIF2α, and it has 
been noted that there is a degree of redundancy in their responses (Sadler and 
Williams, 2007).  In addition to PKR (eIF2α kinase 2) and PERK (eIF2α kinase 3), 
there is also an eIF2α kinase 4 (also known as the general control non-
derepressible-2 kinase [GCN2]) which is induced under amino acid deprivation 
or UV irradiation conditions and eIF2α kinase 1 (or haem-regulated inhibitor [HRI] 
kinase) which is activated by haem deprivation, oxidative stress or heat stress in 
erythroid tissue (Wek et al., 2006).  All of these kinases are able to phosphorylate 
eIF2α, thus potentially acting to regulate the distal signalling cascade of the ERS.  
Wek and colleagues (2006) considered GCN2 an unlikely candidate kinase 
because although it does phosphorylate eIF2α in response to nutrient deprivation 
or UV irradiation, it does not lead to CHOP10 upregulation, a mechanism which 
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has been closely linked with β-cell apoptosis during exposure to SFA (Morgan, 
2009).  It is with interest then, that recent work by Lee and colleagues (2007) 
highlighted the potential of PKR as an alternative candidate for eIF2α 
phosphorylation and a driver of apoptosis under the ERS.   
 
The human PKR gene encodes a 551 amino acid (513 in rat, 515 in mouse) 
protein which consists of two functionally distinct domains: an N-terminal 
regulatory dsRNA-binding domain (dsRBD) and a C-terminal catalytic kinase 
domain.  The N-terminal dsRBD contains two dsRNA-binding motifs (dsRBM) of 
around 65 amino acid residues that adopt similar αβββα folds.  These dsRBMs 
are separated by a 20 amino acid linker, which is made up of a random coil 
conformation, suggested to offer plasticity so the RBD can optimally bind around 
a dsRNA helix (Feng et al., 1992; Nanduri et al., 2000) (Fig. 1.4).   
 
PKR was initially discovered as an interferon-induced mediator of cellular antiviral 
responses (Sonenberg, 1990), where it is activated by ds-RNA, highlighting the 
critical role of PKR in the immune response to viral infection in higher eukaryotes.  
PKR is induced by type I interferons in a latent state.  Upon binding of dsRNA, 
PKR undergoes autophosphorylation and activation, phosphorylating the α-
subunit of eIF2 thereby inhibiting protein synthesis and viral replication in infected 
cells.  PKR is typically activated by dsRNA with sequences of 30 base pairs or 
greater, however, it is known that shorter dsRNA sequences are also capable of 
activating PKR, although it is speculated that this may occur by a different 
mechanism (Cole, 2007; Samuel, 2001).   
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Fig. 1.4 PKR structural domain  
a) PKR structural domain consists of an N-terminal regulatory domain 
comprising two dsRNA-binding motifs: dsRBM1 and dsRBM2, and a C-
terminal kinase domain, as represented schematically in b) (schematic 
adapted from Cole, 2007).  
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1.11.1 Proposed models of PKR activation 
Despite great interest in the PKR protein over the last couple of decades, a 
detailed molecular understanding of how PKR is activated is lacking.  There are 
currently two suggested models for activation of PKR (Fig. 1.5).  The catalytic 
domains of different protein kinases assume remarkably similar structures in their 
active state.  In contrast, there is marked plasticity in these catalytic domains 
when the kinases are inactive.  Tight regulation of protein kinases is critical, and 
intramolecular interactions between the catalytic and regulatory domains are 
often observed as part of this regulatory mechanism.  This acts to inhibit kinase 
activity by allosterically inducing an inactive conformation, or by physically 
inhibiting substrate binding (Huse and Kuriyan, 2002).  In the autoinhibition model 
(Fig. 1.5a)), evidence suggests that latent PKR exists in a closed formation, 
where the dsRBD interacts with and blocks the kinase domain, preventing its 
interaction with its substrate.  Binding of dsRNA releases the kinase domain, 
thereby activating PKR (Nanduri et al., 2000; Wu and Kaufamn, 1997; Bischoff 
and Samuel, 1985; Spanggord et al., 2002; Dey et al., 2005; Vattem et al., 2001; 
Wu and Kaufman, 2004; Saelens et al., 2001).   
 
In the second, more favoured dimerisation model (Fig. 5b)), latent PKR is 
suggested to exist in a monomer-dimer equilibrium, where ATP can bind both 
enzyme forms.  Double-stranded RNA binding induces and enhances PKR 
dimerisation via the catalytic domain and subsequent autophosphorylation, 
resulting in PKR activation (Robertson and Mathews, 1996; Lemaire et al., 2005; 
Gabel et al., 2006; Tian and Mathews, 2001).  Biophysical and structural data do 
not support the physical blockade of the kinase active site by the dsRBD, as it 
has been demonstrated that the kinase active site is readily accessible in both 
53 
 
latent and activated PKR.  Importantly, work has also demonstrated that latent 
PKR can be activated by dimerisation even in the absence of RNA (Lemaire et 
al., 2005), contrary to the suggested mechanism of action proposed in the 
autoinhibition model.  Nevertheless, the proposed dimer model for PKR activation 
is further complicated by the fact that PKR contains multiple phosphorylation sites 
and by evidence suggesting that PKR undergoes both cis and trans 
autophosphorylation when activated by dsRNA (Cole, 2007; Sadler and Williams, 
2007; Lemaire et al., 2005; Williams, 1999; Galabru and Hovanessian, 1997; 
Samuel, 2001).   
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Fig. 1.5 Proposed models of PKR activation.  
There are two proposed models for PKR activation: a) the autoinhibition 
model suggests that latent PKR exists in a closed formation, where the 
dsRBD interacts with and blocks the kinase domain from interacting with its 
substrate. Binding of dsRNA releases the kinase domain, thereby activating 
PKR. The second dimerisation model, b) proposes that PKR exists in an 
open formation, and binding of dsRNA leads to PKR dimerisation, 
autophosphorylation and thereby activation (schematic adapted from Cole, 
2007).   
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1.11.2 PKR dsRNA-independent activatory mechanisms 
Work has shown that PKR can also be activated by dsRNA-independent 
mechanisms (Proud, 1995), for example, in direct response to cellular stressors, 
which include lipid derivatives such as ceramide.  This mechanism is mediated 
by way of a directly upstream regulatory molecule, named protein activator of 
PKR (PACT) (Patel and Sen, 1998; Ruvolo et al., 2001; Sadler and Williams, 
2007).  Furthermore, recent work has demonstrated a pivotal role for PKR within 
nutrient- and pathogen sensing pathways, and as a mediator of inflammatory 
responses within metabolism (Nakamura et al., 2010).  This mechanism has for 
the first time, linked elevated levels of FFA with activation of PKR and β-cell death 
in metabolic disease (Shimabukuro et al., 1998; Newsholme et al., 2007; Wei et 
al., 2006).   
 
1.11.3 PKR as a proapoptotic molecule 
To date, the best-characterised role of PKR is the inhibition of translation via 
eIF2α phosphorylation.  However, work published by Lee and colleagues (2007) 
established that PKR is simultaneously but independently activated alongside 
PERK under lipotoxic-mediated ER stress conditions.  It was demonstrated that 
PERK phosphorylated around 50% of eIF2α; however, PKR was responsible for 
as much as 30 – 40% of eIF2α phosphorylation.  This study also suggested that 
PKR plays the predominant role in β-cell apoptotic mechanisms, by inducing 
proapoptotic downstream eIF2α targets such as ATF4, ATF3 and CHOP10 (the 
p-eIF2α/ATF4/CHOP10 apoptotic pathway).  These findings support conclusions 
reached by other research groups, in that PERK and PKR appear to play different 
roles in lipotoxic conditions.  PERK’s principal role is suggested to influence pro-
survival mechanisms by mediating translational arrest, but the role of PKR role 
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may mediate cell-death related mechanisms through the upregulation of the 
proapoptotic TF CHOP (Harding et al., 2000; Cullinan and Diehl, 2004; Cullinan 
et al., 2003; Lee et al., 2007).   
 
There is much additional evidence to support the idea of PKR as a proapoptotic 
molecule.  For example, PKR has been found to become associated with ASK1 
(mentioned previously in JNK activation as one of the ERS apoptotic pathways), 
STAT1 (signal transducer and activator of transcription) necessary for caspase-
3 expression and also the tumour suppressor p53 (Sadler and Williams, 2007).  
More recent work has associated PKR activation with plaque formation in certain 
central nervous system disorders, such as Huntington’s, Parkinson’s and 
Alzheimer’s diseases (Peel et al., 2001; Peel and Bredesen, 2003).  Notably, 
similar plaque formation is also known to be a characteristic feature of T2D (in 
the form of IAPP) (Potter et al., 2009), thereby implying PKR may act as a 
potential pathogenic factor in T2D progression (Sadler and Williams, 2007).  
When considering this evidence, it is undoubtedly feasible that PERK may not be 
the most critical factor in mediating death in β-cells during lipotoxicity.  Evidence 
clearly points to a role for PKR in general ERS and during β-cell exposure to 
elevated levels of SFAs.  This mechanism is known to underlie the progression 
to T2D, suggesting that PKR may potentially mediate predominantly apoptotic 
cell signalling outcomes (Fig. 1.6).   
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Fig. 1.6 Proposed PKR activity in stress response signalling pathways 
PKR is induced by IFN-γ in response to dsRNA, and phosphorylates the α-
subunit of eIF2, inhibiting global protein translation and preventing replication of 
virally infected cells. PKR is also activated by dsRNA-independent 
mechanisms: ceramide and FAs are suggested to activate PKR via the 
upstream regulator PACT, via a predominantly apoptotic pathway (schematic 
adapted from Protein Lounge, 2012).  
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1.12 Innate immunity and inflammation in obesity and T2D 
Activation of the innate immune system was originally believed to occur solely in 
response to noxious insults, for example, microbial or physical stimuli.  As part of 
this activation response and as a means of protection, inflammation is considered 
as the first line of defence to counter potential infection or tissue injury.  However, 
it is now clear that a prolonged or chronic inflammatory response can be 
deleterious and exacerbate tissue damage.  Interestingly, chronic inflammation 
has been recently implicated in the development and progression of certain 
diseases such as T2D, gout and rheumatoid arthritis (Dinarello, 2010).  It is 
becoming apparent that under certain circumstances, the innate immune system 
can be activated in the absence of an exogenous trigger.  As such, increasing 
evidence has pointed to a role for innate immunity as a custodian for sensing 
metabolic stress (Menu and Vince, 2011; Tannahill and O’Neill, 2011; Yang et al., 
2012; Ciraci et al., 2012; Hotamisligil and Erbay, 2008; Kaufman et al., 2002).   
 
The innate immune system is thought to play a key pathogenic role in a variety 
of diseases where underlying chronic low-level inflammation is observed, such 
as insulin resistance, obesity and T2D, in a mechanism termed 
‘metainflammation’.  Studies have identified a strong association between low-
grade inflammatory markers such as circulating pro-inflammatory cytokines, 
chemokines and acute phase proteins, and metabolic dysfunction (Calle and 
Fernandez, 2012; Donath, 2011; Lavelle, 2008; Hotamisligil, 2006).  Chronic 
systemic inflammation observed in obesity and T2D is a well-established factor 
contributing to the upregulation of SOCS (suppressor of cytokine signalling) 
proteins, which have been recognised to reduce insulin receptor signalling, 
thereby conceivably driving the progression of insulin resistance within metabolic 
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dysfunction (Ueki et al., 2004).  Chronic nutrient overload is now suggested to 
result in a sterile inflammatory process, otherwise termed an autoinflammatory 
response.  Furthermore, evidence has shown that metabolic stress can elicit an 
autoinflammatory reaction specifically in pancreatic islets (Böni-Schnetzler et al., 
2009; Dinarello et al., 2010; Donath et al., 2009; Maedler et al., 2002; Masters et 
al., 2010; Masters et al., 2011).  Consequently, there has been great interest in 
the suggestion that inflammation may well be a common link between metabolic 
diseases and the driving factors underlying their pathogenesis (Böni-Schnetzler 
et al., 2009; Donath, 2011;  Donath and Shoelson, 2011; LaValle, 2008; Masters 
et al., 2011; Wen et al., 2012).   
 
1.13 The link between ER stress, inflammation and metabolic 
disease 
With the prevalence of obesity reaching epidemic proportions, it is becoming 
increasingly important to understand how excess adiposity driven by chronic 
nutrient excess can affect metabolic homeostasis.  It is becoming clear that within 
this metabolically driven dysfunctional state, ER stress and activation of an ERS 
are critical players (Hummasti and Hotamisligil, 2012).  Sequestration of excess 
FFAs as TG is a principal metabolic event in response to nutrient surplus: TG is 
typically deposited in adipocytes, but chronic calorific overload can drive TG 
deposition in other tissues, which can result in lipotoxicity.  Beyond a critical 
threshold, cells begin to exhibit signs of stress, such as disrupted mitochondrial 
function, altered lipid, cytokine and adipokine signalling, hypoxia, production of 
reactive oxygen species (ROS), inflammation and initiation of ER stress resulting 
in apoptosis (Gregor and Hotamisligil, 2007; Hotamisligil, 2010; Cnop et al., 2011).   
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It is becoming apparent that many of these mechanisms are interconnected and 
can influence the function of each other (Hotamisligil, 2010; Cao et al., 2008).  
Metabolism, the immune system, inflammation and ER stress are tightly 
regulated adaptive responses that are absolutely critical to survival, and they are 
dependent on the availability of adequate energy to function properly.  It is 
therefore logical that there is extensive integration and communication between 
these energy-requiring mechanisms.  Equally this also links dysfunctional 
immune responses such as autoinflammation and ER signalling with metabolic 
disease (Hummasti and Hotamisligil, 2012; Wellen and Hotamisligil, 2005; 
Kaufman et al., 2002; Hotamisligil and Erbay, 2008).   
 
1.14 Inflammation and the role of IL-1β 
At the centre of the autoinflammatory response driven by metabolic dysfunction, 
activation of the IL-1β pathway is critical (Böni-Schnetzler et al., 2009; Dinarello 
et al., 2010; Donath et al., 2009; Maedler et al., 2002; Masters et al., 2010; 
Masters et al., 2011).  It has been established that the production and release of 
IL-1β is not only triggered by exogenous infectious danger signals, such as 
bacterial lipopolysaccharide (LPS) or viral ds-RNA, but also by endogenous 
danger signals such as ATP or DNA released from metabolically stressed or 
dying cells (Goldbach-Mansky, 2012).  IL-1β is known as the archetypal 
‘endogenous pyrogen’ (Ehses et al., 2009; Larsen et al., 2007; Sauter et al., 2008) 
and as such, it is highly regulated at all levels of production and secretion.  Pro-
inflammatory cytokine secretion results in the activation of innate immune system 
Toll-like receptors (TLRs) or nucleotide-binding domain (NOD)-like leucine-rich 
repeats (NLRs).  These receptors in turn induce activation of NF-κB and 
subsequent upregulation of pro-IL-1β (Ozkurede and Franchi, 2012).   
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A role for IL-1β in diabetes was first identified when it was established that this 
cytokine was toxic to pancreatic β-cells (Bendtzen et al., 1986).  Although 
pancreatic β-cell loss occurs at a much later stage in T2D than when compared 
with β-cell loss in T1D, there are arguments that link IL-1β involvement with both 
diseases (Dinarello et al., 2010).  Studies have demonstrated that pancreatic islet 
exposure to IL-1β either alone, or in combination with other pro-inflammatory 
cytokines such as IFN-γ or TNF-α, can trigger impaired β-cell function that is 
progressive and may eventually lead to β-cell apoptosis (Eizirik and Mandrup-
Poulsen, 2001).  IL-1β has been shown to activate the c-jun N-terminal kinase 
(JNK) pathway, which constitutes a stress-activated member of the mitogen 
activated protein kinase (MAPK) family of threonine/serine kinases.  These 
participate in stress and apoptotic signalling in many cells, and as such play a 
critical role in cytokine-mediated apoptosis in pancreatic β-cells, as suggested by 
the prevention of apoptosis by inhibition of the JNK pathway (Ammendrup et al., 
2000).  Within the scope of this signalling pathway, both animal and clinical 
studies have demonstrated that inhibition of IL-1β secretion can prevent islet 
inflammation, and in doing so can improve insulin release and glycaemic control.  
This further argues for inflammation as a critical etiological factor in both obesity 
and T2D (Ehses et al., 2009; Larsen et al., 2007; Sauter et al., 2008).   
 
Studies have shown that IL-1β has a closely linked role with glucose metabolism, 
where IL-1β elicits potent effects on decreasing glucose uptake, potentially 
contributing to insulin resistance (del Ray and Besedovsky, 1987; Ling et al., 
1994).  Since these studies, further work has demonstrated that the presence of 
hyperglycaemia, elevated FFAs and human IAPP can induce IL-1β secretion in 
β-cells, consequently launching a proinflammatory cytokine response.  This may 
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initiate metabolic dysregulation which may then impair insulin secretion (Wen et 
al., 2012; Vandanmagsar et al., 2011; Wen et al., 2011; Masters et al., 2012; 
Zhou et al., 2010; Westermark et al., 2011).   
 
1.15 IL-1β and the inflammasome 
The processing of pro-IL-1β to its mature active form of IL-1β is now known to be 
mediated by inflammasome complexes (Fig. 1.7).  Studies have recently provided 
evidence that in addition to inducing IL-1β secretion, factors such as 
hyperglycaemia and IAPP can activate inflammasomes in the pancreatic β-cell 
(Böni-Schnetzler et al., 2009; Dinarello et al., 2009; Donath et al., 2009).  Equally, 
FFAs and ceramides have been demonstrated to activate inflammasomes in 
adipose tissue, further integrating mechanisms that underlie metabolic disease 
with low-grade inflammation (Böni-Schnetzler et al., .2009; Dinarello, 2010; 
Donath et al., 2009; Donath et al., 2010; Maedler et al., 2002; Masters et al., 2010; 
Masters et al., 2011).  There are three distinct steps required for the secretion of 
the mature form of IL-1β.  Firstly, cell activation by TLRs in response to 
exogenous or endogenous danger signals as described previously, leads to the 
transcription of pro-IL-1β.  This is followed by cleavage of pro-IL-1β into the 
biologically active IL-1β form by the caspase-1 complex, a critical step involving 
the inflammasome.  Finally, mature IL-1β is secreted, and the inflammasome is 
thought to also be instrumental in initiating this secretory step (Mankan et al., 
2012).    
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Fig. 1.7 Processing of pro-IL-1β to mature IL-1β 
Secretion of IL-1β is triggered by TLR via activation by exogenous or 
endogenous signals. Transcription of pro-IL-1β is followed by a cleavage step   
involving caspase-1 and other components of the inflammasome complex, 
leading to the biologically active IL-1β form which is then secreted (schematic 
adapted from Protein Lounge, 2012 and Gabay & Palmer, 2010). 
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1.16 The role of adipose tissue in inflammation 
Adipose tissue is known to be a major source of proinflammatory cytokines such 
as IL-1β, IFN-γ and TNF-α under conditions of stress.  Studies have 
demonstrated that obese individuals have higher numbers of infiltrating 
macrophages within their adipose tissue compared to non-obese controls, which 
can trigger inflammatory signalling pathways (Masters et al., 2011; Stienstra et 
al., 2010; Vandanmagsar et al., 2011; Weisberg et al., 2003; Wen et al., 2011).  
Infiltrating macrophages are the primary source of TNF-α in adipose tissue, and 
research has established that this cytokine is secreted at a higher level in obese 
patients than in their lean counterparts (Kern et al., 1995).  TNF-α can promote 
inflammation via an acute local inflammatory response, with the primary aim of 
curtailing infection, which in this capacity is beneficial.  However, if chronic TNF-
α activation occurs as seen in obesity, a detrimental effect on glucose metabolism 
is observed.  The mechanisms by which TNF-α alters glucose metabolism is by 
altering insulin sensitivity through the attenuation of insulin receptor signalling, by 
decreasing the glucose transporter GLUT-4 in adipocytes and by the suppression 
of adiponectin, an important modulator of glucose regulation and fatty acid 
catabolism (Stephens et al., 1997; Wang and Trayhurn, 2006).   
 
1.17 Inflammasome activation by the innate immune system  
In part, activation of the innate immune system is achieved by the recognition of 
highly conserved pathogen-associated molecular patterns (PAMPs), by means 
of a small number of receptors known as pattern-recognition receptors (PRRs) 
(Tannahill and O’Neill, 2011).  There are four major PRR families that can 
independently or co-operatively detect danger signals.  These can be broadly 
characterised into membrane-associated PRRs, namely the TLRs and C-type 
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lectin receptors (CLRs), and cytosolic PRRs comprised of the NLRs and the 
retinoic-acid-inducible protein (RIG)-like receptors (RLRs) (Mankan et al., 2012).   
 
Both TLRs and NLRs have been implicated in initiating downstream signalling 
pathways that can trigger pro-inflammatory responses observed in metabolic 
dysfunction (Tannahill and O’Neill, 2011).  Studies have shown that SFAs can 
induce a TLR4-induced inflammatory response and obesity-associated insulin 
resistance (Shi et al., 2006), and a loss of TLR4 function can partially protect 
against this (Saberi et al., 2009).   
 
Toll-like receptors recognise particular molecular components of viruses, 
bacteria, fungi and parasitic protozoa.  Of the 12 TLR members identified in 
mammals to date, TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are expressed on 
the surface of various immune cells, whereas TLR3, TLR7, TLR8 and TLR9 are 
expressed intracellularly, on compartments such as the ER or endosomes.  Toll-
like receptors are all type 1 transmembrane receptors, characterised by an 
extracellular leucine rich repeat (LRR) domain, and an intracellular Toll-IL1 
receptor-Resistance (TIR) domain.  The TIR domain is essential for adaptor 
molecule recruitment necessary to activate downstream signalling pathways, 
ultimately leading to the transcription of pro-inflammatory cytokines such as IL-
1β and IL-18 (Tannahill and O’Neill, 2011).  The NLRs are activated by a plethora 
of microbial stimuli, such as bacterial RNA, the double-stranded analog poly I:C, 
LPS and microbial peptide.  However, NRLs are also associated with the 
recognition of endogenous microbial danger signals, produced during cellular 
stress or damage, known as danger-associated molecular patterns (DAMPs).  
These include cholesterol, amyloid deposits and FAs (Franchi et al., 2012; 
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Mankan et al., 2012; Tannahill and O’Neill, 2011).  Activation of NLR subsets 
drives the assembly of multimolecular inflammasome complexes, which mobilise 
into a platform allowing activation of proinflammatory caspase-1.  It is noteworthy 
that active caspase 1 has also been shown to be necessary for the production of 
the mature form of IL-1β, further pulling together underlying links between 
inflammation, obesity and T2D.  Six inflammasomes have been identified thus far 
to date: NLRP1, NLRP3, NLRP6, NLRC4, Pyrin and AIM2.  However, of particular 
interest to obesity and T2D is the NLRP3 inflammasome (Tannahill and O’Neill, 
2011; Mankan et al., 2012).   
 
1.18 Nod-like receptors: inflammasome-forming complexes 
The NLRs are the largest group of inflammasome-forming complexes.  In humans, 
these proteins are characterised by three structural domains (Fig. 1.8).  The first 
domain consists of an N-terminal effector domain, which may be a pyrin domain 
(PYD) (belonging to the NLRP family), a caspase recruitment domain (CARD) 
(belonging to the NLRC domain) or a baculovirus inhibitor of apoptosis protein 
repeat (BIR) domain (belonging to the NLRB family) (Ting et al., 2008).  Next 
follows the intermediate NACHT (nucleotide binding and oligomerization domain 
[NOD]) domain, a component critical for NLR activation by oligomerization and 
thereby, formation of the core inflammasome structure.  The final component is 
the C-terminal leucine-rich repeat (LRR) domain, suggested to confer specificity 
and adopt a regulatory role in inflammasome activation.  It is not clear if direct 
ligand interaction occurs, or if intermediary ligands are necessary (Mankan et al., 
2012).   
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Fig. 1.8 Structural components of the NLRP3 inflammasome complex  
The NLRP3 inflammasome is composed of three distinct structural domains: 
an adaptor protein ASC domain composed of a C-terminal caspase 
recruitment domain (CARD) and an N-terminal pyrin (PYD) domain belonging 
to the NLRP family and involved in procaspase-1/caspase-1 interactions; an 
intermediate nucleotide binding and oligomerization domain (NOD) domain 
(NACHT), critical for the formation of the core inflammasome structure, and a 
final C-terminal leucine rich repeat (LRR) domain involved in specificity and 
regulatory processes (schematic adapted from Cole, 2007).   
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1.19 Procaspase-1 in inflammasome activation 
Procaspase-1 activation is a key downstream consequence of inflammasome 
activation.  In the case of the NLRP3 inflammasome, upon activation the 
multimolecular structure is believed to directly recruit pro-caspase 1 via a 
homotypic CARD interaction, or by indirectly recruiting pro-caspase-1 via the 
adaptor protein ASC (apoptosis-associated speck-like protein containing a 
CARD).  ASC has an unusual domain architecture with two death domain 
superfamily domains: an N-terminal pyrin domain (PYD or DAPIN [domain in 
apoptosis and interferon response]) and a C-terminal CARD domain.  Both 
domains are involved in protein-protein complex formation via homotypic PYD-
PYD or CARD-CARD domain interactions (Richards et al., 2001).  The ASC 
CARD domain interacts with procaspase-1, leading to its activation and 
processing, which thereby induces subsequent pro-IL-1β maturation (Srinivasula 
et al., 2002; Wang et al., 2002; Mankan et al., 2012).   
 
1.20 The NLRP3 inflammasome 
NLRP3 has been the most extensively studied inflammasome, and it is unique in 
the fact that it is the only known inflammasome that can be activated by non-
microbial stimuli (Mankan et al., 2012; Franchi et al., 2012).  In contrast to other 
inflammasomes, NLRP3 activation is very tightly regulated to avoid an injurious 
inflammatory response involving an additional regulatory stage at the 
transcriptional level (Bauernfeind et al., 2011; Bauernfeind et al., 2009).  Also 
contrary to the other inflammasomes, NLRP3 is endogenously expressed at low 
levels under resting conditions.  A proinflammatory signal is required to induce 
NLRP3 expression to a high enough level whereby activation is possible.  This 
means that NLRP3 activation requires two distinct steps: firstly, a commonly 
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called ‘priming signal’, where the level of NLRP3 expression is amplified, followed 
by a second ‘activation signal’ which promotes construction of the multiprotein 
inflammasome complex (Mankan et al., 2012).  Endogenous cytokines such as 
IL-1β are sufficient to provide ‘signal 1’ activation of the NLRP3 inflammasome, 
whereas ‘signal 2’ can be in the form of both microbial or non-microbial stimuli 
(Fig. 1.9) (Harder et al., 2009; Muňoz-Planillo et al., 2009).  To date, a vast array 
of NLRP3 ‘signal 2’ activators have been identified, and it is suggested that this 
high promiscuity is likely because NLRP3 activation represents a universally 
broad response mechanism to disturbances in cell integrity.  Despite extensive 
studies, no common upstream molecules have yet been identified which could 
shed light on this extremely adaptable sensing by the NLRP3 inflammasome 
(Mankan et al., 2012).   
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Fig. 1.9 Proposed model of NLRP3 inflammasome involvement in IL-1β 
activation.  
There are three steps required for the secretion of mature IL-1β. A two-
pronged initiation step by exogenous or endogenous pathogen-associated or 
danger-associated signals, is suggested to activate the innate immune system 
via NOD-like or Toll-like receptors. This triggers the initiation of pro-
inflammatory TF such as NF-κB which drives transcription of pro-IL-1β. 
Cleavage of pro-IL-1β into mature IL-1β is mediated via caspase-1, which is 
cleaved into its mature form by the NLRP3 inflammasome (schematic adapted 
from Cole, 2007).   
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1.21 Proposed mechanisms of NLRP3 activation 
Currently, there are three possible mechanisms to explain NLRP3 inflammasome 
activation: lysosomal breakdown and release of phagocytosed matter; increased 
ROS production in mitochondrial membranes, and potassium flux by membrane 
channels.  It is possible that these processes act in concert, or they may be 
sequentially involved in activatory mechanisms (Mankan et al., 2012).   
 
1.21.1 Lysosomal breakdown and phagocytosis 
During macrophage phagocytosis, initiation of numerous enzymatic cascades 
takes place to allow the safe degradation of exogenous material within the 
lysosomal compartments.  However, failure of the proper phagocytic mechanism 
can lead to lysosomal membrane breakdown.  This can result in the leakage of 
lysosomal contents into the cytoplasm, triggering activation of the NLRP3 
inflammasome.  It has been shown that inhibition of lysosomal enzymes, in 
particular cathepsin B, prevented lysosomal rupture and NLRP3 inflammasome 
activation (Hornung et al., 2008; Halle et al., 2008).  However, the addition of a 
chemical compound that can disrupt lysosomes and thereby the process of 
phagocytosis did not impede inflammasome activation.  This suggests that 
phagocytosis per se is not required to initiate the inflammasome.  Additionally, 
known activators of the NLRP3 inflammasome were not blocked by cathepsin B 
inhibitors or other lysosomal inhibitors (for example, Bafilomycin A), suggesting 
this upstream pathway is independent from NLRP3 activation.  Furthermore, 
cathepsin B deficiency appeared to only partially affect NLRP3 activation in 
response to uptake of phagocytic material.  This suggests that there may be a 
level of redundancy in upstream mechanisms of NLRP3 activation (Banerjee and 
Saxena, 2012; Halle et al., 2008).   
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1.21.2 ROS and TXNIP  
A link between ROS production and procaspase-1 activation via NLRP3-linked 
activation has been suggested.  Macrophages treated with ATP display elevated 
ROS production and this initiated phosphatidylinositol 3-kinase (PI3K) activation, 
in turn triggering procaspase-1 activation and IL-1β production (Cruz et al., 2007).  
More recently, TXNIP (thioredoxin (TRX)-interacting protein), a protein involved 
in the anti-oxidant function of thioredoxin, has been shown to interact directly with 
NLRP3 in a ROS-sensitive manner (Zhou et al., 2010).  TXNIP is the single most 
highly upregulated transcript under hyperglycaemic conditions in human 
pancreatic islets (Shalev et al., 2002).  The potential for TXNIP being a direct 
ligand for the NLRP3 inflammasome suggests a mechanism whereby 
hyperglycaemia may activate the inflammasome, leading to increased IL-1β 
levels as observed in T2D.  Elevated ROS levels cause a conformational 
alteration in TXNIP, thereby triggering its dissociation from thioredoxin and 
subsequent association with NLRP3.   
 
The ROS model has been lately refined however, after studies demonstrated that 
mitochondria, not phagosomes, were the primary source of ROS production 
during inflammasome activation.  This corresponds with studies that have 
observed mitochondrial dysfunction in β-cells during T2D (Lowell and Shulman, 
2005; Miani et al., 2012; Popov, 2012).  ROS inhibitors potently block 
proinflammatory gene expression, including the NLRP3 inflammasome (Martin et 
al., 2012).  Although NLRP3 is a unique requirement for inflammasome priming 
(Bauernfiend et al., 2011), the specific blocking activity of ROS inhibitors does 
not automatically exclude a role for ROS in NLRP3 activation.  It may suggest 
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that ROS mechanisms act upstream of NLRP3 activation, rather than ROS 
themselves causing direct activation (Yang et al., 2012; Petrilli et al., 2007).   
 
1.21.3 Potassium flux 
Extracellular concentrations of ATP may be considered as both endogenous and 
exogenous danger signals, and may occur due to cellular damage (Paustian et 
al., 2013).  High extracelluar ATP concentrations are a potent trigger for IL-1β 
processing and release.  ATP-triggered activation involves cytosolic potassium 
efflux, and the purinergic receptors P2X7 are critical for this activation step (Wahli 
and Michalik, 2012).  P2X7 receptor activation causes recruitment of the 
hemichannel protein Pannexin-1, and this has been suggested to cause the 
formation of large, non-selective pores which allow the passage of signalling 
molecules into the cytosol (Miani et al., 2012; Saberi et al., 2009; Shi et al., 2006).  
However, recent studies suggest that the main role for Pannexin-1 is to release 
ATP from dying cells.  Inhibiting NLRP3 activation can typically be achieved by 
increasing the extracellular potassium concentration which effectively blocks K+ 
efflux, however, other inflammasomes can also be affected by this mechanism, 
raising the question of specificity (Arlehamn et al., 2012).  Furthermore, these 
experiments did not address whether potassium efflux was sufficient, or required 
amongst additional events for NLRP3 inflammasome activation.   
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1.22 Pancreatic β-cell models used in Diabetes Mellitus 
research  
There may well be a place for animal models but the 3 R’s of animal testing: 
reduction, refinement and replacement, essentially mean that the use of in vitro 
cell models are a preferable replacement to animal models in diabetes research 
where-ever possible.  Cell models are more readily available than animal models 
with far less legal regulation.  As such, they represent a convenient option for 
studying physiological and pathophysiological processes, and are useful in the 
development of novel pharmacological targets.  Cell lines are cheaper and easier 
to work with, and they provide the opportunity to acquire faster results that can 
often be more consistent and reproducible than working with animals due to their 
natural variability (Skelin et al., 2010).   
 
Over the last few decades, a variety of pancreatic β-cell lines have been 
established as possible models in which to investigate pancreatic β-cell function.  
Many have been rodent cell lines, which have provided a valuable insight into 
functional and molecular studies of rodent islets (Table1.2) (Asfari et al., 1992; 
Gazdar et al., 1980; Santerre et al., 1981; McClenaghan et al., 1996; Efrat et al., 
1988; Miyazaki et al., 1990).   
 
However, despite the usefulness of rodent cell models, there are of course many 
differences between rodent and human pancreatic β-cells.  Any key findings in 
rodent cell lines would still need to be confirmed in primary islets and as these 
have limited availability, much effort has been put into trying to develop human 
pancreatic β-cell lines from human pancreatic sources (Hohmeier and Newgard, 
2004).  These sources have included adult islets, foetal pancreases or 
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insulinomas.  Unfortunately, functional problems with these sources have 
included low insulin secretion, or cells only capable of secreting insulin over a few 
passages.  In the case of adult pancreatic β-cells, supplementation with factors 
to maintain and promote growth also induces their dedifferentiation (Dufayet de 
la Tour et al., 2001; Demeterco et al., 2002; Gueli et al., 1987; Levine et al., 1995; 
Beattie et al., 1999; Russ et al., 2008).   
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Limitations of in vitro cell lines include their ability to grow indefinitely leading to 
dedifferentiation over continuous passage.  Specifically for pancreatic β-cells, this 
often results in loss of insulin synthesis and secretory capacity, likely related to 
their tumoural origin.  Cells may have an abnormal chromosome number and/or 
additional gene mutations that could affect normal protein expression and 
metabolism (Ulrich et al., 2002).  Disruption of cell-cell interactions during 
treatment and passage may well influence typical cell function, and genetic 
manipulation of cells likely alters functional responses.  These points may explain 
why many pancreatic β-cells lines have aberrant secretory responses and do not 
respond to glucose within normal physiological range (Skelin et al., 2010).   
 
An ideal cell model for studying β-cells should have all the characteristics of adult 
pancreatic β-cells.  These features should include high insulin content and the 
ability to control insulin gene expression, processing and secretion, in response 
to typical physiological stimuli (Newgard and McGarry et al., 1995).  Additionally, 
the correct expression of the glucose transporter GLUT-1 and the glucose 
phosphorylating enzyme glucokinase is also essential (Zawalich and Zawalich, 
1996).  Studies have demonstrated that human pancreatic β-cells predominantly 
express GLUT-1.  However, rodent pancreatic β-cells predominantly express 
GLUT-2, suggesting that GLUT-2 is unlikely to be the primary glucose transporter 
in human pancreatic β-cells (De Vos et al., 1995; McCulloch et al., 2011).   
 
In 2011, a paper announced the creation of a new human pancreatic β-cell line, 
denoted as 1.1B4.  The cells were created by electrofusion of human pancreatic 
epithelial carcinoma cells (PANC-1) with cultured human islets on a 1:1 ratio, 
resulting in a hybrid that retains characteristics of both cell lines.  Colonies were 
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screened for insulin-positive hybrid cells, and the highest insulin-secreting clones 
were selected and re-cultured.  A final selection of 3 clones with the highest 
insulin output were selected and the 1.1B4 cells were one of these clones 
(McCluskey et al., 2011).  These human pancreatic β-cells underwent basic 
studies for characterisation of enzyme production and secretory capacity, and 
provide a novel resource for additional functional and characterisation studies.  
These cells have been employed to investigate the in vitro responses to FA within 
the scope of this thesis.   
 
1.23 Summary 
The pathogenesis of T2D is complicated.  Many risk factors, cellular mechanisms 
and signalling pathways have been implicated in the progression of the disease 
that ultimately drives loss of β-cell viability and leads to overt diabetes.  Fatty 
acids have differential effects on β-cells, and these are dependent on the carbon 
chain length, degree of saturation and configuration of species.  The variable 
responses observed in pancreatic β-cells during chronic exposure to different FA 
species suggests that they exert their effects by different mechanisms.  Chronic 
β-cell exposure to LC-SFA leads to a loss of viability due to cytotoxic effects, 
whereas MUFA species are either well-tolerated, can attenuate the cytotoxic 
effects of LC-SFA during co-incubation, or promote viability in response to other 
toxic stimuli such as pro-inflammatory cytokines or nutrient deprivation.  The 
mechanisms underlying these toxic or protective mechanisms are not well 
understood.  Recent evidence has linked PKR with nutrient- and pathogen-
sensing pathways, suggesting that responses within the innate immune system 
can trigger metabolic dysfunction such as ER stress and chronic inflammation.  
These mechanisms are now being regarded as hallmarks of obesity and T2D.  
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The NLRP3 inflammasome is critical to this chronic inflammatory state, and as 
such, represents a common pathway linking autoinflammation within the 
pathogenesis of metabolic dysfunction.  Current knowledge regarding direct or 
indirect ligand activation of NLRP3, modes of activation, or the role of upstream 
components and modulators are still unclear.  Further studies investigating 
specific activatory and inflammasome assembly mechanisms may allow 
therapeutic targeting of components with clinical benefit to patients with T2D.  A 
range of pancreatic β-cell lines have been established over the past few decades 
as models to investigate β-cell function.  While providing useful information 
regarding rodent islet biology, ultimately these cell lines do not compensate for a 
human pancreatic β-cell line with characteristics and responses of functional 
adult pancreatic β-cells.  Therefore, the availability of any new human pancreatic 
β-cell provides a novel resource with which to undertake further functional and 
characterisation studies, to assess the suitability of the cell line for in vitro 
experiments.   
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1.24 Aims of study 
1.  To investigate the role of PKR in mediating proapoptotic effects in 
response to LC-SFAs, by manipulating the activity or expression of PKR 
in pancreatic β-cells using a putative PKR inhibitor Compound-16, and by 
generating a stable rodent β-cell line expressing shRNA against PKR. 
2.  To investigate and characterise the functional responses of a new human 
β-cell line, to assess their suitability for the in vitro study of lipotoxicity.  
3.  To investigate the role of inflammatory mediators through studying the 
effects of activatory stimuli, upstream mediators and pro-inflammatory 
cytokine involvement in rodent β-cell lines, including a β-cell line that 
conditionally over-expresses TXNIP.   
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Chapter 2 Materials and Methods 
2.1 Chemicals and reagents 
All chemicals and reagents were purchased from Sigma (Dorset, UK), unless 
otherwise specified.   
 
Cell culture materials used such as Roswell Park Memorial Institute (RPMI)-1640 
culture medium, Dulbecco's Modified Eagle's Medium (DMEM) culture medium, 
L-glutamine, penicillin/streptomycin, phosphate buffered saline (PBS) and 
trypsin-EDTA (ethylenediaminetetraacetic acid) were purchased from Invitrogen 
(Loughborough, UK).  Fetal bovine serum (FBS) and hygromycin were purchased 
from PAA Laboratories (Yeovil, UK).   
 
All FAs and methyl-FA were purchased from Sigma, except palmitoleate which 
was purchased from MP Biomedicals (Cambridge, UK) along with FA-free BSA.  
Table 2.1 shows a complete list of the composition of buffers and solutions used.  
Table 2.2 provides a complete list of primary and secondary antibodies used, 
along with dilutions and details of purchase origin.   
 
Pre-cast polyacrylamide Bis-Tris-HCl gels (4-12% depending on protocol), MOPS 
running buffer and LDS loading buffer used for electrophoresis were purchased 
from Invitrogen.  Polyvinylidene fluoride (PVDF) membrane was purchased from 
BioRad, while hyperfilm ECL and the developing system for horseradish 
peroxidise-labelled proteins were obtained from Amersham (via Invitrogen).  DNA 
and protein ladders for electrophoresis, Western blot and PCR were purchased 
from Fermentas (Thermo Fisher Scientific, Loughborough, UK).   
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2.2 Cell culture conditions 
The hybrid rat pancreatic β-cell line BRIN-BD11 was derived by the electrofusion 
of an immortal rat insulinoma cell line, RINm5F, with a primary culture of New 
England Deaconess Hospital rat pancreatic islet cells (McClenaghan et al., 
1996).  The 2-mercaptoethanol-dependent INS-1 rat β-cell line was created by 
isolation of β-cells from irradiated rat insulinoma (Asfari et al., 1992).  The mouse 
insulinoma β-cell line MIN6 was derived from tumours arising in transgenic mice 
expressing the SV40 T antigen, under control of the insulin promoter (Miyazaki 
et al., 1990).  The human pancreatic β-cell line 1.1B4 was derived by 
electrofusion of a primary culture of human pancreatic islet cells with the human 
pancreatic carcinoma, epithelial-like cell line PANC-1, and hybrid cells were 
screened for insulin positivity (McCluskey et al., 2011).  Conditional over-
expression of thioredoxin-interacting protein (TXNIP) was achieved by the stable 
transfection of parental INS-1 cells with a TXNIP transgene under the control of 
a tetracycline- (TET) inducible promoter, creating INS-TXNIP cells, along with 
their control INS-EV (empty vector) cells (Kansikas, 2012).  The PKR knock-down 
clones BRIN-333 and BRIN-335, and their control BRIN-SV (scrambled vector) 
cells were created by stable transfection of parental rat BRIN-BD11 and INS-1 β-
cells expressing a rat Origene shRNA ready-cloned retroviral vector against PKR 
(as described in detail in Sections 2.6.2 – 2.6.6).   
 
The BRIN-BD11 and 1.1B4 β-cell lines were cultured in RPMI-1640 medium 
containing 11 mM glucose, and supplemented with 10% FBS, 2 mM L-glutamine, 
100 U/ml penicillin and 100 mg/ml streptomycin.  The INS-1 β-cell line was 
cultured in the same culture medium as BRIN-BD11 cells supplemented with 50 
μM 2-mercaptoethanol.  The MIN6 β-cell line was cultured in DMEM medium, 
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supplemented with 15% FBS, 25 mM glucose, 100 U/ml penicillin, 100 mg/ml 
streptomycin and 50 μM 2-mercaptoethanol.  The INS-TXNIP/INS-EV cells were 
cultured in RPMI-1640 medium containing 11 mM glucose, supplemented with 
10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 50 μM 
2-mercaptoethanol and 150 μg/ml hygromycin B.  The BRIN-BD11 PKR KD 
clones BRIN-333, BRIN-335 and BRIN-SV were cultured in RPMI-1640 medium 
containing 11 mM glucose, supplemented with 10% FBS, 2 mM L-glutamine, 100 
U/ml penicillin and 100 mg/ml streptomycin and 1 mg/ml puromycin.   
 
All cells were grown in 75 cm2 flasks at 37 ºC and with 5% CO2 at 100% humidity 
and were used in experiments when approximately 80% confluent; all 
experiments were performed on cells below passage number 35.   
 
2.2.1 Passaging of cells 
All cell lines were sub-cultured when they had reached approximately 80% 
confluence.  Cells were briefly washed in PBS pre-warmed to 37 ˚C, followed by 
a 5 min incubation period at 37 ˚C with 2 ml/75 cm2 flask of 0.05% Trypsin-0.53 
mM EDTA to assist in the disruption of the adherent cell monolayers from the 
cell-culture flask.  Trypsin-EDTA action was de-activated by the addition of 10 ml 
of appropriate complete culture medium (containing 10% FBS).  Cells were 
centrifuged at 300 g for 5 min, then approximately one tenth to one twentieth of 
the original growing population (depending on cell line and growth rate) were re-
seeded into fresh 75 cm2 cell culture flasks to maintain a stock cell line.   
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2.3 Treatment of cells with fatty acids 
Fifty millimolar stock solutions of laurate (C12:0), myristate (C14:0), palmitate and 
methyl-palmitate (C16:0), stearate and methyl-stearate (C18:0) were prepared in 
50% ethanol by heating to 70 ºC.  Ninety millimolar stock solutions of myristoleate 
(C14:1), palmitoleate and methyl-palmitoleate (C16:1), oleate and methyl-oleate 
(C18:1) were prepared in 90% ethanol at room temperature (RT).  These FA 
preparations were bound to 10% FA-free BSA by incubation for 1 h at 37 ºC and 
then added to RPMI-1640 medium (containing 11 mM glucose) deprived of FBS, 
making the final concentrations present in the cell environment 1% for BSA and 
0.5% for ethanol.  All incubations with FA were performed using serum free 
conditions, as FBS contains FA that could potentially alter final treatment 
concentrations.  Cells were seeded into 6, 12 or 24-well plates at densities of 0.5 
× 105 cells/ml and cultured overnight in complete RPMI-1640 medium.  The 
medium was then removed and replaced with relevant FA/BSA complexes in 
RPMI-1640 medium devoid of FBS for various times.  Control groups received 
BSA and vehicle only.   
 
2.4 Viability assays 
2.4.1    Vital dye staining 
Trypan blue is a vital dye commonly used to determine the viability of living cells 
without killing them.  Live cells have intact plasma membranes and can 
selectively extrude certain stains, whereas dead cells retain the dye and are 
selectively stained when viewed under a light microscope.  This dye exclusion 
test was used to estimate the number of viable cells present in each sample.  
Following incubation with appropriate treatments, the culture medium containing 
any potential floating cells was removed and collected, and then attached cells 
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were harvested after a 5 min incubation with trypsin-EDTA (as previously 
described in Section 2.2.1).  Floating and attached cells were then centrifuged at 
300 g for 5 min and re-suspended in 200 μl complete RPMI-1640 and 200 μl 
Trypan blue (0.4% in PBS) and incubated at room temperature (RT) for 10 min.  
Both viable and dead cells were counted using a haemocytometer and the 
proportion of dead cells was expressed as a percentage of the total for each 
treatment group.   
 
2.4.2 Flow cytometry using propidium iodide staining 
Flow cytometry is a fast, accurate and reproducible method that uses the principle 
of light excitation, emission and scattering of fluorochrome molecules from a 
focused light source (typically a laser), to measure different cellular properties 
such as size, granularity and fluorochrome binding from hydro-dynamically 
focused cells in suspension.  Propidium iodide (PI) is a compound that 
intercalates with the DNA/RNA of cells: PI can only penetrate cells when their 
membrane integrity has been compromised, such as during apoptosis or necrosis.  
As such, PI is commonly used to identify non-viable cells within a cell population 
using flow cytometry.  Following incubation with relevant agents, floating and 
attached cells were trypsinised and collected as described in Section 2.4.1. After 
the centrifugation step, cells were re-suspended and stained using 200 μl of 1 
mg/ml PI and appropriate complete culture medium solution. Cells were 
incubated for 10 min at 4 ˚C and then samples were analysed using a BD 
Biosciences Accuri C6 Flow Cytometer, running the CF-30 CFlow Sample 
Analysis software.   
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Gating of cells was initially applied to untreated PI-stained cells (considered to be 
a negative control treatment group) which encompassed all cell populations, as 
shown by the red gating shown in the density plot in Figure. 2.1.  The forward 
scatter axis (FSC-A) is able to differentiate cells on the basis of their physical 
properties such as size, while the side scatter axis (SCC-A) differentiates cells on 
the basis of their internal granularity (Brown and Wittwer, 2000).   
 
 
 
  
Fig. 2.1 Density plot representing typical gating applied to an 
untreated cell population  
Initial gating of cells was applied to the entire cell population of untreated 
PI-stained cells (considered to be a negative control treatment group), as 
depicted by the red gating. The forward scatter axis (FSC-A) differentiates 
cells on the basis of their size, while the side scatter axis (SCC-A) 
differentiates cells on the basis of their internal granularity.  
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Three typical cell populations were identified when using PI staining in the 
different cell models used.  Figure 2.2 represents a typical scatterplot obtained 
from cells treated with palmitate, showing three distinct cell populations: a healthy 
cell population, a dead PI positive cell population, and a third population which 
were reduced size but not PI positive.  Preliminary experiments on the Accuri C6 
Flow Cytometer have shown that this third cell population were Annexin V positive 
cells.  The Annexin V protein binds to phosphatidylserine (PS) which is typically 
found predominantly in the inner leaflet of the plasma membrane (PM) when cells 
are viable.  However, once apoptosis is triggered, PS is translocated to the 
external face of the PM (to allow targeting of cells for phagocytosis), and the PS 
can be detected using fluorescently labelled Annexin V, marking these cells as 
early apoptotic (Zhang et al., 1997).   
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Fig. 2.2 Scatter plot representing cell death quantification using flow 
cytometry  
Cell death was induced by the addition of treatments (e.g. palmitate), and cells 
were stained with PI to assess viability. The figure represents a typical scatter-
plot obtained from treated cells, showing three distinct cell populations: a 
healthy cell population labelled ‘viable cells’ (bottom right quadrant), a dead 
population labelled ‘PI positive cells’ (upper left quadrant), and a third 
population labelled ‘Reduced size but not PI positive’ (bottom left quadrant). 
This third cell population has been previously analysed in the laboratory and 
found to be Annexin V positive, which is indicative of early apoptosis. For the 
purposes of assessing cell viability, only cells within the healthy population 
were counted; PI-positive and Annexin V positive cells were excluded from the 
viable cell count. 
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2.5 Detection of protein expression by Western blotting 
2.5.1 Whole cell protein isolation 
Cells were seeded at 1 × 105 cell/25 cm2 tissue culture flask at 37 ºC and with 5% 
CO2 and subsequently incubated for varying times depending on the treatment 
used.  Following treatment, cells were washed twice in ice cold PBS, then lysed 
using 200 μl of lysis buffer (Table 2.1) per 25 cm2 flask.  Flasks were kept on ice 
and bathed periodically with lysis buffer for 20 min.  The flasks were thoroughly 
scraped and their contents transferred to microcentrifuge tubes.  Each tube was 
vortexed 6 times for 5 s and incubated on ice between each vortex step, then 
lysates were clarified by centrifugation at 10000 g for 10 min at 4 ºC using a pre-
cooled refrigerated centrifuge (ALC, PK121R).  The supernatants were retained 
for Western blotting by transfer to new microcentrifuge tubes and these were 
stored at -80 ºC.   
 
2.5.2 Estimation of protein concentration 
Protein within cell lysates were estimated using the bicinchoninic acid (BCA) 
protein assay (Thermo Fisher Scientific, Northumberland).  The protein of interest 
reduces Cu2+ to Cu+ via the interaction of the peptide bonds present in the protein 
sample, leading to the concentration dependent development of a purple-
coloured product with a peak absorbance at 562 nm.  The concentration of 
reduced Cu2+ is proportional to the protein concentration present in the sample 
(Smith et al., 1985).  Using a 96 well plate, a range of BSA standards (0-1400 
μg/ml) were prepared, in parallel with 10 μl of each sample dilution in duplicate.  
Reagents A and B (Table 2.1) were mixed in proportions 1:49 and 200 μl of the 
final BCA solution was added to each standard and each protein sample.  These 
were incubated at RT for 15 min and the absorbance was measured at 562 nm 
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using a microplate reader (Tecan GENios).  The protein concentration of test 
samples was estimated by comparing their absorbance to that of the known 
standard concentrations (Fig. 2.3)   
 
 
 
 
 
  
Fig. 2.3 Representative standard curve for calculating protein concentration 
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2.5.3 Electrophoresis and protein transfer 
Gel electrophoresis is a widely used technique that enables the separation of 
individual proteins within a tissue or cell sample homogenate according to 
polypeptide length after denaturation.  The proteins can then be transferred to a 
membrane and the addition of specific antibodies (Ab) identify the proteins of 
interest by Western blotting.  This method allows the determination of the 
molecular weight of a target protein, but can also be used semi-quantitatively to 
determine amounts of target protein(s) present in different samples.  The 
concentration of protein in each lysate was estimated using the BCA protocol as 
detailed in Section 2.5.2., and lysates were standardised to a protein 
concentration of 10-50 μg/19.5 μl loading volume by dilution with lysis buffer, 
depending on the affinity of each antibody used.  Samples were then mixed with 
7.5 μl of 4X LDS sample buffer (Invitrogen) and 3 μl of 2-mercaptoethanol (Sigma) 
and heated to 70 ºC for 10 min.  Ten microlitres of Spectra multicolour broad 
range protein molecular weight marker (Fermentas, York) was loaded into the 
first well of each pre-cast Bis-Tris-HCl gel to monitor protein separation, then 20 
μl of each sample was loaded into each subsequent well of the gel.  The gel was 
developed using MOPS SDS running buffer (Invitrogen) at 200 V using a Bio-
RAD Power Pac 3000 unit for approximately 1 h, or until the molecular weight 
protein marker ladder had reached the bottom of the gel.   
 
A piece of pre-cut PVDF membrane was briefly soaked in 100% methanol 
(Rathburn, Walkerburn), washed three times in dH2O and soaked in transfer 
buffer (Table 2.1) until use.  Two pieces of blotting paper were soaked in transfer 
buffer and placed onto the BioRad wet Trans-Blot Cell transfer tank buffer pad, 
black cassette-side down.  A sandwich was made by placing the pre-cast gel on 
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top of the blotting paper, followed by the PVDF membrane and another two 
pieces of soaked blotting paper.  All air bubbles were removed then the cassette 
was closed and returned to the transfer tank.  The cell was topped up with transfer 
buffer and connected to a Bio-Rad PowerPac HC Power Supply unit; transfer of 
proteins from the gel to the PVDF membrane was conducted at 150 mA and 80 
V overnight.   
 
2.5.4 Probing with antibodies 
Membranes were blocked for 1 h at RT on a roller, in 5% FA-free milk (Sigma) 
dissolved in TBS (Table 2.1), supplemented with 0.05% Tween® 20 to prevent 
non-specific binding of Ab to the membrane.  Membranes were probed with 
primary antibodies in 3 ml TTBS (refer to Table 2.2 for individual dilutions and 
where Abs were purchased from) with 30 μl goat serum and were incubated 
overnight at 4 ºC on a roller.  The following morning the membranes were washed 
three times in TTBS for 30 min.  Appropriate secondary antibodies (Table 2.2) 
were diluted in TTBS containing 2.5% FA-free milk and incubated for 2 h at RT, 
then washed as previously described.  HRP-conjugated proteins were detected 
using the enhanced chemiluminescence (ECL) Plus (Amersham) substrate 
system.  Briefly, reagent B was mixed with reagent A in a 1: 40 ratio and left to 
act on the membrane for 5 min at RT.  Alkaline phosphatase-conjugated proteins 
were incubated with 1 ml of CDP-Star chemiluminescent substrate solution for 5 
min at RT.  Excess liquid was drained, then the membrane was wrapped in Saran 
Wrap and exposed to X-ray film (Healthcare ECL): exposure time was dependent 
on the Ab affinity and the protein load.  The X-ray film was developed using a 
Xograph Imaging System Compact X4 Automatic X-ray film Processor 
(Gloucestershire, UK).  Membranes were stripped with stripping buffer (Table 2.1) 
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for 10 min at RT on a roller, washed 3× for 5 min at RT in TTBS and then re-
probed for loading controls using a an anti-β-actin Ab.   
 
2.6 RNAi 
RNA interference (RNAi) is a conserved biological process whereby cells control 
target gene expression at both a transcriptional and translational level.  The RNAi 
pathway is triggered by short non-coding dsRNA molecules known as micro RNA 
(miRNA), short interfering RNA (siRNA) or short hairpin RNA (shRNA), which 
initiate the sequence-specific degradation of a target RNA within the cell, leading 
to inhibition or knock-down of target gene expression.  This technique can provide 
a convenient mechanism to investigate the effects of a specific gene using both 
in vitro and in vivo models, and as such can be used to determine key functional 
pathways in disease states.  The use of RNAi technology can lead to transient or 
stable knock-down of target genes, depending on the vector used (Leung & 
Whittaker, 2005).   
 
2.6.1 PKR inhibition by adenoviral mutant PKR (Ad-Δ6PKR) 
A dominant negative adenoviral PKR mutant, Ad-Δ6PKR, was kindly provided by 
Abujiang Pataer.  Ad-Δ6PKR is a binary adenoviral vector system which contains 
two adenoviral vectors, often utilised to prevent toxicity that may occur in the 
packaging cell line (Pataer et al., 2009).  Vectors with a dominant negative 
mutation are typically catalytically inactive, but express a dominant phenotype: 
this presents a useful method by which to investigate the effects of transient 
inhibition of PKR expression in selected cell lines.  In vitro expression of the 
Δ6PKR gene product was induced by the co-administration of Ad/GT-Δ6PKR 
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(3000 vp/cell) and Ad/GV16 (1500 vp/cell).  Ad-luc (3000 vp/cell) was used as a 
control vector.   
 
BRIN-BD11 cells were seeded into 25 cm2 flasks at 1 × 105 cells/flask, in 5 ml of 
complete culture medium and left to grow for 18 h.  Cells were transfected via co-
administration of Ad/GT-Δ6PKR (0.5-4 μl/25 cm2 flask) and Ad/GV16 (0.25-2 
μl/25 cm2 flask) or with appropriate Ad-luc control treatments (0.5-4 μl/25 cm2 
flask) using complete culture medium.  Cells were cultured for 16 h, the culture 
medium was aspirated then cells were treated with FA (as detailed in Section 2.3).  
Protein was extracted from all treatment groups and used in Western blots.   
 
2.6.2 PERK inhibition by adenoviral mutant PERK (Ad-PerkΔC) 
Using the same principles as outlined above in Section 2.6.1, a PERK dominant 
negative adenoviral mutant (Ad-PERKΔC) kindly provided by Terry Herbert was 
used to investigate the effects of transient inhibition of PERK expression in the 
BRIN-BD11 cell line (Gomez et al., 2004).  BRIN-BD11 cells were seeded into 25 
cm2 flasks at 1 × 105 cells/flask, in 5 ml of complete culture medium and left to 
grow for 18 h.  Cells were transfected via co-administration of Ad/GT-Δ6PKR (0.5 
μl - 4 μl/25 cm2 flask) and Ad/GV16 (0.25 μl-2 μl/25 cm2 flask), and/or Ad-
PERKΔC (0.5 μl-4 μl/25 cm2 flask) or with appropriate control treatments (0.5 μl 
-4 μl/25 cm2 flask) using complete culture medium and cultured for 16 h, before 
aspirating the culture medium and treating with FA (as detailed in Section 2.3).  
Protein was extracted from all treatment groups and used in Western blots.  
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2.6.3 PKR knockdown using shRNA 
Using a different strategy, a commercially available rat shRNA ready-cloned 
retroviral vector (Origene) with four constructs targeted against multiple splice 
variants of PKR (Table 2.3) was used according to the manufacturer’s instruction, 
to transfect both BRIN-BD11 and INS-1 cells creating stable PKR knock-down 
cell lines.  A scrambled shRNA vector was used as a control. Kanamycin 
resistance was used as an initial plasmid selection marker, followed by puromycin 
resistance as a marker of cell transfection.   
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2.6.4 Transformation and plasmid purification using shRNA 
For successful transfection of target cell lines, the shRNA plasmids were 
transformed into competent bacterial cells, which have the ability to take up 
extracellular DNA.  Briefly, this was achieved by mixing 100 ng/μl of each plasmid 
DNA with 65 μl of competent NEB 5- E. coli (109 cfu/μg, New England Biolabs, 
Herts), and incubation on ice for 10 min.  The cells were then heat shocked for 
30 s at 42 °C and incubated again on ice for 5 min.  Super Optimal broth with 
Catabolite repression (SOC) growth medium (950 μl) (NEB) was added to each 
plasmid/bacteria suspension, and these were then incubated on a shaker at 250 
RPM for 1 h at 37 °C.  From each culture, 25 μl was streaked over one half of 
pre-warmed, pre-made kanamycin-(25 μg/ml) containing liquid broth agar plates 
(35 g/l).  The remaining suspensions were centrifuged for 2 min at 1000 g, then 
~ 800 μl of the supernatant was aspirated and the pellet resuspended in the 
remaining volume.  Twenty-five microlitres of this culture was used to streak the 
remaining half of each agar plate, and these were incubated overnight at 37 °C.  
From these initial plates, a single colony was selected for each plasmid using a 
sterile inoculation loop, and streaked onto a second kanamycin-containing agar 
plate (as detailed previously), which was incubated overnight at 37 °C.  A sterile 
inoculation loop was used to select a single colony from each plate, and used to 
inoculate 5 ml LB broth (20 g/l) containing kanamycin (25 μg/ml).  Each culture 
was incubated in a shaker at 250 RPM and 37 °C for 8 h, and then used to 
inoculate a further 250 ml LB broth containing kanamycin, and incubated in a 
shaker at 250 RPM and 37 °C for 18 h.  Plasmid extraction was conducted when 
the E. coli were in log-phase growth, using a plasmid maxi prep kit (Qiagen), 
according to the manufacturer’s instructions.   
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2.6.5 Quantification of plasmid DNA 
The DNA from each plasmid was quantified by measuring the absorbance at 260 
nm using an Eppendorf Biophotometer spectrophotometer.  DNA concentration 
was calculated by assuming that an absorbance of 1 at 260 nm corresponds to 
50 μg of DNA/ml (Barbas et al., 2007).   
 
2.6.6 DNA preparation for transfection 
The DNA from each plasmid was precipitated using 0.7 volume of isopropanol, 
mixed by inversion and immediately centrifuged at 2000 g for 30 min at 4°C.  The 
resulting pellet was washed by centrifugation using room temperature 70% 
ethanol, at 2000 g for 10 min.  The pellet was then air-dried and resuspended in 
250 μl TE buffer (Table 2.1).   
 
2.6.7 Generation of stable cell lines expressing shRNA against 
PKR 
BRIN-BD11 and INS-1 cells were seeded into 6 well plates at 3 × 105 cells/well, 
in 2 ml of complete culture medium and left to grow for 18 h.  Cells were 
transfected using 1 μg of each plasmid DNA, diluted with 3 μl of TransFast™ 
transfection reagent per well, and mixed with serum free culture medium which 
was vortexed and incubated at RT for 15 min before use.  The transfection 
mixture was added to the cells at 1 ml/well, then incubated for 1 h at 37 °C.  After 
1 h, an additional 1 ml of complete culture medium with 20% FBS was added to 
each well and the cells were cultured for a further 24 h.   
 
TransFast™ transfection reagent is a liposome reagent used to deliver nucleic 
acids into eukaryotic cells by the process of transfection.  TransFast™ is made 
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from a synthetic cationic lipid (+)-N,N [bis (2-hydroxyethyl)-N-methyl-N-[2,3-
di(tetradecanoyloxy)propyl] ammonium iodide and the neutral lipid DOPE (L-
dioleoyl phosphatidylethanolamine).  Incubation of this liposome reagent with 
DNA causes compaction of the nucleic acid and neutralisation of its negative 
charge, thereby allowing closer association of the liposome/DNA complex with 
the negatively charged plasma membrane.  The liposome complex enters the cell 
by endocytosis or by fusion with the plasma membrane.   
 
The transfection mixture was aspirated after 24 h and replaced with complete 
culture medium for a further 24 h.  Following this, puromycin (1 mg/ml) in 
appropriate complete culture medium was added, and cells were cultured in this 
medium until small colonies of transfected cells were seen with the naked eye.  
Only transfected cells should survive, as the puromycin resistance gene was 
encoded within the plasmids.  Individual colonies were picked using cloning 
cylinders, and passaged into separate wells until growth of cells was such that 
they could be transferred to 75 cm2 flasks.  Both RNA and protein was extracted 
from all constructs (including scrambled vector), and used in Western blots to 
screen for PKR knockdown.   
 
2.7 Detection of mRNA expression (ReverseTranscriptase-
PCR) 
2.7.1 DEPC-treated water 
The extraction and storage process of RNA required diethylpyrocarbonate 
(DEPC)-treated water, which inactivates RNase enzyme activity (via the covalent 
modification of histidine residues) and therefore minimises the risk of RNA 
degradation.  A 0.1% DEPC/H2O solution was prepared by dissolving the DEPC 
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in the H2O: this was then incubated for 12 h at 37 ˚C, followed by autoclaving for 
15 min at 121 ˚C to remove any remaining DEPC, followed by storage in aliquots 
at -20 ˚C until required.   
 
2.7.2 RNA extraction  
Cells were seeded at 1 × 105 cell/25 cm2 tissue culture flask at 37 ºC and with 
5% CO2 and subsequently incubated for various incubation times depending on 
the treatment used.  The culture medium was aspirated from the flasks, then 
TRIzol® reagent (Invitrogen) was used to lyse and extract cell RNA.  TRIzol® 
reagent maintains the RNA integrity of the cells during the homogenisation 
process, while simultaneously lysing cells and organelles.  Briefly, 1 ml Trizol®/25 
cm2 tissue culture flask was added and cell lysates were passed through RNase-
free sterile filter pipette tips several times to homogenise the sample, before the 
contents were transferred to sterile microfuge tubes, and allowed to incubate at 
RT for 5 min.  Chloroform (200 μl/1 ml TRIzol® reagent used) was added to the 
lysate and briefly vortexed, then incubated at RT for 10 min to allow the aqueous 
and organic phases to separate.  Samples were centrifuged at 4 ˚C, 10000 g for 
15 min and the resulting upper colourless phase containing the RNA was carefully 
aspirated and transferred to a fresh sterile microfuge tube, without disturbing the 
interface (containing DNA) or the organic lower phase (containing proteins).  The 
RNA was precipitated using 0.5 ml isopropanol/1 ml TRIzol® reagent, briefly 
vortexed then incubated at -20 ˚C for 1 h, before being centrifuged again at 4˚ C, 
10000 g for 20 min.  The resulting RNA pellet was washed twice using 75% 
ethanol and centrifuged at 4˚C, 10000 g for 15 min.  Finally, the RNA pellet was 
air-dried to allow any remaining alcohol to evaporate, and the pellet was 
resuspended in 25 μl DEPC-treated water and stored at -80 ˚C until needed.   
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2.7.3 Quantification of RNA  
To determine the RNA yield, the previously frozen RNA/DEPC suspension was 
quantified using an Eppendorf Biophotometer spectrophotometer.  Absorbance 
readings at 260 nm were taken, using DEPC-treated water as a blank.  RNA 
purity was determined by calculating the absorbance ratio measured at 260/280 
nm, where a ratio between 1.8 and 2 signified high purity RNA (Barbas et al., 
2007).   
 
2.7.4 cDNA synthesis 
One microgramme of extracted RNA/DEPC suspension was mixed to make a 
total of 10 μl of DEPC-treated water for each reverse transcription (RT) reaction.  
To this volume, 1 μl of 500 ng/ml random primers (Promega) was added and the 
mixture heated to 70 ˚C for 10 min, then incubated on ice.  Random primers are 
used to initiate cDNA synthesis from the total RNA population, by random 
annealing throughout the RNA.  Next, a reaction mix was prepared using 3.5 μl 
DEPC-treated water, 4 μl 5× RT buffer, 0.5 μl RNasin Plus RNase Inhibitor (40 
U/μl), 1 μl dNTP (10mM) mix and 1 μl RT enzyme (all from Promega).  Nine 
microlitres of this mix was added to 11 μl RNA/DEPC/random primer mix.  The 
final mix was incubated at 25 ˚C for 15 min, at 42 ˚C for 50 min and finally at 70 
˚C for 15 min using a BioRad iCycler, to allow synthesis of complementary DNA.  
A separate mix was prepared using 1 μl nuclease-free dH2O instead of RT 
enzyme as a negative control, which when run simultaneously with the RT-
positive samples, should not produce any amplified product during the PCR 
process.   
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2.7.5 Primer design 
Individual primers were designed using the software available online at the 
Primer3 website (http://primer3.souceforge.net/) (Figure 2.4, 2.5 and 2.6) and 
were purchased from Invitrogen (Table 2.4).   
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Fig. 2.4 Rat IL-1β mRNA nucleotide sequence and primers (set 1) 
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Fig. 2.5 Rat IL-1β mRNA nucleotide sequence and primers (set 2) 
106 
 
 
 
  
Fig. 2.6 Human IL-1β mRNA nucleotide sequence and primers  
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2.7.6 PCR 
The reverse transcriptase polymerase chain reaction (RT-PCR) is a universally 
adopted thermal cycling technique used to amplify a few copies of DNA, by the 
addition of a heat-stable DNA polymerase (such as Taq polymerase).  Such 
polymerases can construct a new DNA strand by reverse transcribing a single-
stranded DNA used as a template, and simultaneously utilising primers to initiate 
DNA synthesis.  An initial high temperature denaturation step separates the two 
target DNA strands, followed by a lower temperature step which enables the 
primers to anneal to each separated DNA strand.  These individual strands are 
then used as a template by the DNA polymerase to amplify the target DNA during 
an extension step.  The cycle is then repeated numerous times to amplify the 
DNA product.   
 
2.7.6.1 RT-PCR reactions 
All RT-PCR reactions used 22.5 μl PCR Master Mix (containing 1.5 mM MgCl2) 
(Thermo Scientific) (Table 2.1 for detailed composition) in a BioRad iCycler.  One 
microliter of cDNA and 1 μl of each forward and reverse custom primer (25 μM) 
were added to the Master Mix.  The PCR reaction comprised an initial 5 min 
denaturation step at 95 ˚C, followed by 35 cycles of amplification consisting of: a 
30 s denaturation step at 95 ˚C, a 30 s annealing step (46-56 ˚C depending on 
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primers), and a 30 s extension step at 72 ˚C.  The reaction was completed by a 
final 5 min extension step at 72 ˚C.  The annealing temperature was determined 
by the average melting temperature (Tm) – 3 ˚C of the custom primers used.  
Detection of the PCR products was carried out by electrophoresis, using 1% 
agarose (Invitrogen) gel in either Trizma-EDTA-buffer (TAE) or Trizma-BORATE-
buffer (TBE) buffer (Table 2.1), containing 3 μl/60 ml agarose Gel Red Nucleic 
Acid Stain (Biotium).  TAE buffer is typically used when the DNA product needs 
to be isolated for sequencing or for high resolution of larger DNA products, 
whereas TBE buffer is preferable for the resolution of smaller DNA products and 
also has better buffering capacity so can be used more than once.  Gels using 
TBE buffer were run at 200 V for 30 min, or 100 V for 1 h using TAE buffer.  Gel 
Red is a fluorescent dye which intercalates with and stains dsDNA, ssDNA or 
RNA and therefore can be used to visualise the fluorescent DNA product within 
the gel using an ultraviolet lamp to illuminate the dye (BioDoc-It™ Imaging 
System).  Images were captured using Labworks software. A DNA ladder 
(Fermentas) was also run simultaneously, to allow determination of the 
approximate size of visualised bands.   
 
2.7.7 Checking for genomic contamination of cDNA  
It is difficult to completely exclude the presence of genomic DNA (gDNA) from 
RNA samples, so it is important to prepare samples carefully in separate areas 
and using dedicated equipment and to include proper controls.  Typically this 
would entail using identically-prepared samples that include all the reagents 
except the reverse transcriptase enzyme, i.e. a negative control, plus a dH2O 
control.  The presence of an amplified DNA product in the control lanes would be 
indicative of contaminating gDNA.  Depending on the level of contamination, new 
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RNA extraction could be repeated or DNase treatment of the existing cDNA 
sample could be performed to eradicate modest DNA contamination.   
 
2.7.8 Confirmation of PCR products 
While a detected DNA product may appear to be the correct size, this does not 
necessarily mean that the correct DNA product has been amplified.  Therefore, 
in order to be assured that this was the case, direct sequencing of the product 
was performed.  The DNA product was run on a TAE gel (as detailed in Section 
2.7.6.1), and excised under UV light using a sterile blade.  The DNA was 
extracted from the gel fragment using a QIAquick Gel Extraction kit (Qiagen) as 
per the manufacturer’s instructions, and the purified DNA product was dispatched 
to Eurofins MWG Operon  MWG (Ebersberg, Germany), for sequencing to 
confirm the identity of the excised DNA product.   
 
2.8 Detection of pro-inflammatory cytokines by ELISA 
Enzyme-linked immunosorbent assay (ELISA) is a widely used and sensitive 
method to detect and quantify relatively low concentrations of substances for 
example, proteins, antibodies and cytokines.  The target antigen is immobilised 
to a solid surface, typically a 96-well plate and then complexed with an enzyme-
linked antibody.  Detection and quantification of the target antigen is performed 
by measuring the conjugated enzyme activity via incubation with a substrate that 
produces a colorimetric product.  A Rat IL-1 beta Tissue Culture ELISA Ready-
SET-Go!® kit (eBioscience, Hatfield, UK) was used as per the manufacturer’s 
protocol to monitor IL-1β secretion from cells that had been subjected to various 
treatment combinations.  Cells were seeded in complete appropriate culture 
medium at 2.5 × 105 cells/well 18 h before the required treatment incubation 
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period.  The medium was aspirated and replaced with relevant reagents for the 
designated incubation period.  One day prior to performing the ELISA, the 96-
well plate was coated with capture Ab/coating buffer solution and incubated 
overnight at 4 ˚C.  The following morning, wells were washed for 1 min 5× with 
275 μl wash buffer (Table 2.1), then blocked with 200 μl/well 1× assay diluent for 
1 h at RT, followed by a wash step.  Interleukin-1β standards (39-2500 pg/ml) 
were prepared using 2-fold serial dilutions of 1× assay diluent and 1μg/ml 
recombinant rat IL-1β cytokine, and 100 μl/well were added in duplicate, in 
repeats of 6 along with 100 μl/well of samples.  The plate was sealed and 
incubated overnight at 4 ˚C.  The following morning, wells were washed and then 
100 μl of detection Ab/assay diluent solution was applied to each well, the plate 
re-sealed and allowed to incubate at RT for 1 h.  Another wash step was followed 
by the application of 100 μl/well of Avidin-HRP/assay diluent solution; the plate 
was sealed and incubated at RT for 30 min.  A final set of 7× 2 min wash steps 
was performed, then 100 μl/well of substrate solution added and the plate was 
incubated at RT for 15 min.  The final step was the addition of 50 μl/well of stop 
solution (Table 2.1).  The absorbance of the samples/standards was read at 450 
nm using a Tecan GENios microplate reader.  The unknown IL-1β concentration 
of samples was estimated by comparing their absorbance to that of the known 
IL-1β standard concentrations (Fig. 2.7).   
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Fig. 2.7 ELISA standard curve for calculating IL-1β concentration 
112 
 
2.9 Detection of cytosolic inflammasome protein components 
by immunocytochemistry (ICC) 
Immunocytochemistry is a commonly used technique that allows the detection 
and visualisation of individual proteins expressed within cultured adherent cells, 
using antigen-specific antibodies.  Thirteen millimetre glass coverslips were heat-
sterilised at 140˚ C for 2 h and allowed to cool, then coated with a 5 mg/11.5 ml 
poly-D-lysine/dH2O solution, allowed to dry overnight and kept sterile until used. 
Poly-D-lysine is a synthetic positively-charged amino acid chain, which promotes 
the adhesion of cells to the coverslips.   
 
Cells were seeded onto coverslips placed into individual wells of a 24 well plate, 
at a density of 5 × 103 cells/15 μl culture medium.  Cells were incubated for 2 h 
to allow them to fully adhere to the coverslips, then each well was topped up to 
500 μl of appropriate complete culture medium and left overnight, before 
treatments were conducted over various time periods.   
 
Following incubation, the culture medium was aspirated and cells were fixed at 
RT with 400 μl/well 4% paraformaldehyde (Table 2.1) for 15 min, followed by two 
washes using 1 ml PBS.  Paraformaldehyde is a cross-linking reagent that 
typically forms intermolecular bridges via free amino groups, resulting in a 
network of linked antigens that preserve cell structure.  Paraformaldehyde-fixed 
cells were blocked and permeabilised to allow penetration of antibodies to 
intracellular target proteins, using 50 μl/CS 0.2% Triton X-100 antibody dilution 
solution (ADST) (Table 2.1) for 30 min at RT.  The blocking solution was tipped 
off, and cells were probed using appropriate primary antibodies diluted in ADS 
overnight at 4 ˚C (Table 2.2).  Cells were washed six times in PBS, and then 
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incubated for 30 min at RT using appropriate Alexa Fluor® conjugated secondary 
antibodies with DAPI to stain the nucleus of the cells.  Cells were again washed 
six times in PBS, then mounted cell-side down on glass microscope slides using 
a small drop of Citifluor™ AF1 anti-fadent glycerol/PBS solution (Citifluor Ltd, 
London).  The coverslips were then secured and sealed carefully around the edge 
to prevent movement and evaporation using clear nail varnish.  Antibodies were 
visualised using a Nikon Eclipse 90i fluorescence microscope using DAPI and 
FITC channels, and micrographs were taken using NIS Elements software.   
 
2.10 Data imaging and analysis 
All experiments were performed in at least triplicate for each treatment group and 
repeated on at least three separate occasions.  Results were expressed as mean 
± SEM; significance levels were calculated using Minitab General Linear Model 
ANOVA and were regarded as significant when p=<0.05.  Densitometry was 
performed using analysis by Quantity One software, where optical density 
readings were normalised against loading controls in each well to eliminate 
variability in total protein loading.   
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Chapter 3 The role of PKR in pancreatic β-cell apoptosis  
3.1 Introduction 
Chronically elevated FFA concentrations as seen in obesity are proposed to exert 
a deleterious effect on pancreatic β-cell survival in a mechanism termed 
lipotoxicity.  Although the exact mechanisms underlying this process are not well 
understood, lipotoxicity is suggested to underlie the progression of insulin 
resistance and insulin deficiency, and to drive a long-term reduction in β-cell mass, 
features that can be commonly seen in T2D (Cunha et al., 2008; Butler et al., 
2003; Cnop et al., 2005).  The in vitro culture of pancreatic β-cell lines has 
provided many key observations regarding the molecular mechanisms that may 
cause lipotoxicity.  Many studies have demonstrated that the degree of toxicity or 
protection afforded by a FA species during chronic incubation with pancreatic β-
cells, can markedly vary according to the carbon chain length, degree of 
saturation or configuration of the individual FA species being studied (Newsholme 
et al., 2007; Welters et al., 2004; Eitel et al., 2003; Dhayal et al., 2008; Karaskov 
et al., 2006; Diakogiannaki et al., 2007; Diakogiannaki et al., 2008; Morgan et al., 
2008).  Long-chain-SFAs (≥C16:0) exert a detrimental effect on β-cell viability, 
whereas medium and shorter-chain SFAs (≤C14:0) or LC-MUFAs (≥C16:1) are 
well tolerated by β-cells and do not exert a detrimental effect on cell viability 
(Newsholme et al., 2007; Welters et al., 2004; Eitel et al., 2003; Diakogiannaki et 
al., 2007; Diakogiannaki et al., 2008; Morgan et al., 2008).  An additional 
important finding is that the in vitro co-incubation of LC-MUFAs with LC-SFAs, 
attenuates the cytotoxic effects observed in β-cells when they are incubated 
solely with LC-SFAs (Karaskov et al., 2006; Welters et al., 2004; Diakogiannaki 
et al., 2007; Diakogiannaki et al., 2008; Morgan et al., 2008).  This protective 
mechanism exerted by LC-MUFA during co-incubation with toxic SFAs, is also 
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seen when rodent pancreatic β-cells are subjected to other detrimental stimuli, 
such as pro-inflammatory cytokines or serum withdrawal (Welters et al., 2004).   
 
The exact molecular mechanisms that mediate proapoptotic or protective actions 
of FFAs in pancreatic β-cells have yet to be fully elucidated, but recently, strong 
evidence has pointed towards a role for ER stress when associated with 
lipotoxicity (Qu et al., 2009; Breckenridge et al., 2003; Laybutt et al., 2007).  A 
lipotoxic environment is suggested to cause perturbations in normal ER balance 
and trigger an ERS (Eizirik et al., 2008; Özcan et al., 2004; Kharroubi et al., 2004; 
Scheuner and Kaufman, 2008; Karaskov et al., 2006; Cnop et al., 2007).  An ERS 
initiates the induction of four adaptive signal transduction responses termed the 
UPR, a predominantly protective response that attempts to restore ER 
homeostasis.  However, prolonged or persistent ER stress may eventually lead 
to β-cell apoptosis (Qu et al., 2009; Fonseca et al., 2009).  Apoptotic progression 
of pancreatic β-cells under ER stress conditions has been well established 
involving the PERK-dependent arm of the ERS (Morgan et al., 2008; 
Diakogiannaki et al., 2008; Cnop et al., 2008; Diakogiannaki and Morgan, 2008; 
Scheuner and Kaufman, 2008; Laybutt et al., 2007; Song et al., 2007; Lee et al., 
2007).   
 
Research has recently questioned whether PERK is the sole apoptotic-inducing 
factor within ER stress conditions.  Results from studies suggest that PERK may 
have a less significant role in ER stress-mediated apoptosis than previously 
thought (Lee et al., 2007; Lai et al., 2008; Morgan, 2009).  Williams (1999) first 
suggested a link between PKR and cellular stress mechanisms.  However, in 
2007, Lee and colleagues showed that PKR is simultaneously but independently 
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activated alongside PERK under lipotoxic conditions.  In these circumstances it 
has been proposed that PERK may take on a predominantly cell survival role, 
whereas PKR may assume a predominantly proapoptotic role (Lee et al., 2007).  
This was the first time an association had been made between PKR and nutrient 
overload.   
 
Therefore these studies aimed to more fully investigate the role of PKR in rodent 
pancreatic β-cells exposed to FA species.  Specifically, the aim was to explore 
whether the PKR protein is responsible for mediating proapoptotic responses 
when β-cells are subjected to lipotoxic conditions.  Manipulation of PKR 
expression using a small molecule inhibitor, a dominant negative adenoviral 
vector system and RNAi methods were adopted, to examine whether alterations 
to the level of PKR activation in β-cells in vitro, had an impact on cell viability 
within a lipotoxic environment.  
 
3.2 Materials and methods 
3.2.1 Cell culture and FA treatment conditions 
The culture of all rodent pancreatic β-cell lines was performed as described in 
Section 2.2.  The use of PERK and PKR dominant negative adenoviral vectors 
were conducted as cited in Sections 2.6.1 and 2.6.2.  The stable BRIN-BD11 PKR 
KD clonal cell lines (BRIN-BD11 PKR KD 333, BRIN-BD11 PKR KD 335, BRIN-
BD11 PKR SV) were generated and cultured as described in Sections 2.2 and 
2.6.6.  Fatty acid solutions were prepared and experiments conducted using 
serum free culture medium (Section 2.3).  Cell viability was assessed using vital 
dye staining (Section 2.4.1) or using PI staining via flow cytometry (Section 2.4.2), 
and this was used to calculate the proportion of dead cells which were expressed 
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as a percentage of the total for each treatment group.  Western blotting was 
performed as described in Section 2.5.   
 
3.2.2 Compound-16 treatment conditions 
A 25 mM stock solution of Compound-16 (Fig. 3.1) was prepared in DMSO.  All 
stocks were stored at -80 °C until required.  Lower molar solutions of Compound-
16 were prepared by diluting in serum free culture medium to the required 
concentration, and cells were pre-treated for 1 h before the addition of FA 
treatments.   
 
 
Fig. 3.1 A putative selective PKR inhibitor: Compound-16 structure  
Imidazolo-oxindole (Compound-16) is reported to be a selective and 
potent inhibitor of PKR. Its inhibitory effect on PKR is ATP-binding site 
directed. Compound-16 is stated to specifically inhibit the apoptotic 
PKR/eIF2α/ATF4/CHOP10 pathway without stimulating the proliferative 
mTOR/p70S6K signalling pathway (Sigma-Aldrich Co., 2012). 
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3.3 Results 
3.3.1 SFAs are cytotoxic to rodent pancreatic β-cells 
Many earlier studies have established that chronic incubation with LC-SFAs 
(≥C16:0) such as palmitate is cytotoxic to rodent pancreatic β-cells (BRIN-BD11, 
MIN6, RIN and INS-1) and isolated human pancreatic β-cells (Diakogiannaki et 
al., 2007; Biden et al., 2004; Eitel et al., 2003; Eitel et al., 2002; El-Assaad et al., 
2003; Kharroubi et al., 2004).  Our initial experiments were conducted to verify 
that previous results from our group were reproducible using laboratory-specific 
protocols and cell lines.  There have been inconsistencies in the extent of SFA-
induced toxicity reported in different rodent pancreatic β-cells in vitro (Lai et al., 
2008; Busch et al., 2005).   
 
Therefore, the first set of experiments employed the BRIN-BD11, INS-1 and MIN6 
rodent pancreatic β-cells to compare the percentage cell death observed 
between the cell lines, when they were incubated with 250 μM palmitate over a 
24 h incubation period.  This concentration of palmitate was adopted as it has 
been consistently used by our group and considered representative of FFA 
concentrations that may typically be observed in a physiologically 
hyperlipidaemic state (Welters et al., 2004; Diakogiannaki et al., 2007).   
 
From the results obtained, it was apparent that the BRIN-BD11 cells were far 
more susceptible to palmitate-induced cell death than the INS-1 and MIN6 cell 
lines during this incubation period (Fig. 3.2).  Nonetheless, all palmitate-treated 
cells exhibited a significant increase in percentage cell death compared to their 
control (p=<0.001).  The percentage cell deaths observed from this experiment 
were as follows: BRIN-BD11 control (6.4%), BRIN-BD11 treated with palmitate 
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(93.1%); INS-1 control (5.2%), INS-1 treated with palmitate (37.1%); MIN6 control 
(4.2%), MIN6 treated with palmitate (22.3%).   
 
 
 
 
  
Fig. 3.2 The cytotoxic effect of palmitate on rodent β-cell death 
over a 24 h incubation period 
The rodent β-cell lines BRIN-BD11, INS-1 and MIN6 were treated 
with 250 μM palmitate over a 24 h incubation period. Cell death was 
assessed by trypan blue vital dye staining. Results represent mean ± 
SEM from experiments in triplicate (N=3). *** p=˂ 0.001 vs. control 
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These experiments were subsequently repeated to determine an optimal 
incubation period for each individual cell line, with the aim of observing a similar 
magnitude of percentage of cell death in each cell line for comparison purposes.  
The incubation period with palmitate was extended to 24 h for INS-1 cells and to 
72 h for MIN6 cells.  This resulted in a similar level of cell death seen over an 18 
h incubation period using BRIN-BD11 cells (Fig. 3.3).  Again, all palmitate-treated 
cells demonstrated a significant increase in percentage cell death compared to 
their control group (p=<0.001).  To fully quantify these results, percentage cell 
deaths were as follows: BRIN-BD11 control (6.2%), BRIN-BD11 treated with 
palmitate (36.9%); INS-1 control (5.4%), INS-1 treated with palmitate (37.9%); 
MIN6 control (9.8%), MIN6 treated with palmitate (59%).  Unless stated otherwise, 
the incubation periods for individual cell lines remained as detailed here for the 
rest of the studies in this section.   
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Fig. 3.3 The cytotoxic effect of palmitate on rodent β-cell death: 
optimal incubation times 
Rodent β-cells were treated with 250 μM palmitate: BRIN-BD11 cells 
were incubated for 18 h, INS-1 cells were incubated for 24 h and MIN6 
cells were incubated for 72 h. Cell death was assessed by trypan blue 
vital dye staining. Results represent mean ± SEM from experiments in 
triplicate (N=3). *** p=˂ 0.001 vs. control 
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Although the exact mechanism whereby palmitate causes β-cell apoptosis is yet 
to be fully elucidated, there has been much recent evidence to suggest that ER 
stress plays a role in this process.  Western blotting was used to examine the 
effect of palmitate on rodent pancreatic β-cells, to investigate any changes in the 
phosphorylation of the widely-accepted ER stress marker eIF2α (denoted as 
phospho-eIf2α) (Fig. 3.4).  Results for the BRIN-BD11 cells (Fig. 3.4a) showed a 
3.9-fold increase in phospho-eIF2α expression in the 250 μM palmitate group 
compared to the control group (p=<0.001).  The INS-1 cells (Fig. 3.4b) showed a 
4.3-fold increase in phospho-eIF2α expression in the 250 μM palmitate group 
compared to the control (p=<0.001).  Finally, the MIN6 cells (Fig. 3.4c) showed a 
1.3-fold increase in phospho-eIF2α expression in the 250 μM palmitate group 
compared with the control (p=<0.01).   
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Fig. 3.4 The effect of palmitate on ER stress in rodent β-cells 
Rodent β-cells were treated with 250 μM palmitate: BRIN-BD11 cells were 
incubated for 18 h, INS-1 cells were incubated for 24 h and MIN6 cells were 
incubated for 72 h. After incubation, whole cell lysates were probed using 
phospho-eIF2α antibody. Results represent blots from experiments 
performed in triplicate (N=3). 
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Our group has previously reported that the cytotoxic effect observed when BRIN-
BD11 β-cells are incubated with palmitate is dose-dependent (Welters et al., 2004; 
Welters et al., 2006, Diakogiannaki et al., 2007).  To corroborate these findings 
and to compare variability between cell lines, we conducted experiments using 
BRIN-BD11, INS-1 and MIN6 cells incubated with palmitate concentrations that 
ranged from 10 μM to 250 μM (Fig. 3.5).  The results showed that palmitate clearly 
increased percentage cell death in a dose-dependent manner in all three cell lines 
tested.  To quantify these results, percentage cell deaths in the BRIN-BD11 cells 
(Fig. 3.5a) were as follows: control (15.7%); 10 μM palmitate (20.2%); 25 μM 
palmitate (35.6%, p=<0.01); 50 μM palmitate (45.6%, p=<0.001); 100 μM 
palmitate (66.4%, p=<0.001) and 250 μM palmitate (81.6%, p=<0.001).  The EC50 
of this dose-response curve for the BRIN-BD11 cells was ~20 μM.  Percentage 
cell deaths in the INS-1 cells (Fig. 3.5b) were: control (7.9%); 10 μM palmitate 
(6.5%); 25 μM palmitate (10.6%); 50 μM palmitate (19.2%, p=<0.05); 100 μM 
palmitate (31.1%, p=<0.001) and 250 μM palmitate (70.3%, p=<0.001).  The EC50 
in the INS-1 cells was ~80 μM.  Finally, the percentage cell deaths in the MIN6 
cells (Fig. 3.5c) were: control (13.2%); 15 μM palmitate (27.7%, p=<0.001); 25 
μM palmitate (39.8%, p=<0.001); 50 μM palmitate (56.8%, p=<0.001); 100 μM 
palmitate (61.5%, p=<0.001) and 250 μM palmitate (72.2%, p=<0.001).  The EC50 
in the MIN6 cells was ~10 μM.   
 
Furthermore, the increased percentage cell deaths observed in all cell lines 
incubated with 250 μM palmitate, correlated with the increased phosphorylation 
status of eIF2α under the same experimental conditions as demonstrated by our 
previous study.    
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Fig. 3.5 The cytotoxic effect of palmitate on rodent β-cell death is 
dose-dependent 
Rodent β-cells were treated with increasing palmitate concentrations: 
a) BRIN-BD11 incubated for 18 h, b) INS-1 incubated for 24 h, c) MIN6 
incubated for 72 h. Cell death was assessed by trypan blue vital dye 
staining. Results represent mean ± SEM from experiments in triplicate 
(N=3). *** p=˂0.001, ** p=<0.01, * p=<0.05 vs. control 
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3.3.2 MUFAs are cytoprotective to rodent pancreatic β-cells 
The loss of viability observed in pancreatic β-cells when they are incubated with 
the LC-SFA palmitate is ameliorated during co-incubation with the LC-MUFA 
palmitoleate.  When cultured alone with pancreatic β-cells, palmitoleate is shown 
to be well-tolerated and does not affect cell death.  Our group and others have 
also demonstrated that palmitoleate exerts a protective effect against 
proapoptotic stimuli such as serum withdrawal (Welters et al., 2004; Dhayal et al., 
2008; Diakogiannaki et al., 2007; Diakogiannaki and Morgan, 2008; 
Diakogiannaki et al., 2008; Eitel et al., 2003; Eitel et al., 2002; Maedler et al., 
2003).  Therefore, the cytoprotective action of palmitoleate was investigated in 
BRIN-BD11, INS-1 and MIN6 cells (Fig. 3.6).  Incubation with 250 μM palmitate 
resulted in a significant increase in percentage cell death in all cell lines when 
compared with control groups (p=<0.001) and this is in line with our previous 
results.  Palmitoleate at 250 μM was well-tolerated in all three cell lines, as no 
increase in percentage cell death was observed when compared to the control.  
More critically however, was the observation that co-incubation of 250 μM 
palmitoleate with 250 μM palmitate completely ameliorated the increased 
percentage cell death observed when cells were incubated with 250 μM palmitate 
alone.  To fully quantify these results, percentage cell deaths in the BRIN-BD11 
cells (Fig. 3.6a) were as follows: control (6.4%); 250 μM palmitate (36.9%); 250 
μM palmitoleate (5.8%) and both palmitate and palmitoleate (5.2%, p=<0.001 vs 
250 μM palmitate).  The percentage cell deaths in the INS-1 cells (Fig. 3.6b) were: 
control (5.2%); 250 μM palmitate (37.1%); 250 μM palmitoleate (4.2%) and both 
palmitate and palmitoleate (5.8%, p=<0.001 vs 250 μM palmitate).  Finally, the 
percentage cell deaths in the MIN6 cells (Fig. 3.6c) were: control (13.2%); 250 
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μM palmitate (61.2%); 250 μM palmitoleate (9.5%) and both palmitate and 
palmitoleate (11.5%, p=<0.001 vs 250 μM palmitate).   
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 Fig. 3.6 The cytoprotective effect of palmitoleate on rodent β-cell 
death  
Rodent β-cells were treated with 250 μM palmitate, 250 μM 
palmitoleate or a combination of both FA: a) BRIN-BD11 incubated 
for 18 h, b) INS-1 for 24 h and c) MIN6 incubated for 72 h. Cell death 
was assessed by trypan blue vital dye staining. Results represent 
mean ± SEM from experiments in triplicate (N=3). *** p=˂ 0.001 vs. 
control; ### p=< 0.001 vs. palmitate  
129 
 
Western blotting was used to investigate the effect of these LC-FAs on the 
phosphorylation status of eIF2α in BRIN-BD11 pancreatic β-cells (Fig. 3.7).  
Results showed a 7.1-fold increase in eIF2α phosphorylation compared to the 
control when BRIN-BD11 cells were incubated with 250 μM palmitate (p=<0.001), 
and this correlated with significantly increased percentage cell death as shown in 
the previous study.  The phosphorylation of eIF2α when BRIN-BD11 cells were 
incubated with palmitoleate alone showed a 3.2-fold increase compared to the 
control and although this was significant (p=<0.01), upregulation of phospho-
eIF2α under these treatment conditions did not affect cell viability as no increase 
in percentage cell death was observed.  Finally, phosphorylation of eIF2α when 
BRIN-BD11 cells were co-incubated with palmitate and palmitoleate showed a 
6.7-fold increase compared to the control and again, although this was significant 
(p=<0.001), upregulation of phospho-eIF2α under these experimental conditions 
did not result in increased percentage cell death.   
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Fig. 3.7 Palmitoleate can ameliorate ER stress in BRIN-BD11 
cells 
BRIN-BD11 β-cells were incubated for 18 h with 250 μM palmitate 
or 250 μM palmitoleate alone, or co-incubated with both 250 μM 
palmitate and palmitoleate, compared to control. Following 
incubation, whole cell lysates were probed using phospho-eIF2α 
antibody. Results represent blots from experiments performed in 
triplicate (N=3). 
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In contrast to the dose-dependent cytotoxic effect observed when incubating 
rodent cells with palmitate, palmitoleate has been reported to exert a dose-
dependent cytoprotective effect in BRIN-BD11 and INS-1 cells.  This 
cytoprotective effect was investigated here in MIN6 cells, and BRIN-BD11 and 
INS-1 cells by co-incubating them with 250 μM palmitate, and adding palmitoleate 
in concentrations ranging from 10 μM to 250 μM.  Results from these studies 
clearly demonstrated that the co-incubation of palmitoleate with palmitate exerts 
a significant cytoprotective effect in all cell lines (Fig. 3.8).  Results were most 
striking in the BRIN-BD11 cells and INS-1 cells, and showed that the addition of 
even the lowest concentration of palmitoleate (10 μM), significantly reduced the 
extent of cell death (EC50 ~15 μM).  This cytoprotective effect was slightly less 
efficacious in MIN6 cells, but nevertheless still showed a significant protective 
action (EC50 ~45 μM).  The percentage cell deaths observed in the BRIN-BD11 
cells (Fig. 3.8a) were as follows: control (250 μM palmitate), 75.2%; 250 μM 
palmitate and 10 μM palmitoleate, 47.8% (p=<0.001); 250 μM palmitate and 25 
μM palmitoleate, 27.9% (p=<0.001); 250 μM palmitate and 50 μM palmitoleate, 
7.6% (p=<0.001); 250 μM palmitate and 100 μM palmitoleate, 2.6% (p=<0.001) 
and 250 μM palmitate and 250 μM palmitoleate, 1.6% (p=<0.001).  The 
percentage cell deaths observed in the INS-1 cells (Fig. 3.8b) were: control (250 
μM palmitate), 64.3%; 250 μM palmitate and 10 μM palmitoleate, 40.7% 
(p=<0.01); 250 μM palmitate and 25 μM palmitoleate, 16.7% (p=<0.001); 250 μM 
palmitate and 50 μM palmitoleate, 13.7% (p=<0.001); 250 μM palmitate and 100 
μM palmitoleate, 6.4% (p=<0.001) and 250 μM palmitate and 250 μM 
palmitoleate, 4.8% (p=<0.001).  Finally, percentage cell deaths observed in the 
MIN6 cells (Fig. 3.8c) were: control (250 μM palmitate), 60.1%; 250 μM palmitate 
and 10 μM palmitoleate, 58.7%; 250 μM palmitate and 25 μM palmitoleate, 41.1% 
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(p=<0.001); 250 μM palmitate and 50 μM palmitoleate, 27.5% (p=<0.001); 250 
μM palmitate and 100 μM palmitoleate, 11.6% (p=<0.001) and 250 μM palmitate 
and 250 μM palmitoleate, 11.9% (p=<0.001).  
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Fig. 3.8 The cytoprotective effect of palmitoleate on rodent β-cell 
death is dose-dependent 
Rodent β-cells were treated with 250 μM palmitate and increasing 
concentrations of palmitoleate: a) BRIN-BD11 incubated for 18 h, b) 
INS-1 for 24 h, c) MIN6 cells for 72 h. Cell death was assessed by 
trypan blue vital dye staining. Results represent mean ± SEM from 
experiments in triplicate (N=3). *** p=˂0.001, ** p=<0.01 vs. control 
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3.3.3 Compound-16 is cytoprotective to BRIN-BD11 rodent 
pancreatic β-cells under lipotoxic stress 
The molecular mechanism underlying the cytotoxic action of palmitate in rodent 
β-cells in not well understood.  The involvement of the stress-sensing PKR protein 
has been recently suggested to be a potential key player in mediating the 
proapoptotic responses observed in rodent β-cells during lipotoxic conditions.  
Therefore, the availability of a reputedly specific small molecule PKR inhibitor 
(Compound-16), offered a potential method to investigate whether inhibition of 
this protein had an impact on cytotoxicity induced in rodent β-cells upon exposure 
to palmitate.  Initial experiments were conducted to assess the effect of 
Compound 16 on the viability of BRIN-BD11 cells when co-incubated with 
palmitate.  BRIN-BD11 cells were incubated with Compound-16 using various 
concentrations ranging from 1 μM to 25 μM.  A second group was pre-incubated 
for 1 h with Compound-16, but then co-incubated with 250 μM palmitate for the 
remaining incubation period.   
 
Our results have demonstrated here for the first time in BRIN-BD11 pancreatic β-
cells, that Compound-16 did not detrimentally affect viability when cultured alone 
at any concentration (Fig. 3.9).  Furthermore, this novel data also shows that 
between 5 μM and 25 μM concentrations, Compound-16 afforded significant 
cytoprotection against palmitate-induced cell death (p=<0.001) when compared 
to the control group (IC50 ~5 μM).  To fully quantify these findings, percentage cell 
deaths in the control group (no palmitate) were as follows: control, 16.7%; 5 μM 
Compound-16, 16.4%; 10 μM Compound-16, 16.3% and 25 μM Compound-16, 
15.6%.  Percentage cell deaths in the group co-incubated with 250 μM palmitate 
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and Compound-16 were: control (250 μM palmitate), 59.8%; 5 μM Compound-16, 
31.3%; 10 μM Compound-16, 30.6% and 25 μM Compound-16, 36.4%.   
 
 
 
 
 
  
Fig. 3.9 The cytoprotective effect of Compound-16 on BRIN-BD11 
β-cell death when incubated with palmitate 
BRIN-BD11 rodent β-cells were treated with various concentrations of 
Compound-16. A second treatment group of BRIN-BD11 cells were pre-
incubated with the same concentrations of Compound-16 for 1 h, then 
incubated for a further 17 h with 250 μM palmitate. Cell death was 
assessed by trypan blue vital dye. Results represent mean ± SEM from 
experiments in triplicate (N=3). *** p=˂0.001 vs. control  
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Recent studies have identified PKR as a protein central to nutrient sensing 
(Nakamura et al., 2010).  Therefore, we sought to investigate in the BRIN-BD11 
cell model whether PKR may be activated in response to nutrient deprivation as 
well as nutrient overload as shown previously in mouse models (Nakamura et al., 
2010).  We conducted experiments to examine whether incubation with 
Compound-16 might rescue BRIN-BD11 cells from death induced by serum-
starvation.  Cells were cultured in serum-free conditions, and incubated with 
various concentrations of Compound-16 over increasing time intervals.  Results 
from these studies demonstrate for the first time that at 10, 15 and 25 μM 
concentrations, Compound-16 was able to significantly protect BRIN-BD11 cells 
against death induced by serum-starvation (p=<0.001).  Fully quantified 
percentage cell deaths for these studies were: complete culture medium control, 
12.1%; serum-free, 64.2%; serum-free and 10 μM Compound-16, 41.5%; serum-
free and 15 μM Compound-16, 38.3%; serum-free and 25 μM Compound-16, 
46.7%.  Furthermore, through repeated time-course experiments, it was 
established that this cytoprotective action was effective for up to a 30 h incubation 
period before significant protection by Compound-16 was lost (Fig. 3.10).   
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Fig. 3.10 The cytoprotective effect of Compound-16 on BRIN-BD11 
β-cell death during serum starvation 
BRIN-BD11 rodent β-cells were cultured in serum–free conditions, with 
varying concentrations of Compound-16 for up to a 30 h incubation 
period. Cell death was assessed by trypan blue vital dye. Results 
represent mean ± SEM from experiments (N=6). *** p=˂0.001 vs. control  
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3.3.4 Compound-16 improves BRIN-BD11 viability but 
upregulates the ER stress marker phospho-eIF2α under lipotoxic 
stress 
The results from our previous experiments clearly demonstrate that incubating 
cells with Compound-16 significantly reduced palmitate-induced cytotoxicity in 
BRIN-BD11 cells.  Western blotting was conducted using the ER stress marker 
eIF2α, to investigate whether any changes in the phosphorylation status of this 
protein correlated with the improved cell viability seen.  BRIN-BD11 cells were 
incubated with 250 μM palmitate, 5 μM Compound-16 (the previously established 
IC50), and co-incubated with 5 μM Compound-16 and 250 μM palmitate (Fig. 3.11).  
Whole cell lysates were probed for phospho-eIF2α as described in Section 2.5.  
There was a 7.5-fold increase in phospho-eIF2α (p=<0.001) compared to the 
control.  Somewhat surprisingly, there was an even greater 8.9-fold upregulation 
of phospho-eIF2α observed in BRIN-BD11 cells when they were incubated with 
Compound-16 compared to untreated control cells (p=<0.001), despite the 
reduction in percentage cell death as shown in our previous results.  There was 
a 7.9-fold increase in phospho-eIF2α upregulation when cells were co-incubated 
with 250 μM palmitate and Compound-16 (p=<0.001), and this was 1.1-fold less 
than when cells were incubated with 250 μM palmitate alone.   
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Fig. 3.11 The effect of Compound-16 on the ER stress marker 
phospho-eIF2α in BRIN-BD11 cells 
BRIN-BD11 β-cells were incubated for 18 h with various combinations of 
250 μM palmitate, 5 μM Compound-16 or 250 μM palmitoleate. Following 
incubation, whole cell lysates were probed using phospho-eIF2α 
antibody. Results represent blots from experiments performed in triplicate 
(N=3).  
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3.3.5 Compound-16 is toxic to INS-1 cells 
The cytoprotection afforded by Compound-16 in BRIN-BD11 cells was 
investigated here for the first time to our knowledge in the INS-1 cell model.  
These cells were incubated following the protocol as detailed previously in 
Section 3.3.3.  Cell viability was assessed by trypan blue vital dye.  Surprisingly, 
despite multiple replications to test a wide range of Compound-16 concentrations, 
it was clear that this compound was poorly tolerated by the INS-1 cells (Fig. 3.12).  
Incubation with Compound-16 alone resulted in significant cell death at 
concentrations of 5 μM or above (p=<0.001).  The percentage cell deaths for this 
palmitate-free control group were as follows: control, 14.4%; 1 μM Compound-16, 
8.5%; 2.5 μM Compound-16, 11.8% and 5 μM Compound-16, 71%.  Furthermore, 
in contrast to our results presented in the BRIN-BD11 cells, co-incubation of 
Compound-16 and 250 μM palmitate did not afford significant protection against 
palmitate-induced cell death at any concentration tested.  Indeed, there was a 
significant increase in percentage cell death seen when 5 μM Compound-16 was 
co-incubated with 250 μM palmitate compared to the 250 μM palmitate control in 
this group (p=<0.001).  The percentage cell deaths for this co-incubation group 
were: control (250 μM palmitate), 64.7%; 250 μM palmitate and 1 μM Compound-
16, 55.3%; 250 μM palmitate and 2.5 μM Compound-16, 52.7% and finally, 250 
μM palmitate and 5 μM Compound-16, 82.4%.   
  
141 
 
 
 
 
  
Fig. 3.12 The cytotoxic effect of Compound-16 on INS-1 cell 
viability 
INS-1 rodent β-cells were incubated with increasing concentrations of 
Compound-16 and incubated for 24 h. A second treatment group were 
pre-incubated with the identical concentrations of Compound-16 for 1 
h, then incubated for a further 23 h with 250 μM palmitate. Cell death 
was assessed by trypan blue vital dye. Results represent mean ± SEM 
from experiments (N=8). *** p=˂0.001 vs. control, ### p=<0.001 vs. 
250 μM palmitate control 
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3.3.6 Compound-16 is toxic to MIN6 cells 
The effect of Compound-16 cells was investigated in MIN6, again for the first time 
to our knowledge.  We undertook repeated incubations testing a range of 
Compound-16 concentrations, following the protocol detailed previously in 
Section 3.3.3.  Our results showed that Compound-16 was potently toxic to MIN6 
cells (Fig. 3.13).  The incubation of Compound-16 alone with the MIN6 cells was 
highly toxic at all concentrations tested and statistically significant at all 
concentrations (p=<0.001).  The percentage cell deaths in this group were: 
control, 16.1%; 5 μM Compound-16, 82.9%; 10 μM Compound-16, 97.1%; 15 μM 
Compound-16, 98.1%; 20 μM Compound-16, 99.1% and 25 μM Compound-16, 
99.5%.  Likewise, the co-incubation of Compound-16 with 250 μM palmitate 
afforded no significant protection against palmitate-induced cell death at all 
concentrations tested.  In fact, there was significant increase in percentage cell 
death seen when all concentrations of Compound-16 were co-incubated with 250 
μM palmitate compared to the 250 μM palmitate control group (p=<0.001).  The 
percentage cell deaths when MIN6 cells were co-incubated with 250 μM palmitate 
and Compound-16 were: control (250 μM palmitate), 63.3%; 250 μM palmitate 
and 5 μM Compound-16, 88.9%; 250 μM palmitate and 10 μM Compound-16, 
98.2%; 250 μM palmitate and 15 μM Compound-16, 99.7%; 250 μM palmitate 
and 20 μM Compound-16, 99.3% and finally, 250 μM palmitate and 25 μM 
Compound-16, 98.9%.   
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Fig. 3.13 The cytotoxic effect of Compound-16 on MIN6 cell viability 
MIN6 rodent β-cells were treated with increasing concentrations of 
Compound-16 and incubated for 72 h. A second treatment group of MIN6 
cells were pre-incubated with identical concentrations of Compound-16 for 
1 h, then incubated for a further 72 h with 250 μM palmitate. Cell death was 
assessed by trypan blue vital dye. Results represent mean ± SEM from 
experiments (N=6). *** p=˂0.001 vs. control in both groups 
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3.3.7 The role of PERK and PKR in ER stress in BRIN-BD11 cells: 
use of adenoviral vectors  
Lee and colleagues (2007) were one of the first groups to propose a less major 
role for PERK in apoptotic pathways, and suggested that this role may be fulfilled 
by PKR.  Following on from the targeted small molecule inhibition of PKR using 
Compound-16, we used an alternative investigative technique employing 
dominant negative (DN) adenoviral vectors to transiently reduce protein function 
of both PERK and PKR.  The aim here was to study in parallel the individual and 
the combined activity of PERK and PKR kinases when BRIN-BD11 cells were 
incubated with 250 μM palmitate.   
 
Culture conditions and the use of DN adenoviral vectors in BRIN-BD11 cells were 
carried out as described in Sections 2.6.1 and 2.6.2.  All groups were treated with 
250 μM palmitate and transfected with DN vectors individually or co-transfected 
with both vectors.  Whole cell lysates were extracted for Western blotting and 
probed using the ER stress marker eIF2α to investigate alterations to its 
phosphorylation status (Fig. 3.14).   
 
There was no statistically significant difference between the expression of 
phospho-eIF2α in parental BRIN-BD11 cells with normal kinase activity treated 
with 250 μM palmitate, and the expression of phospho-eIF2α in cells transfected 
with the Ad/GV16 empty vector incubated with 250 μM palmitate.  By contrast, 
there was a 3.8-fold decrease in phospho-eIF2α expression in the cells 
transfected with the Ad-PERKΔC vector incubated with 250 μM palmitate, 
compared with the 250 μM palmitate-treated control cells (p=<0.001).  However, 
a 5.4-fold decrease in phospho-eIF2α expression was also detected in the cells 
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transfected with the Ad-Δ6PKR vector incubated with 250 μM palmitate, when 
compared with the 250 μM palmitate treated control cells (p=<0.001).  Finally, a 
4.6-fold decrease in phospho-eIF2α expression was detected in the cells 
transfected with both Ad-PERKΔC and Ad-Δ6PKR vectors treated with 250 μM 
palmitate, compared with the 250 μM palmitate-treated control cells (p=<0.001).   
 
 
 
 
  
Fig. 3.14 The effect of PERK and PKR DN vectors on the ER stress 
marker phospho-eIF2α in BRIN-BD11 β-cells 
BRIN-BD11 cells were transfected with empty vector or dominant 
negative vectors (1 μl/25 cm2 flask) and cultured for 16 h in complete 
medium. This was replaced with serum-free culture medium and 250 μM 
palmitate before a further 18 h incubation period. Following incubation, 
whole cell lysates were probed using phospho-eIF2α antibody. Results 
represent blots from experiments performed in triplicate (N=3). 
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3.3.8 Quantification and selection of BRIN-BD11 PKR KD clonal 
cells 
To supplement our existing data, a different approach to investigate the role of 
PKR was employed.  By using RNAi techniques to specifically target PKR, clonal 
BRIN-BD11 PKR knockdown (KD) cells were created to manipulate PKR 
expression as detailed previously in Sections 2.6.3 – 2.6.7.  Initially, whole cell 
lysates from the various PKR KD clones created were subjected to Western 
blotting and probed with a PKR antibody, to determine the extent of PKR KD (Fig. 
3.15).  This enabled the selection of suitable clones for experiments.   
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Fig. 3.15 Western blot of BRIN-BD11 PKR KD clones 
BRIN-BD11 cells were transfected with rat PKR shRNA plasmid DNA with 
a puromycin-resistant marker. Cells were subsequently incubated with 
puromycin positive culture medium so only cells with the puromycin 
resistance survived. Individual colonies of transfected cells were picked and 
further cultured and grown. Once adequate cell growth had been achieved, 
whole cell lysates were probed using PKR antibody. Results represent blots 
from experiments performed in triplicate (N=3).   
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Two clones were selected along with a PKR scrambled vector (SV) as control 
cells.  There was no statistically significant difference between the expression of 
PKR in the parental BRIN-BD11 cells or the SV PKR clone.  There was 
approximately 70% KD in the BRIN-BD11 PKR KD 333 clonal cells and 
approximately 95% KD in the BRIN-BD11 PKR KD 335 clonal cells when 
compared to the level of PKR expression in the parental control cells (p=<0.001).   
 
3.3.9 BRIN-BD11 PKR KD clonal cell responses to palmitate 
The selected PKR clones were used to investigate whether KD of the PKR protein 
affected cell viability in response to incubation with different FA species.  It was 
important however, to initially establish that there was no observable difference 
in responses to FA species between the parental BRIN-BD11 cells and the 
control BRIN-BD11 PKR SV cells.   
 
Our results from these novel experiments demonstrated that when both cell lines 
(parental BRIN-BD11 cells and BRIN-BD11 PKR SV cells), were incubated with 
increasing concentrations of palmitate, a dose-dependent increase in cell death 
was observed in line with our previous findings presented in Section 3.3.1.  More 
critically however, there was no significant difference in the amount of percentage 
cell death seen between the parental BRIN-BD11 cells and the BRIN-BD11 PKR 
SV cells (Fig 3.16).   
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Fig. 3.16 The cytotoxic effect of palmitate on BRIN-BD11 PKR SV 
β-cell death is the same as parental BRIN-BD11 β-cells 
BRIN-BD11 β-cells and BRIN-BD11 PKR SV cells were treated with 
increasing palmitate concentrations and incubated for 18 h. Cell death 
was assessed by flow cytometry using propidium iodide staining. 
Results represent mean ± SEM from experiments in triplicate (N=3).  
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The next set of studies aimed to assess the level of cell death observed in the 
individual PKR KD clonal cell lines compared to the BRIN-BD11 SV control cells 
during the same experimental conditions.  Our results here showed that palmitate 
induced a dose-dependent cytotoxic effect on the BRIN-BD11 PKR KD 333 cells 
(Fig. 3.17).  These findings correlated with other rodent cell models presented in 
Section 3.3.1.  We observed a 1.2-fold increase in cell death in the 10 μM 
palmitate-treated group compared to the BRIN-BD11 PKR KD 333 control.  
Although showing a trend towards increasing cell death, this was not statistically 
significant.  There was a 1.9-fold increase in cell death in the 25 μM palmitate-
treatment group compared to the BRIN-BD11 PKR KD 333 control (p=<0.01).  
We observed a 2.7-fold increase in cell death in the 50 μM palmitate-treatment 
group compared to the BRIN-BD11 PKR KD 333 control (p=<0.001).  There was 
a 4-fold increase in cell death in the 100 μM palmitate-treatment group compared 
to the BRIN-BD11 PKR KD 333 control (p=<0.001), and finally we saw a 4.6-fold 
increase in cell death in the 250 μM palmitate-treatment group compared to the 
BRIN-BD11 PKR KD 333 control (p=<0.001).   
 
Furthermore, when comparing the amount of cell death between the two cell lines, 
there was a 3.2-fold decrease in cell death observed in the BRIN-BD11 PKR KD 
333 control cells when compared to the BRIN-BD11 PKR SV control cells 
(p=<0.001).  A 3-fold decrease in cell death was seen when comparing the BRIN-
BD11 PKR KD 333 cells treated with 10 μM palmitate, with the BRIN-BD11 PKR 
SV cells treated with 10 μM palmitate (p=<0.001).  A 2.8-fold decrease in cell 
death was seen when comparing the BRIN-BD11 PKR KD 333 cells treated with 
25 μM palmitate, with the BRIN-BD11 PKR SV cells treated with 25 μM palmitate 
(p=<0.001).  A 2.7-fold decrease in cell death was seen between the BRIN-BD11 
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PKR KD 333 cells treated with 50 μM palmitate and the BRIN-BD11 PKR SV cells 
treated with 50 μM palmitate (p=<0.001).  Finally, a 1.7-fold decrease was 
observed when comparing the BRIN-BD11 PKR KD 333 cells treated with 100 
μM palmitate, with the BRIN-BD11 PKR SV cells treated with 100 μM palmitate 
(p=<0.01).  No statistical difference was seen between either cell line treated with 
250 μM palmitate.   
 
 
 
 
  
Fig. 3.17 The cytotoxic effect of palmitate on BRIN-BD11 PKR KD 
333 β-cell death is less than in BRIN-BD11 PKR SV β-cells 
BRIN-BD11 PKR SV β-cells and BRIN-BD11 PKR KD 333 clonal cells 
were treated with increasing palmitate concentrations and incubated for 
18 h. Cell death was assessed by flow cytometry using propidium iodide 
staining. Results represent mean normalised data ± SEM from 
experiments in triplicate (N=3). *** p=˂0.001, ** p=<0.01 vs. BRIN-BD11 
PKR SV control cells; ### p=<0.001, ## p=<0.01 vs. BRIN-BD11 333 
control 
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Our next results are data presented from the BRIN-BD11 PKR KD 335 cells.  
Again, in line with our other rodent data, these show that palmitate induced a 
dose-dependent cytotoxic effect in the BRIN-BD11 PKR KD 335 cell line (Fig. 
3.18).  There was a modest 1.1-fold and 1.3-fold increase in cell death seen in 
the 10 and 25 μM palmitate-treatment groups respectively, compared to the 
BRIN-BD11 PKR KD 335 control.  Although demonstrating a trend towards 
increasing cell death, these were not statistically significant.  There was a 1.6-
fold increase in cell death in the 50 μM palmitate-treatment group compared to 
the BRIN-BD11 PKR KD 335 control (p=<0.05).  We observed a 2.8-fold increase 
in cell death in the 100 μM palmitate-treatment group compared to the BRIN-
BD11 PKR KD 335 control (p=<0.001).  Finally, we saw a 4-fold increase in cell 
death in the 250 μM palmitate-treatment group compared to the BRIN-BD11 PKR 
KD 335 control (p=<0.001).   
 
Upon comparison of the BRIN-BD11 PKR KD 335 cells with the BRIN-BD11 PKR 
SV cells, there was a 3.3-fold decrease in the amount of cell death seen when 
comparing the PKR KD 335 control cells with the PKR SV control cells (p=<0.001).  
A 3-fold decrease in cell death was seen when comparing the BRIN-BD11 PKR 
KD 335 cells treated with 10 μM palmitate, with the BRIN-BD11 PKR SV cells 
treated with 10 μM palmitate (p=<0.001).  A 2.8-fold decrease in cell death was 
seen when comparing the BRIN-BD11 PKR KD 335 cells treated with 25 μM 
palmitate, with the BRIN-BD11 PKR SV cells treated with 25 μM palmitate 
(p=<0.001).  A 2.7-fold decrease in cell death was seen between the BRIN-BD11 
PKR KD 333 cells treated with 50 μM palmitate and the BRIN-BD11 PKR SV cells 
treated with 50 μM palmitate (p=<0.001).  A 1.7-fold decrease was observed 
when comparing the BRIN-BD11 PKR KD 335 cells treated with 100 μM palmitate, 
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with the BRIN-BD11 PKR SV cells treated with 100 μM palmitate (p=<0.001).  
Finally, a 1.3-fold decrease in cell death was seen between the BRIN-BD11 PKR 
KD 335 cells treated with 250 μM palmitate and the BRIN-BD11 PKR SV cells 
treated with 250 μM palmitate (p=<0.01). 
 
 
 
  
Fig. 3.18 The cytotoxic effect of palmitate on BRIN-BD11 PKR KD 335 
β-cell death is less than in BRIN-BD11 PKR SV β-cells 
BRIN-BD11 PKR SV control β-cells and BRIN-BD11 PKR KD 335 clonal 
cells were treated with increasing palmitate concentrations and incubated 
for 18 h. Cell death was assessed by flow cytometry using propidium 
iodide staining. Results represent mean normalised data ± SEM from 
experiments in triplicate (N=3). *** p=˂0.001, ** p=<0.01 vs. BRIN-BD11 
PKR SV control cells, ### p=<0.001, # p=<0.05 
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In these last results for this section, we report that the BRIN-BD11 PKR KD 335 
clonal cells were more resistant to palmitate-induced cell death than the BRIN-
BD11 PKR KD 333 clonal cells (Fig. 3.19).  There was no significant difference in 
percentage cell death seen between the controls (no palmitate), 10 or 25 μM 
palmitate-treatment groups of either cell line, although there was a trend of 
decreased percentage cell death in the BRIN-BD11 PKR KD 335 cells.  However, 
there was a 1.7-fold decrease in percentage cell death observed in the BRIN-
BD11 PKR KD 335 cells treated with 50 μM palmitate, when compared to the 
BRIN-BD11 PKR KD 333 cells treated with 50 μM palmitate (p=<0.001).  A 1.5-
fold decrease in percentage cell death was observed when comparing the BRIN-
BD11 PKR KD 335 cells treated with 100 μM palmitate, with the BRIN-BD11 PKR 
KD 333 cells treated with 100 μM palmitate (p=<0.001).  Finally, we observed a 
1.2-fold decrease in percentage cell death in the BRIN-BD11 PKR KD 335 cells 
treated with 250 μM palmitate, compared to the BRIN-BD11 PKR KD 333 cells 
treated with 250 μM palmitate (p=<0.01).   
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Fig. 3.19 The cytotoxic effect of palmitate is less in BRIN-BD11 
PKR KD 335 β-cells than BRIN-BD11 PKR KD 333 β-cells 
BRIN-BD11 PKR KD 333 clonal β-cells and BRIN-BD11 PKR KD 335 
clonal β-cells were treated with increasing palmitate concentrations 
and incubated for 18 h. Cell death was assessed by flow cytometry 
using propidium iodide staining. Results represent mean ± SEM from 
experiments in triplicate (N=3). *** p=˂0.001, ** p=<0.01 vs. BRIN-
BD11 PKR KD 333 cells 
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3.3.10 BRIN-BD11 PKR KD clonal cell responses to palmitoleate 
As the final set of experiments in this section, we aimed to investigate the 
responses of the PKR KD β-cells to incubation with the LC-MUFA palmitoleate.  
The treatment of both cell lines with 250 μM palmitate resulted in a significant 
increase in percentage cell death compared to the controls (p=<0.001).  This was 
in line with our previous findings.  Incubation with 250 μM palmitoleate alone was 
well-tolerated in both cell lines, with an approximate 3-fold reduction in 
percentage cell death seen in the 250 μM palmitoleate-treatment groups 
compared to the 250 μM palmitate-treatment groups (p=<0.001).  Likewise, 
percentage cell death was significantly reduced when cells were co-incubated 
with both palmitate and palmitoleate, compared to the palmitate treated groups 
(p=<0.001).  Importantly, there was no significant difference in the amount of 
percentage cell death observed between the parental BRIN-BD11 cells or the 
BRIN-BD11 PKR SV cells (Fig. 3.20).  To fully quantify these findings, percentage 
cell deaths observed in the parental BRIN-BD11 cells were as follows: control, 
20.2%; 250 μM palmitate, 63.6%; 250 μM palmitoleate, 9.8% and both FA 
species, 10.5%.  The percentage cell deaths seen in the BRIN-BD11 PKR SV 
cells were: control, 20.8%; 250 μM palmitate 66.2%; 250 μM palmitoleate 11% 
and finally, both FA species, 11.4%. 
  
157 
 
 
 
  
Fig. 3.20 The cytoprotective effect of palmitoleate on BRIN-BD11 
PKR SV β-cell viability is the same as parental BRIN-BD11 β-cells 
Parental BRIN-BD11 β-cells and BRIN-BD11 PKR SV cells were treated 
250 μM palmitate, 250 μM palmitoleate or a combination of both FA 
species and incubated for 18 h. Cell death was assessed by flow 
cytometry using propidium iodide staining. Results represent mean ± 
SEM from experiments in triplicate (N=3). *** p=˂0.001 vs. controls; ### 
p=<0.001 vs. palmitate-treated cells 
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The cytoprotective effect of PKR KD was greater in the BRIN-BD11 PKR KD 333 
clonal β-cells than in the BRIN-BD11 PKR SV cells (Fig. 3.21).  There was a 
significant 1.5-fold decrease in percentage cell death seen between the control 
group of the BRIN-BD11 PKR KD 333 cells, compared to the control group of the 
BRIN-BD11 PKR SV cells (p=<0.01).   Furthermore, there was a 1.6-fold 
decrease in percentage cell death seen in the BRIN-BD11 PKR KD 333 cells 
treated with 250 μM palmitate compared to the palmitate-treatment group of the 
BRIN-BD11 PKR SV cells (p=<0.001).  There was no statistical difference 
between either cell line when comparing the percentage cell deaths observed in 
the 250 μM palmitoleate-treatment groups, or the groups co-incubated with both 
FA species.  To fully quantify these results, percentage cell deaths in the BRIN-
BD11 PKR 333 cell line, percentage cell deaths were as follows: control, 13.6%; 
250 μM palmitate, 40.8%; 250 μM palmitoleate, 10.2% and both FA species, 
8.7%.   
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Fig. 3.21 The cytoprotective effect of palmitoleate on BRIN-BD11 
PKR KD 333 β-cells is greater than in parental BRIN-BD11 β-cells 
Parental BRIN-BD11 β-cells and BRIN-BD11 PKR KD 333 cells were 
treated 250 μM palmitate, 250 μM palmitoleate or a combination of both 
FA species and incubated for 18 h. Cell death was assessed by flow 
cytometry using propidium iodide staining. Results represent mean ± 
SEM from experiments in triplicate (N=3). *** p=˂0.001, ** p= 0.01 vs. 
BRIN-BD11 PKR SV cells 
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The cytoprotective effect of PKR KD was significantly greater in the BRIN-BD11 
PKR KD 335 clonal β-cells compared to the BRIN-BD11 PKR SV cells when 
treated alone or when co-incubated with both FA species (Fig. 3.22).  There was 
a significant 3.9-fold decrease in percentage cell death observed in the control 
group of the BRIN-BD11 PKR KD 335 cells compared to the BRIN-BD11 PKR 
SV control group (p=<0.001).  A 2.2-fold decrease in percentage cell death was 
seen in the 250 μM palmitate-treatment group of the BRIN-BD11 PKR KD 335 
cells compared to the BRIN-BD11 PKR SV cells treated with 250 μM palmitate 
(p=<0.001).  There was a 2.8 fold reduction in percentage cell death observed in 
the BRIN-BD11 PKR KD 335 cells treated with 250 μM palmitoleate, compared 
to the BRIN-BD11 PKR SV group treated with 250 μM palmitoleate (p=<0.001).  
Finally, there was a 2.9-fold decrease in percentage cell death observed in the 
BRIN-BD11 PKR KD 335 cells treated with both FA species, compared to the 
BRIN-BD11 PKR SV group treated with both FA species (p=<0.001).  Full 
quantification of percentage cell death results in the BRIN-BD11 PKR KD 335 
cells are as follows: control, 5.4%; 250 μM palmitate, 29.5%; 250 μM palmitoleate, 
4.1% and both FA species, 4.1%. 
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Fig. 3.22 The cytoprotective effect of palmitoleate on BRIN-BD11 
PKR KD 335 β-cells is greater than in parental BRIN-BD11 β-cells 
Parental BRIN-BD11 β-cells and BRIN-BD11 PKR KD 335 cells were 
treated 250 μM palmitate, 250 μM palmitoleate or a combination of both 
FA species and incubated for 18 h. Cell death was assessed by flow 
cytometry using propidium iodide staining. Results represent mean ± 
SEM from experiments in triplicate (N=3). *** p=˂0.001 vs. BRIN-BD11 
cells 
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A final comparison was made between the two PKR KD clonal cell lines (Fig. 
3.23).  From this comparison, we saw that there was significantly less percentage 
cell death seen in the BRIN-BD11 PKR KD 335 clonal cells in all treatment groups 
compared to the BRIN-BD11 PKR KD 333 cells.  There was a 2.5-fold reduction 
in percentage cell death seen in the BRIN-BD11 PKR KD 335 control group 
compared to the control of the BRIN-BD11 PKR KD 333 cells (p=<0.001).  We 
observed a 1.4-fold reduction in percentage cell death in the BRIN-BD11 PKR 
KD 335 cells treated 250 μM palmitate compared to the 250 μM palmitate-
treatment group in the BRIN-BD11 PKR KD 333 cells (p=<0.01).  There was a 
2.6-fold decrease in percentage cell death seen in the BRIN-BD11 PKR KD 335 
cells treated with 250 μM palmitoleate, compared to the 250 μM palmitoleate-
treatment group in the BRIN-BD11 PKR KD 333 cells (p=<0.01).  Finally, we saw 
a 2.2-fold decrease in percentage cell death seen in the BRIN-BD11 PKR KD 335 
cells treated with both FA species, compared to the co-incubation of FA species 
in the BRIN-BD11 PKR KD 333 cells (p=<0.01).   
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Fig. 3.23 The cytoprotective effect of palmitoleate on BRIN-BD11 
PKR KD 335 β-cells is greater than on BRIN-BD11 PKR KD 333 β-
cells 
BRIN-BD11 PKR KD 333 β-cells and BRIN-BD11 PKR KD 335 cells 
were treated 250 μM palmitate, 250 μM palmitoleate or a combination 
of both FA species and incubated for 18 h. Cell death was assessed 
by flow cytometry using propidium iodide staining. Results represent 
mean ± SEM from experiments in triplicate (N=3). *** p=˂0.001, ** 
p=<0.01 vs. BRIN-BD11 PKR KD 333 cells 
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3.4 Summary of novel results 
 A transient KD approach using Compound-16, a putative small molecule 
inhibit of PKR, showed that between concentrations of 5 – 25 μM, Compound-
16 significantly protected BRIN-BD11 cells (p=<0.001) against palmitate-
induced cell death compared to control cells treated with palmitate (Fig. 3 .9). 
 Compound-16 significantly protected BRIN-BD11 cells against serum-
starvation (p=<0.001).  This was effective for up to a 30 h incubation period 
before significant protection by Compound-16 was lost (Fig. 3.10).   
 Western blotting of lysates from BRIN-BD11 cells incubated with 5 μM 
Compound-16 showed a significant increase (p=<0.001) in the ER stress 
marker phospho-eIF2α (Fig. 3.11), despite improving cell viability during 
chronic palmitate exposure.   
 Compound-16 is significantly cytotoxic to INS-1 cells (Fig. 3.12) at ≥ 5 μM 
concentrations (p=<0.001).  Moreover, Compound-16 is potently cytotoxic to 
MIN6 cells (Fig. 3.13) at all concentrations tested (0.5 – 25 μM, p=<0.001).   
 The use of PERK and PKR DN adenoviral vectors demonstrated that transient 
KD of these kinases individually, or together, significantly reduced eIF2α 
phosphorylation (p=<0.001) (Fig. 3.14).   
 The use of shRNA to create stable PKR KD clones in BRIN-BD11 cells, 
demonstrated that KD of PKR significantly protected cells against palmitate-
induced cell death (p=<0.001), when compared to the PKR SV control clone.  
The 95% KD clone afforded greater protection than the 70% KD clone 
(p=<0.001).  Furthermore, PKR KD significantly potentiated the cytoprotective 
action of palmitoleate (p=<0.001) (Fig. 3.16 – Fig. 3.23).   
  
165 
 
3.4 Discussion  
The structural requirements for the cytotoxic or cytoprotective action of different 
FA species when incubated with rodent pancreatic β-cells have been well 
established in previous studies.  However, there are inconsistencies within the 
literature with regard to the potency of cytotoxicity or cytoprotection seen between 
the various FA species (Welters et al., 2004; Eitel et al., 2003; Dhayal et al., 2008, 
Newsholme et al., 2007; Wei et al., 2006; El-Assaad et al., 2003; Moffitt et al., 
2005; Diakogiannaki et al., 2007; Diakogiannaki et al., 2008; Morgan et al., 2008).  
This is likely attributable to a varied approach to experimental design between 
studies.  For example, different cell models and passage number have been 
adopted; varying incubation periods and glucose concentrations, and different 
ratios of FA species to BSA are all notable examples of experimental variability 
that have been documented throughout the literature.  
 
For our studies, we sought to investigate the most appropriate cell model to 
investigate the role of the PKR protein in response to LC-SFA and LC-MUFA 
species in conditions of lipotoxicity.  To do this, we first needed to validate and 
standardise our experimental conditions between the cell models used.  We used 
chronic palmitate incubation conditions to evoke an ER stress response and 
induce cell death within our pancreatic β-cell models.  Our first experiment 
demonstrated that indeed, palmitate was cytotoxic to our cells over a chronic 24 
h incubation period.  Importantly however, our data served to emphasise that the 
extent of percentage cell death induced by palmitate was very different between 
the cell lines.   
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MIN6 cells are reported to express signiﬁcantly higher levels of ER chaperone 
proteins, such as GRP78, than INS-1 and BRIN-BD11 cells and as such, it is 
noted these cells are more resistant to apoptosis and ER stress induced by 
palmitate incubation (Lai et al., 2008; Diakogiannaki et al., 2008).  MIN-6 β-cells 
are also reported to express high levels of stearoyl-CoA desaturase 1 (SCD1), 
an enzyme that desaturates FA and favours TG synthesis, a capacity that may 
confer protection by making these pancreatic β-cells less susceptible to 
lipotoxicity (Busch et al., 2005).  This may account for the higher resistance to ER 
stress and subsequently lower levels of palmitate-induced cell death seen in 
MIN6 cells during lipotoxic incubation conditions.  This may also explain why 
conversely the protective effects of palmitoleate in MIN6 cells are not so 
pronounced, and correlates with the reduced upregulation state of phospho-
eIF2α observed in MIN6 cells when they were incubated with palmitate in these 
studies.   
 
Our results showed a 4.2 fold-decrease in percentage cell death between the 
BRIN-BD11 cells and the MIN6 β-cells, and a 2.5-fold decrease in percentage 
cell death between the BRIN-BD11 cells and the INS-1 β-cells, indicating that the 
BRIN-BD11 cells are more susceptible to palmitate-induced cell death.  This data 
correlates with results shown previously by our group (Welters et al., 2004; 
Dhayal et al., 2008, Newsholme et al., 2007; Diakogiannaki et al., 2007; 
Diakogiannaki et al., 2008; Morgan et al., 2008).  However, given this in vitro β-
cell variability in response to chronic FA incubation, for meaningful comparisons 
to be made between cell models, we needed to determine an optimal incubation 
period for each cell line.  Time-course experiments allowed us to define these 
cell-model specific incubation periods.   
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Having achieved this, we demonstrated comparable percentage cell deaths 
between the cell models in dose-curve studies.  The LC-SFA palmitate exerts a 
dose-dependent cytotoxic effect on pancreatic β-cells, and the LC-MUFA 
palmitate induces a dose-dependent cytoprotective effect on the pancreatic β-
cells.  Furthermore, the in vitro co-incubation of palmitate with palmitoleate was 
able to attenuate the cytotoxic effects observed when pancreatic β-cells are 
incubated with palmitate.  In addition, we showed that the incubation of β-cells 
with palmitate led to an upregulation of the ER stress marker phospho-eIF2α, a 
protein integral to cell survival pathways in cells subjected to persistent ER stress.  
This outcome was consistently observed in all three rodent pancreatic β-cell lines 
tested under the same experimental conditions.  This preliminary set of 
experiments was felt to be a critical standardisation step, and to confirm that 
previous results were not specific to a particular cell model.   
 
Notwithstanding the previous validation steps, these results do not shed light on 
specific molecular mechanisms that may underlie these cytotoxic or 
cytoprotective actions.  It has been suggested that lipotoxicity initiates ER stress, 
which if persistent drives β-cell apoptosis.  This mechanism is thought to underlie 
the progression of T2D, but the exact molecular processes that mediate these 
proapoptotic effects in response to FA are unclear (Qu et al., 2009; Breckenridge 
et al., 2003; Laybutt et al., 2007; Eizirik et al., 2008; Özcan et al., 2004; Kharroubi 
et al., 2004; Scheuner and Kaufman, 2008; Karaskov et al., 2006; Cnop et al., 
2007).  However, pancreatic β-cell apoptosis involving the PERK-dependent arm 
of the ER stress pathway as a result of lipotoxicity has been well established 
(Morgan et al., 2008; Diakogiannaki et al., 2008; Cnop et al., 2008; Diakogiannaki 
and Morgan, 2008; Scheuner and Kaufman, 2008; Laybutt et al., 2007; Song et 
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al., 2007; Lee et al., 2007).  This suggests a pathway by which lipotoxicity-
induced β-cell death may be targeted.  
 
Interestingly, a more recent study suggested that the PERK protein may have a 
less significant role in ER stress-mediated apoptosis than formerly thought.  Lee 
and colleagues (2007) proposed that PERK may have a predominant cell-survival 
role under ER stress conditions.  By contrast, the PKR protein was found to be 
simultaneously but independently activated alongside PERK under lipotoxic 
conditions and as such, was suggested to assume a greater proapoptotic role 
than previously thought (Lee et al., 2007; Lai et al., 2008; Morgan, 2009).  
Adopting the use of suitable cell models to conduct more in-depth investigations 
into the functional properties of PKR may be instrumental in understanding the 
exact role of this protein in lipotoxic mechanisms, and furthermore, may indicate 
whether PKR could be a potential viable target for pharmacological intervention 
in the treatment of T2D.   
 
There are currently two models of PKR-null mice, but results suggest that these 
models elicit a normal response to IFN and furthermore, they respond almost 
normally to viral infection.  These results are atypical, because by knocking out 
PKR, one would expect an effect on the anti-viral, anti-tumoral and apoptotic 
pathways where PKR is an integral protein, but this is not the case.  These 
aberrant responses have been explained by the possible activation of redundant 
pathways involving other eIF2-α kinases, suggested to compensate for the loss 
of functional PKR in these mice (Abraham et al., 1999; Yang et al., 1995; Jammi 
et al., 2003).  Notwithstanding this, these findings highlight the unsuitability of 
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these particular mouse models for PKR-specific studies, and emphasise the need 
for different approaches to enable exclusive manipulation of PKR activity.   
 
A small molecule inhibitor of PKR could potentially provide a solution to this 
redundancy problem, because the induced inhibition of translation could be 
blocked precisely with PKR as a sole and specific target, if indeed PKR is the 
upstream mediator that phosphorylates eIF2α.  2-Aminopurine (2-AP) was 
heralded as one such small molecule, and has been historically widely used to 
disrupt protein synthesis following viral infection (Huang and Schneider, 1990; 
Frémont et al., 2006; Jammi et al., 2003).  However, 2-AP was demonstrated to 
inhibit other protein kinases so was clearly not specific to PKR, which questions 
the validity of any such results (Posti et al., 1999).  Jammi and colleagues (2003) 
screened a library of different ATP-binding site-directed inhibitors of PKR and 
found a high-affinity PKR inhibitor named Compound-16.  This molecule was 
demonstrated to effectively inhibit RNA-induced PKR autophosphorylation (IC50 
= 210 ± 0.04 μM) and rescued PKR-dependent translation block to 50% (vs. 
control) at a concentration of 10 μM.   
 
This brings us to the main investigative aim of this chapter.  Preliminary 
experiments by our group suggested that Compound-16 may exert an inhibitory 
effect on palmitate-mediated toxicity in BRIN-BD11 cells.  This compound was 
therefore adopted in these studies to selectively inhibit autophosphorylation and 
activation of the PKR protein in rodent β-cell lines incubated with different FA 
species.  Following dose-curve experiments, our results here confirm that indeed, 
Compound-16 is capable of significantly rescuing BRIN-BD11 cells from 
palmitate-induced cell death with an effective range between 5 μM – 25 μM in 
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line with our previous findings.  Furthermore, results established that the BRIN-
BD11 cells were not detrimentally affected by sole incubation with Compound-16 
at the concentrations tested.   
 
It has been generally accepted that the GCN2 kinase is activated in response to 
nutrient deprivation (Wek et al., 2006), although a newly identified role for PKR 
within nutrient sensing pathway suggests that there is a level of redundancy 
within this kinase family (Nakamura et al., 2010).  It is important to consider that 
a role for PKR involvement in nutrient sensing may include nutrient deprivation 
as well as nutrient overload.  Therefore, the effect of Compound-16 under 
conditions of serum starvation was also investigated in BRIN-BD11 cells.  Our 
results here for the first time, show a significant reduction in cell death when cells 
were incubated with 10, 15 and 25 μM concentrations of Compound-16.  
Furthermore, our results demonstrate that the cytoprotective effect of Compound-
16 was able to significantly ameliorate cell death induced by serum withdrawal, 
and this cytoprotection was significant for up to a 30 h incubation period.  This 
suggests that the inhibition of PKR phosphorylation during lipotoxic conditions 
can improve cell viability.  However, these results alone do not prove that the 
inhibition of the PKR protein is solely responsible for this outcome.   
 
The eIF2α protein has been extensively used to demonstrate that cells incubated 
with palmitate exhibit ER stress, as seen by upregulation of the phosphorylation 
status of this protein.  Elevated phospho-eIF2α is consistently shown to correlate 
with an in vitro increase in percentage cell death in cell models incubated with 
SFA species (Dhayal et al., 2008; Diakogiannaki et al., 2007; Diakogiannaki et 
al., 2008; Cnop et al., 2007).  By contrast, sole or co-incubation of pancreatic β-
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cells with palmitoleate confers protection against palmitate-induced toxicity.  This 
is shown by a decrease in percentage cell death (Welters et al., 2004) and a 
reduction in the level of phospho-eIF2α seen (Dhayal et al., 2008; Diakogiannaki 
et al., 2007; Diakogiannaki et al., 2008; Cnop et al., 2008).  Western blotting to 
investigate the phosphorylation of eIF2α was conducted on cells incubated with 
Compound-16.  It was expected that due to the improved cell viability observed, 
a reduction in the phosphorylation status of eIF2α would also be seen.   
 
However, our results showed that despite improved cell viability, the 
phosphorylation status of eIF2α was consistently higher when cells were co-
incubated with Compound-16 and palmitate, than when cells were incubated with 
palmitate alone.  This suggests that Compound-16 may exert its cytoprotective 
effects via a different signalling pathway, not involving eIF2α.  This may be a cell-
specific phenomenon but interestingly, Chen et al., (2008) also found that while 
Compound-16 conferred protection against death in a neuronal cell model they 
used, it did not reduce phosphorylation of eIF2α.  Therefore, our data appears to 
support this phenomenon.  Furthermore, Shimazawa and Hara (2006) reported 
that Compound-16 successfully inhibited PKR following tunicamycin-induced ER 
stress and improved cell viability in a different neuronal cell model.  However, a 
limitation of the Shimazawa and Hara (2006) study was that improved cell viability 
was not correlated with phospho-PKR or phopho-eIF2α quantification; therefore 
it is difficult to make any conclusions regarding PKR or eIF2α involvement from 
this.   
 
Nonetheless, we decided to extend our studies to test the efficacy of Compound-
16 in INS-1 cells and MIN6 cells, as to our knowledge, PKR inhibition in these 
172 
 
cell lines using this compound has not yet been reported.  Surprisingly, 
Compound-16 was potently cytotoxic when incubated alone or when co-
incubated with palmitate.  Our results demonstrated a huge increase in 
percentage cell death compared to the control cells in both cell models.  
Cytotoxicity was greater in the MIN6 cells compared to the INS-1 cells but 
nevertheless, it was clear that no protection was afforded by Compound-16 in 
either cell model.  Section 4.3.4 covers additional Compound-16 studies 
conducted in a novel human pancreatic β–cell 1.1B4, but to prevent repetition, 
has been collectively discussed below.  
 
Initially, it was considered that the DMSO concentration used to dissolve 
Compound-16 may have been responsible for such a dramatic loss of cell 
viability.  DMSO-related toxicity in cell culture models has been suggested within 
the literature (Hanslick et al., 2009), although this appears to be more commonly 
associated with high concentrations used for cryopreservation purposes 
(Zambelli et al., 1998).  However, we conducted extensive dose-dependent 
experiments using DMSO in the BRIN-BD11, INS-1, MIN6 and 1.1B4 cell lines 
(data not shown) and these results demonstrated that DMSO (≤ 10%) was well 
tolerated in chronic incubation conditions (≤24 h) before exerting any significant 
detrimental effect on cell viability.  The experimental conditions we followed under 
which DMSO was used as a vehicle to introduce Compound-16 into the cell 
models, dictated that we essentially used DMSO at very low concentrations 
(<0.01%).  Moreover, in light of the clear cytoprotective effect in the BRIN-BD11 
cells using Compound-16 dissolved in DMSO in identical culture conditions, when 
taken together, we considered it unlikely that DMSO-toxicity was the cause for 
such extensive cell death.   
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Furthermore, during the course of testing DMSO for cytotoxicity in the cell 
models, it became evident that additional factors were involved.  In contrast to 
our previously reported findings, the incubation of Compound-16 with the BRIN-
BD11 cells unexpectedly resulted in extreme toxicity to this cell-line, whereas 
previously, it had afforded consistent cytoprotection against palmitate-induced 
cell death.  The MSDS sheet recommended storing the diluted Compound-16 
stock solution at -20 °C.  However, after a storage period of about 3 – 4 weeks, it 
became apparent that the stock solution degraded at -20 °C and became 
cytotoxic in a manner not typically observed when fresh stocks were used in the 
initial BRIN-BD11 cell experiments.  As a consequence of this previously 
undocumented observation, and following extensive supervisory discussion, a 
new stock of Compound-16 was purchased.  It was pre-diluted in an identical 
manner to the original stock solution, but was stored at -80 °C until required.  This 
successfully prevented the unexpected degradation-related toxicity observed in 
the BRIN-BD11 cells when using the compound after it had been stored at -20 
°C.   
 
In light of this, we conducted further dose-dependent testing of Compound-16 but 
it was clear that this compound remained potently toxic to the INS-1, MIN6 and 
1.1B4 cells.  It is not clear why this was the case when it was significantly 
cytoprotective in BRIN-BD11 cells under conditions of palmitate toxicity and 
serum starvation.  One possibility is that Compound-16 caused 100% PKR KD 
resulting in complete loss of cell viability in vitro.  However, given that PKR-null 
mice are viable this scenario is unlikely (Abraham et al., 1999; Yang et al., 1995).   
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Another possibility is that Compound-16 is not solely PKR-specific, and may 
target other e-IF2α kinases within this family, perhaps in a manner suggested to 
occur with 2-AP (Jammi et al., 2003).  This may prevent the activation of 
redundant pathways in response to PKR KD, thus preventing cell rescue from 
loss of functional PKR as mentioned earlier with regard to PKR-null mice aberrant 
responses.   
 
Jammi and colleagues (2003) also report that Compound-16 is an inhibitor of 
RNA-induced PKR autophosphorylation, that is, RNA-dependent activatory 
mechanisms.  However, it has been established that PKR can be activated by 
RNA-independent mechanisms such as lipotoxicity.  This suggests Compound-
16 may only effectively inhibit PKR when RNA-induced activation initiates PKR 
autophosphorylation, thus the compound may not able to inhibit PKR-
autophosphorylation in response to lipotoxic RNA-independent activatory 
mechanisms.   
 
It is possible that the cytoprotective effects observed in the BRIN-BD11 cells are 
an in vitro cell model-specific phenomenon.  Clearly, whatever nutrient sensing 
pathway that allows Compound-16 to rescue BRIN-BD11 cells during persistent 
stress conditions, is not active in the INS-1, MIN6 cells, or 1.1B4 cells.  Further 
studies are necessary to elucidate the exact targets of this Compound in different 
cell models, before any conclusions as to its suitability as a specific inhibitor of 
PKR can be made.   
 
Nonetheless, with specific regard to the studies in this chapter, the extreme 
toxicity of Compound-16 to INS-1 and MIN6 cells, and an established increased 
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resistance to palmitate-induced cell death in MIN6 cells, meant that these two cell 
lines were not considered to be appropriate models for further investigation.  
What can be concluded is that in BRIN-BD11 cells under our experimental 
conditions, Compound-16 was significantly cytoprotective against lipotoxicity at 
concentrations of 5 – 25 μM.  Furthermore, Compound-16 was able to 
significantly confer cytoprotection for up to 30 h against serum withdrawal at 
concentrations of 10 – 25 μM in BRIN-BD11 rodent pancreatic β-cells.   
 
To complement our Compound-16 data, we adopted the use of DN adenoviral 
vectors for transient protein inhibition.  Given the overlapping role more recently 
assigned to PKR alongside PERK within ER stress-induced pathways, it was 
considered an important step to define the independent activation status of each 
protein during lipotoxic culture conditions.  Hence, our aim was to use these 
vectors to transiently inhibit the PKR and PERK proteins so Western blotting 
could be performed, to ascertain their phosphorylation status for quantification 
and comparison purposes.   
 
Extensive validation and titration experiments were conducted to establish a viral 
titre that did not result in potent cytotoxicity.  Preliminary experiments using the 
PERK and PKR vectors resulted in 100% cell death, or caused significant visible 
and aberrant cell morphology, and atypical monolayer growth patterns in the 
BRIN-BD11 and INS-1 cells used for these studies.  This suggested that the 
vectors triggered a potent toxicity-related stress response in the cells, thus 
Western blotting of ER stress markers under these experimental conditions would 
not have been useful.  However, an appropriate viral titre and pre-dosing 
incubation period was established and confirmed through morphology studies, 
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and the absence of increased expression of phospho-eIF2α was confirmed by 
Western blotting.  Our results, shown for the first time using these vectors in the 
BRIN-BD11 cells under our unique experimental conditions, demonstrated that 
individual and combined transient KD of the PERK and PKR protein resulted in 
reduced phosphorylation of eIF2α.  Thus, our novel results in rodent pancreatic 
β-cells appear to correlate with findings by Lee and colleagues (2007), where 
they demonstrated that in HEK293 and HeLa cells, PKR KD resulted in 
decreased eIF2α activity and increase cell viability.  
 
The ability to target PKR for KD within cell culture models provides the opportunity 
to investigate the effect of PKR manipulation on both ER stress and cell viability 
during experimental conditions of lipotoxicity.  This allows an insight into the 
functional responses of cells to various FA species, where PKR function has been 
specifically targeted.  Therefore, we created stable PKR knock-down clones 
using shRNA against PKR in INS-1 and BRIN-BD11 cells.  We ultimately selected 
two BRIN-BD11 clonal cell lines and a BRIN-BD11 SV clone for use as a control 
within these novel studies.   
 
In the first instance, to ensure there were no off-target effects of the PKR 
construct, the effect of dose-dependent palmitate-induced cell death in parental 
BRIN-BD11 cells was compared against the PKR SV clone, and indeed, there 
was no significant difference in percentage cell death between either cell line.  
This was an important initial step to verify that the SV cells responded to our 
experimental conditions in the same way as the parental BRIN-BD11 cells.  
Furthermore, this suggested that no immediate off-targets effects due to the PKR 
vector were apparent.   
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Our two clones BRIN-BD11 PKR 333 and PKR 335, with PKR KD of 
approximately 70% and 95% respectively, were used to investigate functional 
responses to FA species under conditions of lipotoxicity.  Our results from these 
studies clearly showed a significant reduction in percentage cell death in both 
PKR clones compared to the parental BRIN-BD11 cells.  Furthermore, the most 
significant protection against palmitate-induced cell death was observed in the 
clone with the highest level of PKR KD.   
 
It has been well cited-in the literature that the incubation of pancreatic β-cell 
models with palmitoleate can protect against palmitate-induced toxicity (Welters 
et al., 2004; Dhayal et al., 2008; Diakogiannaki et al., 2007; Diakogiannaki et al., 
2008; Cnop et al., 2008; Eitel et al., 2003; Morgan et al., 2008).  However, while 
the underlying molecular mechanisms of this protection are not yet fully 
elucidated, it has been suggested that due to the rapid initiation of protection, 
cytoprotection may be receptor-mediated (Morgan, 2009).  Our results here for 
the first time demonstrate that PKR KD appears to mediate enhanced 
cytoprotection by palmitoleate, above the level of cytoprotection seen when 
incubating cells with palmitoleate alone or when cells are co-incubated with both 
LC-FA species.  While not definitive, these results do suggest that this may 
involve the downstream eIF2α/ATF4/CHOP10 apoptotic signalling pathway with 
a role for PKR as a direct upstream mediator.   
 
In summary, our results clearly suggest that PKR does appear to be integral to 
nutrient sensing pathways within the pancreatic β-cell.  Targeted inhibition of 
normal PKR function in BRIN-BD11 cells significantly improves cell viability, and 
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correlates with reduced upregulation of the ER stress marker phospho-eIF2α in 
response to lipotoxicity.   
 
It is not possible to fully conclude this section without identifying limitations of this 
work.  Alterations to cell viability and to the phosphorylation status of eIF2α, along 
with our PKR KD data, have provided valuable correlative information.  Results 
from our studies, combined with evidence from others (Lee et al, 2007; Nakamura 
et al., 2010), strongly suggests that PKR mediates cytotoxic or cytoprotective 
mechanisms in pancreatic β-cells, in response to chronic incubation with FA 
species.  However, we have also cited that redundancy from the activity of other 
kinases such as PERK, HRI and GCN2 has been reported (Wek et al., 2006; Ron 
& Walter, 2007; Chen et al., 2008).  As such, defining the activity of the PKR 
protein itself is a logical step to more clearly understand the exact underlying 
molecular mechanisms within the ER stress pathways in response to lipotoxicity.   
 
A predominant aim throughout these studies was to investigate how changes in 
β-cell viability in response to chronic incubation with LC-FAs impacted on 
alterations to PKR activity: specifically, looking at changes in the phosphorylation 
status of PKR.  A known issue at the outset of the study was the absence of 
commercially available rat phospho-PKR antibodies.  Nonetheless, there is 
relatively high amino acid sequence homology between human vs. rat, and 
mouse vs. rat phospho-PKR proteins (Fig. 3.24 and Fig. 3.25).  Therefore, it was 
considered entirely feasible to use phospho-PKR antibodies raised in mouse and 
human, against the lysates we extracted from rodent models.  Extensive 
validation experiments were performed using all current commercially available 
mouse and human phospho-PKR antibodies, including variations in epitope 
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specificities, to determine if any of these products were able to detect phospho-
PKR in the BRIN-BD11 cell lysates.   
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Fig. 3.24 Alignment of human vs. rat phospho-PKR amino acid 
sequence  
A comparison of the human PKR amino acid sequence and of the 
PKR amino acid sequence found in the rat was made to determine 
percentage homology.  
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Fig. 3.25 Alignment of mouse vs. rat phospho-PKR amino 
acid sequence  
A comparison of the mouse PKR amino acid sequence with the 
rat PKR amino acid sequence was made to determine 
percentage homology.  
182 
 
Initially, it was thought a band at the correct predicted molecular weight of 
phospho-PKR (~68 kDa) was detected.  However, upon more-detailed 
examination, it was evident that a second band at a lower molecular weight (~40 
kDa) was also routinely detected on each blot.  This second erroneous band 
reflected the same pattern as the band we initially suspected to be phospho-PKR 
band.  This suggested that these bands may have been non-specific, so further 
extensive validation experiments were performed using various secondary 
antibodies.  In addition, after further literature reviews, we adopted the use of 
positive control lysates, blocking peptides and gel shift electrophoresis analysis 
in an attempt to identify the phospho-PKR band with certainty.  Unfortunately, 
results from these studies were also inconclusive.   
 
Nonetheless, alternative markers within the PKR signalling pathway were also 
investigated by Western blot.  The PACT protein, a well-cited upstream activator 
of PKR, along with downstream proapoptotic markers ATF4, ATF3 and nuclear 
protein CHOP10 were examined.  In the absence of being able to detect 
phospho-PKR, alterations to the activity and expression of distal and proximal 
proteins to PKR, would have provided important information regarding the 
signalling pathways involved in lipotoxic conditions.  It was unfortunate that these 
antibodies exhibited poor specificity, thus results from these studies were 
inconclusive.   
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Chapter 4 Characterisation of the responses of 1.1B4 human 
pancreatic β-cells to FFA 
4.1 Introduction 
Various in vitro cell models are readily available and convenient for use in 
diabetes research (Skelin et al., 2010).  The last few decades has seen a range 
of β-cell lines established as models to investigate β-cell function and many of 
these models have been rodent cell lines (Asfari et al., 1992; Gazdar et al., 1980; 
Santerre et al., 1981; McClenaghan et al., 1996; Efrat et al., 1988; Miyazaki et 
al., 1990).  While these models have yielded valuable information from functional 
and molecular studies, there are many differences between rodent and human β-
cells.  Any significant results found in rodent cell lines also need to be established 
in primary islets and due to their limited availability, a great deal of effort has been 
invested in developing human β-cell lines from human pancreatic sources 
(Hohmeier and Newgard, 2004).   
 
The limitations with human and rodent cell lines have included low insulin 
secretion, poor insulin secretion capacity in response to secretagogues, or cells 
only capable of secreting insulin over limited passage.  In the case of some adult 
β-cell lines, the supplementation of factors necessary to maintain and promote 
growth also initiates dedifferentiation (Dufayet de la Tour et al., 2001; Demeterco 
et al., 2002; Gueli et al., 1987; Levine et al., 1995; Beattie et al., 1999; Russ et 
al., 2008), or de-differentiation may occur over continuous passage.  Cells may 
contain abnormal chromosome numbers or express gene mutations that may 
affect typical protein expression and metabolism; all these considerations may go 
some way towards explaining why many pancreatic β-cells lines have aberrant 
secretory responses (Ulrich et al., 2002; Skelin et al., 2010).   
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In 2011, a UK group described the development of a novel human insulin-
secreting β-cell line designated as 1.1B4.  The cells were created by the 
electrofusion of an immortal human pancreatic epithelial carcinoma cell line 
(PANC-1) with normal cultured human islets, creating a cell line that has been 
reported to be stable in culture and to display characteristics of typical pancreatic 
β-cells.  For example, these cells were responsive to known insulin 
secretagogues, and expressed major genes involved in proinsulin processing 
and the insulin secretory pathway such as the GLUT-1 glucose transporter and 
glucokinase (McCluskey et al., 2011).   
 
There have been extensive studies into the molecular mechanisms underlying 
lipotoxicity, and the structural properties required of various FA species that elicit 
a cytotoxic or cytoprotective effect in rodent β-cells, but these have not been 
investigated in the 1.1B4 human pancreatic β-cell line.  Therefore, for the first 
time, we used the 1.1B4 human pancreatic β-cells to investigate their in vitro 
responses to different FA species, to consider their suitability as an appropriate 
model for the study of β-cell dysfunction during lipotoxic conditions such as those 
seen in T2D.   
 
4.2 Materials and methods 
The human pancreatic β-cell line 1.1B4 was obtained from the Human Protection 
Agency Culture Collections.  Cells were cultured in RPMI-1640 medium 
containing 11 mM glucose, supplemented with 10% FBS, 2 mM L-glutamine, 100 
U/ml penicillin and 100 mg/ml streptomycin.  All cells were grown in 75 cm2 flasks 
at 37 ºC and with 5% CO2 at 100% humidity and were used in experiments when 
approximately 80% confluent; all experiments were performed on cells below 
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passage number 35.  Cells were passaged as described in Section 2.2.1, and 
treatment with FA was conducted as described in Section 2.3.  Cell death was 
assessed using PI staining and flow cytometry (Section 2.4.2).   
 
4.3 Results 
4.3.1 Medium-chain SFA responses in 1.1B4 human pancreatic 
β-cells 
The effects of incubating different FA species with rodent pancreatic β-cells have 
already been well-established, so it was important to elucidate the differential 
responses of incubating various FA species with this novel insulin secreting 
human pancreatic β-cell line.  Initial time course experiments were conducted 
(data not shown) to determine a suitable incubation period where a similar level 
of cell death was evoked by incubation with 250 μM palmitate, as we saw in our 
previously used rodent models.  This was determined to be 24 h.  Increasing 
concentrations of two medium-chain-SFA, laurate (C12:0) (Fig. 4.1) and 
myristate (C14:0) (Fig. 4.2) were shown to be well-tolerated by the human 
pancreatic β-cells and exerted no significant detrimental effect on percentage cell 
death over the 24 h incubation period, when treatment groups of any 
concentration were compared to the control.   
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Fig. 4.1 The effect of laurate (C12:0) on 1.1B4 human pancreatic β-
cells 
1.1B4 human pancreatic β-cells were treated with increasing 
concentrations of laurate and incubated for 24 h. Cell death was 
assessed by flow cytometry using propidium iodide staining. Results 
represent mean ± SEM from experiments performed in quadruplicate 
(N=4). 
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Fig. 4.2 The effect of myristate (C14:0) on 1.1B4 human 
pancreatic β-cells 
1.1B4 human pancreatic β-cells were treated with increasing 
concentrations of myristate and incubated for 24 h. Cell death was 
assessed by flow cytometry using propidium iodide staining. Results 
represent mean ± SEM from experiments performed in quadruplicate 
(N=4). 
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4.3.2 LC-SFA responses in 1.1B4 human pancreatic β-cells 
The LC-SFA species palmitate (C16:0) (Fig. 4.3) and stearate (C18:0) (Fig. 4.4) 
were demonstrated to exert a cytotoxic effect on the 1.1B4 human pancreatic β-
cells in a dose-dependent manner.  Results for cells incubated with palmitate 
showed cell death to be: control (no palmitate) (8.9%); 10 μM (10.9%); 25 μM 
(9.6%); 50 μM (10.6%); 100 μM (17.4%) and 250 μM (35.5%).  These results 
demonstrated that palmitate at 100 and 250 μM induced a significant increase in 
percentage cell death when compared to the control (p=<0.01 and p=<0.001 
respectively).  Results for stearate showed cell death to be: control (no stearate) 
(8.8%); 10 μM (9%); 25 μM (9.6%); 50 μM (10.1%); 100 μM (14.1%) and 250 μM 
(18.6%).  These results determined that stearate at 100 and 250 μM also induced 
a significant increase in percentage cell death when compared to the control 
(p=<0.01 and p=<0.001 respectively).  Figure 4.5 shows the combined effects of 
the four different SFA species used to induce lipotoxicity for comparison purposes.  
It is noteworthy from this figure that the cytotoxic effect of stearate (C18:0) is less 
than that observed with palmitate (C16:0).   
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Fig. 4.3 The effect of palmitate (C16:0) on 1.1B4 human pancreatic 
β-cells 
1.1B4 human pancreatic β-cells were treated with increasing 
concentrations of palmitate and incubated for 24 h. Cell death was 
assessed by flow cytometry using propidium iodide staining. Results 
represent mean ± SEM from experiments performed in quadruplicate 
(N=4). *** p=˂0.001, ** p=<0.01 vs. control 
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Fig. 4.4 The effect of stearate (C18:0) on 1.1B4 human pancreatic 
β-cells 
1.1B4 human pancreatic β-cells were treated with increasing 
concentrations of stearate and incubated for 24 h. Cell death was 
assessed by flow cytometry using propidium iodide staining. Results 
represent mean ± SEM from experiments performed in quadruplicate 
(N=4). *** p=˂0.001, ** p=<0.01 vs. control   
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Fig. 4.5 Comparison of the effects of incubating SFA species on 
1.1B4 human pancreatic β-cells 
1.1B4 human pancreatic β-cells were treated with different length 
saturated fatty acids to assess their effect on cell viability over a 24 h 
incubation period. Cell death was assessed by flow cytometry using 
propidium iodide staining. Results represent mean ± SEM from 
experiments performed in quadruplicate (N=4).  
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4.3.3 The cytoprotective effect of LC-MUFA on 1.1B4 human 
pancreatic β-cell death 
It has been well-observed in rat pancreatic β-cells that the cytotoxic effects 
observed when incubating cells with LC-SFA is ameliorated when cells are co-
incubated with both palmitate and the LC-MUFA palmitoleate (C16:1).  It has also 
been established that palmitoleate is well tolerated when cultured alone with rat 
pancreatic β-cells.  Indeed, palmitoleate has been shown to be cytoprotective 
against serum starvation and pro-inflammatory cytokines (Welters et al., 2004).  
However, the cytoprotective effects of MUFA have not yet been reported in the 
1.1 B4 human pancreatic β-cell line.  Experiments were conducted to determine 
the effect of palmitoleate on percentage cell death in the 1.1B4 β-cells, where 
cells were incubated with each FA species alone, or co-incubated with both LC-
FA species (palmitate and palmitoleate).   
 
Results in this study (Fig. 4.6) were found to be: control (4.5%); 250 μM palmitate 
(47.3%); 250 μM palmitoleate (2.1%) and both FA species (2.8%).  These results 
demonstrate that palmitate induced a 10.5-fold increase in percentage cell death 
compared to the control (p=<0.001), and this is in line with our previous findings.  
Palmitoleate at 250 μM was shown to be well-tolerated and had no effect on 
percentage cell death when compared to the control.  Importantly, the co-
incubation of palmitoleate and palmitate brought about a 17-fold decrease in 
percentage cell death, so was able to completely ameliorate the cytotoxic effect 
observed when cells were incubated with 250 μM palmitate alone (p=<0.001).   
 
The 1.1B4 human pancreatic β-cells were incubated with 250 μM palmitate 
(considered the control group) and increasing concentrations of palmitoleate 
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(C16:1) (Fig. 4.7).  The percentage cell deaths for this experiment were found to 
be: control (51.5%); 10 μM (32%); 25 μM (23.9%); 50 μM (12.4%); 100 μM (9.2%) 
and 250 μM (8.2%).  Palmitoleate reduced percentage cell death in a dose-
dependent manner; and all concentrations were significant when compared to the 
control (p=<0.001).   
 
The effect of the LC-MUFA species oleate (C18:1) on percentage cell death in 
the 1.1B4 cells was investigated next (Fig. 4.8).  Results from this experiment 
were: control (51.7%); 10 μM (45.5%); 25 μM (33%); 50 μM (25.2%); 100 μM 
(24.2%) and 250 μM (26.2%).  Again, it was apparent that all concentrations of 
oleate were able to significantly reduce percentage cell death compared to the 
control (p=<0.001).  Figure 4.9 shows the two different MUFA species for 
comparison purposes.  It is again notable that the cytoprotective effect of oleate 
(C18:1) is less that that observed with palmitoleate (C16:1).   
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Fig. 4.6 The cytoprotective effect of palmitoleate (C16:1) on 
1.1B4 human pancreatic β-cells 
1.1B4 human pancreatic β-cells were treated with 250 μM palmitate, 
250 μM palmitoleate or a combination of both FA and incubated for 
24 h. Cell death was assessed by flow cytometry using propidium 
iodide staining. Results represent mean ± SEM from experiments 
(N=6). *** p=˂0.001 vs. control, ### p=˂0.001 vs. palmitate  
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Fig. 4.7 The cytoprotective effect of palmitoleate on 1.1B4 
human pancreatic β-cells is dose-dependent 
1.1B4 human pancreatic β-cells were treated with 250 μM palmitate 
and increasing concentrations of the monounsaturated fatty acid 
palmitoleate and incubated for 24 h. Cell death was assessed by flow 
cytometry using propidium iodide staining. Results represent mean 
± SEM from experiments (N=5). *** p=˂0.001 vs. control  
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Fig. 4.8 The cytoprotective effect of oleate (C18:1) on 1.1B4 
human pancreatic β-cells is dose-dependent 
1.1B4 human pancreatic β-cells were treated with 250 μM palmitate 
and increasing concentrations of the monounsaturated fatty acid 
oleate and incubated for 24 h. Cell death was assessed by flow 
cytometry using propidium iodide staining. Results represent mean 
± SEM from experiments (N=5). *** p=˂0.001, ** p=<0.01 vs. control 
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Fig. 4.9 Comparison of the effects of incubating MUFA species 
on 1.1B4 human pancreatic β-cells 
1.1B4 human pancreatic β-cells were treated 250 μM palmitate and 
different length monounsaturated fatty acids to assess their effect on 
cell viability over a 24 h incubation period. Cell death was assessed 
by flow cytometry using propidium iodide staining. Results represent 
mean ± SEM from experiments (N=5). 
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4.3.4 Compound-16 is toxic to 1.1B4 cells 
We have shown in Section 3.3.3 that Compound-16 exerts a cytoprotective effect 
in BRIN-BD11 cells during lipotoxic conditions, so we investigated here for the 
first time, whether Compound-16 was able to act as a cytoprotective agent in 
1.1B4 human pancreatic β-cells.  Cells were incubated for 24 h with Compound-
16 using concentrations ranging from 1 μM to 25 μM.  A second group of 1.1B4 
cells were pre-incubated for 1 h with Compound-16, then they were additionally 
co-incubated with 250 μM palmitate for the remaining 23 h incubation period (Fig. 
4.10).  Cell viability was assessed by flow cytometry using PI staining, and the 
proportion of dead cells was expressed as a percentage of the total for each 
treatment group.   
 
Similar to the effects observed in both INS-1 and MIN6 rodent cells, incubation 
with Compound-16 alone proved to be toxic to the human pancreatic β-cells.  The 
percentage cell death observed from cells incubated solely with Compound-16 
were: control (24.7%); 1 μM (60.9%); 5 μM (59.2%); 10 μM (53.6%); 15 μM 
(48.2%), 20 μM (55.4%) and 25 μM (71.6%).  These results demonstrated a 
significant increase in percentage cell death compared to the control at all 
concentrations tested (p=<0.001).  The co-incubation of cells with 250 μM 
palmitate and Compound-16 demonstrated that the addition of Compound-16 did 
not afford any protection against palmitate-induced cell death as was previously 
observed in the BRIN-BD11 cell line.  Percentage cell death in this case was 
found to be: control (250 μM palmitate) (65.4%); 1 μM (87.4%); 5 μM (85.9%); 10 
μM (87%); 15 μM (91%), 20 μM (92.8%) and 25 μM (92.1%).   
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Fig. 4.10 The effect of Compound-16 on 1.1B4 human pancreatic 
β-cells  
1.1B4 human pancreatic β-cells were treated with increasing 
concentrations of Compound-16. A second treatment group were pre-
incubated with identical concentrations of Compound-16 for 1 h, then 
incubated for a further 23 h with 250 μM palmitate. Cell death was 
assessed by flow cytometry using propidium iodide staining. Results 
represent mean ± SEM from experiments performed in triplicate (N=3). 
*** p=˂ 0.001 vs. control  
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4.3.5 The effect of methyl FAs on 1.1B4 and BRIN-BD11 
pancreatic β-cells 
Methyl-fatty acids are alkylated derivatives of their FA counterparts, but the 
addition of a methyl group on the functional carboxyl group inhibits the 
carboxylate action, rendering the FA metabolically inert.  It has been suggested 
that the presence of a functional carboxylate group is necessary for the 
cytoprotective or cytotoxic effects of the different FA species used in in vitro 
lipotoxicity studies in human islets and rodent β-cells (El-Assaad et al., 2003; 
Hardy et al., 2003).  Therefore, experiments to investigate whether the addition 
of a methyl group can affect the cytotoxic or cytoprotective action of FA species 
in the 1.1B4 human pancreatic β-cells were conducted for the first time to our 
knowledge. 
 
Cells were incubated for 24 h with increasing concentrations of methyl-palmitate 
(Fig. 4.11a)).  The percentage cell death seen when cells were incubated with 
this methylated SFA were found to be: control (18.7%); 10 μM (16%); 25 μM 
(17.8%); 50 μM (13.9%); 100 μM (16.7%), and 250 μM (14.6%).  Although 
showing a slight downward trend, these results demonstrated that there was no 
significant effect on percentage cell death at any concentration compared to the 
control.  This investigation was repeated in BRIN-BD11 cells for comparison 
purposes (Fig. 4.11b)), where again, although a slight downward trend was seen, 
there was no significant effect on percentage cell death at any concentration.  
Percentage cell death for the BRIN-BD11 cells were: control (19.2%); 10 μM 
(18.2%); 25 μM (17.3%); 50 μM (16.4%); 100 μM (17.5%), and 250 μM (13.8%).  
Furthermore, no difference in the amount of percentage cell death was observed 
between each cell line.   
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The 1.1B4 human pancreatic β-cells were incubated with increasing 
concentrations of the C18:0 methyl-stearate FA species (Fig. 4.12a)).  Results 
for the percentage cell death from this experiment were found to be: control 
(14.9%); 10 μM (11.9%); 25 μM (14.8%); 50 μM (13.4%); 100 μM (12.9%), and 
250 μM (9.9%).  No detrimental effect on percentage cell death was observed at 
any concentration compared to the control, although results did follow a 
downward trend.  For the BRIN-BD11 cells (Fig. 4.12b)), in contrast to the human 
pancreatic β-cells, a slight increasing trend in percentage cell death was 
observed, but these results were not significant when compared to the control.  
Results were found to be: control (22.4%); 10 μM (23.6%); 25 μM (23.3%); 50 μM 
(25.9%); 100 μM (28.1%), and 250 μM (27.3%).  Methyl-stearate exerted a 
greater cytotoxic effect on the BRIN-BD11 cells than the human β-cells at all 
concentrations tested (p=<0.0001).  Fig. 4.13 shows the effect of the two methyl-
SFA species in the 1.1B4 human pancreatic β-cells for comparison purposes.   
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Fig. 4.11 The effect of methyl-palmitate on pancreatic β-cells  
1.1B4 human pancreatic β-cells and BRIN-BD11 rat pancreatic β-cells 
were treated with increasing concentrations of methyl-palmitate: (a) 
1.1B4 human β-cells were incubated for 24 h, (b) BRIN-BD11 cells were 
incubated for 18 h and effect on cell death was compared. Cell death 
was assessed by flow cytometry using propidium iodide staining. 
Results represent mean ± SEM from experiments performed in triplicate 
(N=3).  
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Fig. 4.12 The effect of methyl-stearate on pancreatic β-cells  
1.1B4 human pancreatic β-cells and BRIN-BD11 rat pancreatic β-cells 
were treated with increasing concentrations of methyl-stearate: a) 
1.1B4 human β-cells were incubated for 24 h, b) BRIN-BD11 cells 
were incubated for 18 h and effect on cell death was compared. Cell 
death was assessed by flow cytometry using propidium iodide 
staining. Results represent mean ± SEM from experiments performed 
in triplicate (N=3). *** p=˂0.001 vs. 1.1B4 β-cells 
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Fig. 4.13 Comparison of the effect of incubating methyl-SFA 
species on 1.1B4 human pancreatic β-cells 
1.1B4 human pancreatic β-cells were treated with different length 
methyl-fatty acids to assess their effect on cell viability over a 24 h 
incubation period. Cell death was assessed by flow cytometry using 
propidium iodide staining. Results represent mean ± SEM from 
experiments performed in triplicate (N=3).  
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The cytoprotective effect of methyl-palmitoleate on rat BRIN-BD11 cells has been 
reported previously by our group (Dhayal et al., 2008; Diakogiannaki et al., 2007), 
so this was investigated here in the 1.1B4 human pancreatic β-cells, where cells 
were incubated with 250 μM palmitate (considered as the control group), and 
increasing concentrations of methyl-palmitoleate (Fig. 4.14a).  Our results 
showed that the incubation of the human pancreatic β-cells with 100 and 250 μM 
methyl-palmitoleate significantly decreased the percentage cell death seen 
compared to the control.  Results were found to be: 250 μM palmitate (control), 
91.6%; 10 μM methyl-palmitoleate, 90.8%; 25 μM methyl-palmitoleate, 89.6%; 50 
μM methyl-palmitoleate, 88.1%; 100 μM methyl-palmitoleate, 83.6%, (p=<0.001), 
and 250 μM methyl-palmitoleate, 60.9%, (p=<0.001).  
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Fig. 4.14 The effect of methyl-palmitoleate on cultured pancreatic 
β-cells  
1.1B4 human pancreatic β-cells and BRIN-BD11 rat pancreatic β-cells 
were treated with 250 μM palmitate and increasing concentrations of 
methyl-palmitate: a) 1.1B4 human β-cells were incubated for 24 h, b) 
BRIN-BD11 cells were incubated for 18 h and effect on cell viability was 
compared. Cell death was assessed by flow cytometry using propidium 
iodide staining. Results represent mean ± SEM from experiments 
performed at least in triplicate (N=3). *** p=˂ 0.001 vs. 1.1B4 control; 
### p=˂ 0.001 vs. BRIN-BD11 control 
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Methyl-palmitoleate was also co-incubated in BRIN-BD11 cells, and results 
demonstrated that at 50, 100 and 250 μM concentrations, incubation of cells with 
methyl-palmitoleate significantly decreased the percentage cell death observed 
compared to the control group (Fig. 4.14b)).  The results for this cell line were as 
follows: control (93.1%); 10 μM (92.7%); 25 μM (91.7%); 50 μM (80.2%, 
p=<0.001); 100 μM (81.9%, p=<0.001) and 250 μM (61.6%, p=<0.001).  Again, 
there was no difference in percentage cell death observed between either the 
human or rodent pancreatic β-cell lines.   
 
In the final set of experiments for this section, 1.1B4 human pancreatic β-cells 
were incubated with 250 μM palmitate and increasing concentrations of the C18:1 
methyl-MUFA oleate.  Similar to the results observed with methyl-palmitoleate, 
100 and 250 μM methyl-oleate significantly reduced the percentage cell death 
observed, so was protective against palmitate-induced cell death (Fig. 4.15a)).  
Results in this case were found to be: 250 μM palmitate (no methyl-oleate) 
considered as the control (91.6%); 10 μM methyl-palmitoleate (90.8%); 25 μM 
methyl-palmitoleate (89.6%); 50 μM methyl-palmitoleate (88.1%); 100 μM 
methyl-palmitoleate (83.6%, p=<0.001), and 250 μM methyl-palmitoleate (60.9%, 
p=<0.001).   
 
BRIN-BD11 cells were incubated with methyl-oleate, where a significant 
decrease in percentage cell death was also observed at 100 and 250 μM 
concentrations (Fig. 4.15b)).  Results here were shown to be: 250 μM palmitate 
(no methyl-oleate) considered as the control (50.9%); 10 μM methyl-oleate 
(50.6%); 25 μM methyl-palmitoleate (49.6%); 50 μM methyl-palmitoleate (48.5%); 
100 μM methyl-palmitoleate (45.7%, p=<0.01), and 250 μM methyl-palmitoleate 
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(32%, p=<0.001).  Fig. 4.16 shows the effect of the two methyl-MUFA species in 
the 1.1B4 human pancreatic β-cells for comparison purposes.  
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Fig. 4.15 The effect of methyl-oleate on cultured pancreatic β-
cells   
1.1B4 human pancreatic β-cells and BRIN-BD11 rat pancreatic β-cells 
were treated with 250 μM palmitate and increasing concentrations of 
methyl-oleate: a) 1.1B4 human β-cells were incubated for 24 h, b) 
BRIN-BD11 cells were incubated for 18 h and effect on cell viability 
was compared. Cell death was assessed by flow cytometry using 
propidium iodide staining. Results represent mean ± SEM from 
experiments performed in triplicate (N=3). *** p=˂ 0.001, ** p=<0.01 
vs. control, ### p=˂0.001, ## p=<0.01 vs. BRIN-BD11 control.  
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Fig. 4.16 Comparison of the effect of incubating methyl-MUFA 
species on 1.1B4 human pancreatic β-cells 
1.1B4 human pancreatic β-cells were treated with different length 
methyl-fatty acids to assess their effect on cell viability over a 24 h 
incubation period. Cell death was assessed by flow cytometry using 
propidium iodide staining. Results represent mean ± SEM from 
experiments performed in triplicate (N=3).  
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4.4 Summary of novel results 
 Medium-chain SFAs (C12:0 and C14:0) are well tolerated in 1.1B4 human 
pancreatic β-cells under chronic incubation conditions (Fig. 4.1 – 4.2).  
 Incubation of 1.1B4 cells with palmitate (C16:0) leads to a dose-dependent 
increase in percentage cell death under chronic incubation conditions, 
significant at 100 and 250 μM (p=<0.01 and p=<0.001 respectively) (Fig. 4.3). 
 Incubation of 1.1B4 cells with stearate (C18:0) (Fig. 4.4) leads to a dose-
dependent increase in percentage cell death under chronic incubation 
conditions, significant at 100 and 250 μM (p=<0.001).  Stearate does not exert 
a greater cytotoxic effect than palmitate (Fig. 4.5).   
 Co-incubation of 1.1B4 cells with palmitate and palmitoleate (C16:1), leads to 
a significant dose-dependent decrease in percentage cell death (p=<0.001) 
under chronic incubation conditions (Fig. 4.7).   
 Co-incubation of 1.1B4 cells with palmitate and oleate (C18:1) leads to a 
dose-dependent decrease in percentage cell death under chronic incubation 
conditions, significant at 10 μM (p=<0.01) and 25 – 250 μM (p=<0.001) (Fig. 
4.8).  Oleate is not more cytoprotective effect than palmitoleate (Fig. 4.9).   
 Compound-16 is significantly cytotoxic to 1.1B4 cells (Fig. 4.10) at all 
concentrations tested (1 – 25 μM, p=<0.001).   
 The incubation of 1.1B4 or BRIN-BD11 cells with methyl-SFA species (C16:0 
and C18:0) does not affect cell viability (Fig. 4.11 – 4.12).   
 Methyl-palmitoleate (C16:1) exerts a dose-dependent cytoprotective effect on 
palmitate-induced cell death in 1.1B4 MUFA species under chronic incubation 
conditions (Fig. 4.14a)), significant at 100 and 250 μM concentrations 
(p=<0.001).   
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 Methyl-oleate (C18:1) exerts a dose-dependent cytoprotective effect on 
palmitate-induced cell death in 1.1B4 MUFA species under chronic incubation 
conditions (Fig. 4.15a)), significant at 100 and 250 μM concentrations 
(p=<0.01 and p=<0.001 respectively).  Methyl-oleate was less cytoprotective 
than C16:1 methyl-palmitoleate.   
 In BRIN-BD11 cells (Fig. 4.15b)), methyl-oleate provides dose-dependent 
cytoprotection against palmitate-induced cell death, significant at 100 and 250 
μM concentrations (p=<0.01 and p=<0.001 respectively).   
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4.5 Discussion 
The presence of raised concentrations of FFAs in physiological conditions are 
suggested to exert a damaging effect on pancreatic β-cell viability.  It has been 
reported that the potential of FAs to stimulate insulin secretion increases with 
chain length, and conversely decreases with the degree of unsaturation of the FA 
species being studied (Opara et al., 1994; Dobbins et al., 1998).  In the event of 
the chronic supraphysiological presence of FFAs as is suggested to occur during 
obesity, it is believed that the availability of predominantly LC-SFAs released from 
adipose tissue contributes towards the long-term detriment to pancreatic β-cell 
viability, by driving constant pancreatic β-cell stimulation due to persistent insulin 
release.  This is thought to culminate in ‘β-cell exhaustion’, a mechanism defined 
as depleted insulin stores due to the chronic exposure to secretagogues.  As such, 
this mechanism may explain why LC-SFAs may induce pancreatic β-cell 
apoptosis (Poitout & Robertson, 2002).   
 
The effects of chronic exposure to different FA species on rodent pancreatic β-
cell lines and in human primary islets have been clearly established.  These 
studies have demonstrated that the structural requirements for the cytotoxic 
action of SFAs increases as the chain length of the species being studied 
increases.  Long-chain SFAs exert a potent and detrimental dose-dependent 
effect on cell viability, whereas medium- and shorter-chain SFAs are well-
tolerated and do not exhibit any detrimental effects on cell viability (Welters et al., 
2004; Eitel et al., 2003; Dhayal et al., 2008).  Mono-unsaturated FA species are 
also well-tolerated and do not exert a detrimental effect on β-cell death and this 
is has been shown to be independent of chain length.  Furthermore, LC-MUFA 
species can be cytoprotective during co-incubation with their LC-SFA 
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counterparts (Dhayal et al., 2008; Newsholme et al., 2007; Cnop et al., 2001; 
Welters et al., 2004; Maedler et al., 2001, Eitel et al., 2002; Maedler et al., 2003; 
Karaskov et al., 2006).  Additional studies have shown that this appears to be 
true for both monounsaturated and polyunsaturated species in human islets and 
rodent β-cells (Maedler et al., 2003; Morgan et al., 2008; Keane & Newsholme, 
2008; Morgan, 2008).  However, the effects of FA species, either saturated or 
monounsaturated have not yet been reported in the human pancreatic β-cell line.  
Therefore, in these studies, we employed the use of 1.1B4 human pancreatic β-
cells to investigate for the first time, how their in vitro responses to different FA 
species compare with existing rodent models and human islets.   
 
We report that medium-chain SFAs are well-tolerated in the 1.1B4 human 
pancreatic β-cells.  Chronic incubation with laurate (C12:0) and myristate (C14:0) 
did not induce cell death at any of the concentrations tested.  The LC-SFA 
species palmitate (C16:0) and stearate (C18:0) were found to exert toxic effects 
on the human pancreatic β-cells and these were dose-dependent.  These results 
correlate with reported findings from our previous studies, and work by others 
using rodent pancreatic β-cell models (Newsholme et al., 2007; Welters et al., 
2004; Eitel et al., 2003; Dhayal et al., 2008).   
 
The C14:1 MUFA myristoleate did not affect the percentage cell death observed 
in the 1.1B4 human pancreatic β-cells, and this observation correlates with the 
effects of myristoleate that have been previously observed in BRIN-BD11 cells 
(Dhayal et al., 2008).  The LC-MUFA palmitoleate (C16:1) and oleate (C18:1) 
were able to completely ameliorate the cytotoxic action of palmitate in the human 
β-cells during co-incubation studies.  Our results investigating the effects of 
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MUFA in human pancreatic β-cells show for the first time, a correlation between 
the cytoprotective effects observed in human 1.1B4 cells and what has been 
reported in previous studies using rodent cell lines and human islets (Dhayal et 
al., 2008; Cnop et al., 2001; Welters et al., 2004; Maedler et al., 2001, Eitel et al., 
2002; Maedler et al., 2003; Karaskov et al., 2006).   
 
However, it has been suggested that the length of FA species entering the β-
oxidation pathway does not impact upon their mode of metabolism and as such, 
is unlikely to explain the differences observed in cytotoxicity or cytoprotection as 
a FA chain length increases.  The addition of a methyl group on the functional 
carboxyl group blocks the initial esterification step of FAs in the β-oxidation 
pathway, and as such FA methyl esters can prevent FA oxidation.  It has been 
shown that using methyl-MUFA species does not impede their cytoprotective 
action, as methyl-MUFA species are still able to effectively inhibit rodent β-cell 
death when co-incubated with palmitate (El-Assaad et al., 2003; Hardy et al., 
2003; Newsholme et al., 2007).  Furthermore, our group (Dhayal et al., 2008; 
Diakogiannaki et al., 2008) demonstrated that in BRIN-BD11 and INS-1 cells, 
equipotent protection was achieved using methyl-palmitoleate as with 
palmitoleate, during co-incubation studies with palmitate, and as such supports 
the hypothesis that FA length does not affect how they are metabolised.   
 
With this knowledge, it would be reasonable to expect that the C18 SFA species 
stearate might exert a greater cytotoxic effect than C16 palmitate in the 1.1B4 
human pancreatic β-cells.  We would have expected to see increased percentage 
cell death in the 1.1B4 cells incubated with stearate, but this was not the case.  
Equally, it would have been reasonable to expect that the C18 MUFA species 
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oleate would exert a greater cytoprotective effect than C16 palmitoleate in the 
1.1B4 cells, so we would have anticipated a decrease in percentage cell death 
when cells were incubated with oleate, but again, the opposite was true.  These 
unexpected findings in this cell line are difficult to interpret in light of the fact that 
the mechanisms that underlie why increasing carbon chain length, or why the 
degree of saturation or unsaturation of a fatty acid species elicits cytotoxic or 
cytoprotective effects in pancreatic β-cells, are still not yet fully understood.  It 
may be that alternative signalling pathways are activated in the human pancreatic 
β-cell line due to its tumoural origin, or there may be greater redundancy within 
the 1.1B4 ER stress response pathways, going some way to explain why this cell 
line responds differently to C18 FA species, compared to rodent β-cells and 
human islets.   
 
There is currently a paucity of data on the effects of methyl-FA species on 
pancreatic β-cells.  However, research has shown that in human and rat islets, 
methyl-palmitate does not affect cell viability or lead to the upregulation of ER 
stress markers such as ATF3, CHOP, BiP and XBP1s (Briaud et al., 2001; Cunha 
et al., 2008).  It has been suggested that elevated TG formation may be a 
mechanism for the differential effects of FA species (Moffitt et al., 2005).  
However, the use of methyl-palmitoleate has demonstrated that the 
cytoprotective action of MUFA species is not through alterations to intracellular 
TG formation in BRIN-BD11 cells (Diakogiannaki et al., 2007; Dhayal et al., 2008).  
The use of methyl FA species in viability studies using 1.1B4 human cells, 
revealed for the first time that both methyl-palmitoleate and methyl-oleate were 
cytoprotective when cells co-incubated with 250 μM palmitate.  In the BRIN-BD11 
β-cells, methyl-palmitoleate co-incubated with 250 μM palmitate was 
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cytoprotective at 50, 100 and 250 μM, and this correlates with previous findings 
by our group (Dhayal et al., 2008; Diakogiannaki et al., 2008).  Again, it is 
interesting that in the 1.1B4 human pancreatic β-cells, while methyl-oleate was 
protective, it was less potent than C16:1 methyl-palmitoleate.  This has not yet 
been reported elsewhere. A further finding is that in the 1.1B4 cells, no significant 
detrimental effect on percentage cell death was seen using methyl-SFA species.  
This is a novel finding in the 1.1B4 cells, although the response in this human cell 
line correlates with previous work showing that methyl-palmitate is not toxic to 
rodent β-cell lines (Welters et al., 2004, Cunha et al., 2008).   
 
Our results from the Compound-16 studies demonstrated that this small molecule 
inhibitor was toxic to the 1.1B4 human pancreatic β-cells.  This is in contrast to 
what we reported in the previous chapter in the BRIN-BD11 cell line, but given 
that this potent toxicity was observed in both INS-1 and MIN6 rodent pancreatic 
β-cells, it was not unduly surprising.  It is possible that there is redundancy in the 
BRIN-BD11 nutrient sensing pathway which compensates for the transient 
knockdown of PKR, which is not present in the INS-1, MIN6 or 1.1B4 β-cells.   
 
In summary, results from our studies presented here demonstrate that the 1.1B4 
human pancreatic β-cells may represent a suitable model for the study of lipotoxic 
mechanisms.  Our results show that these cells respond to glucose in a normal 
physiological range, and importantly, we have shown novel evidence to 
demonstrate that these cells respond to FA species in a manner demonstrated in 
primary human islets.   
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The only published work to date pertaining to the effects of lipotoxicity in the 
1.1B4 β-cells has been limited to the group who developed the cell line.  They 
report that 500 μM palmitate over an 18 h incubation period significantly 
increased cell death, and this was established using cell death and cell 
proliferation assays (Vasu et al., 2013).  However, no other investigations to 
characterise 1.1B4 responses to other FA species have been conducted to our 
knowledge.  In conclusion, our results support the use of 1.1B4 human pancreatic 
β-cells as a useful model for in vitro studies for functional responses to FAs, and 
as such these cells may provide valuable information about the underlying role of 
FAs in the pathophysiology of T2D.   
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Chapter 5 The role of TXNIP and inflammatory mediators in 
pancreatic β-cell apoptosis  
5.1 Introduction 
Thioredoxin proteins are highly-conserved antioxidant enzymes present 
abundantly within intracellular compartments (Arner & Holmgren, 2000; Hirota et 
al., 1997; Hirota et al., 1999; Martin & Dean, 1991).  The predominant role of 
thioredoxin, along with other antioxidant proteins and peptides such as 
glutathione within the cell, is to maintain an intracellular reducing environment.  
This occurs by the reduction of the thiol group of the cysteine side chains in 
proteins (Gilbert, 1990; Berndt et al., 2007).  Thioredoxins are integral to one of 
the primary reducing pathways within a cell (Collet & Messens, 2010), although 
they also have numerous other roles.  These include reductase activity (Holmgren, 
1985), protecting cells against stress particularly from ROS (Landino et al., 2004), 
regulation of apoptosis (Ravi et al., 2005), modulation of the inflammatory 
response (Nakamura et al., 2005) and the promotion of protein folding within the 
ER (Kern et al., 2003).   
 
The activity of thioredoxin is regulated by an endogenous inhibitor protein called 
thioredoxin-interacting protein (TXNIP).  TXNIP has been identified as one of the 
most highly inducible genes expressed in cultured human islets during elevated 
glucose conditions (Shalev et al., 2002).  TXNIP also modulates the cellular redox 
state but by an opposite mechanism to thioredoxin, making this protein a known 
initiator of oxidative stress within the cell (Nishiyama et al., 1999; Nishiyama et 
al., 2001).  TXNIP has been shown to be a proapoptotic factor in pancreatic β-
cells during hyperglycaemia although the exact mechanism by which this occurs 
is still unclear (Shalev, 2008).  Overexpression of TXNIP can be induced by 
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hyperglycaemia, a condition which has been demonstrated to induce apoptosis 
in pancreatic β-cell models (Minn et al., 2005, Junn et al., 2000).  This suggests 
that TXNIP may have a role in glucotoxicity-associated pancreatic β-cell 
apoptosis, as seen in T2D (Chen et al., 2008).   
  
There are several other mechanisms suggested to contribute to pancreatic β-cell 
toxicity in response to hyperglycaemic conditions.  One is the production of ROS 
during the course of normal oxidative phosphorylation (Robertson, 2006).  This 
may result in heightened cell death due to reduced redox potential, thereby 
rendering the pancreatic β-cell more susceptible to ROS and oxidative stress 
(Junn et al., 2000; Wang et al., 2002).  It is already known that the pancreatic β-
cell is very susceptible to oxidative stress, having some of the lowest levels of 
antioxidant enzyme expression compared to most other tissues (Robertson & 
Harmon, 2006; Lenzen, 2008).  The production of pro-inflammatory cytokines 
such as IL-1β is now a commonly accepted mechanism that is involved in 
apoptotic pathways seen in chronic inflammatory conditions such as obesity and 
T2D (Maedler & Donath, 2004).  It has further been suggested that chronic 
hyperglycaemia induces ER stress which may drive β-cell apoptosis (Marchetti 
et al., 2007; Maedler & Donath; 2004; Eizirik et al., 2008).  These mechanisms 
may individually, or more likely collectively, contribute to the ultimate decline of 
pancreatic β-cell mass and the induction of an insulin-resistant state.   
 
The use of antioxidants and inhibitors of ROS production as a means to reduce 
mitochondrial oxidative damage, insulin resistance and inflammatory signalling 
have been areas of great interest in attempts to minimise the risk of diabetic 
complications (Green et al., 2004; Kim et al., 2007).  As such, the TCA cycle 
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intermediate succinate had been proposed as a potential cytoprotective agent via 
its ability to inhibit the production of ROS and ameliorate dysfunctional 
mitochondrial oxidative phosphorylation.  Succinate has a potent action to 
stimulate insulin release, and is suggested to limit oxidative stress mechanisms 
that may drive mitochondrial dysfunction under glucolipotoxic conditions (Fahien 
and MacDonald, 2002; Vengerovskii et al., 2007; Zavodnik et al., 2011).  
Protection has also been suggested to occur through the prevention of 
peroxidative damage, protein cross-linking and by stabilising mitochondrial 
membrane permeability (Tretter et al., 1987).  It has been suggested that 
glucolipotoxicity results in impaired metabolism due to the depletion of TCA cycle 
intermediates, and it was proposed that supplementation with intermediary 
metabolites may enhance anaplerosis, a mechanism that may protect cells 
against the detrimental effects of high glucose and high SFA concentrations (Choi 
et al., 2011).   
 
The links between a chronic inflammatory response and the progression of insulin 
resistant states such as obesity and T2D are well established.  Under 
metabolically dysfunctional conditions, ER stress and activation of the ERS are 
suggested to be critical players in driving pancreatic β-cell apoptosis (Hummasti 
and Hotamisligil, 2012).  Deposition of excess FFA in adipose tissue is suggested 
as a further key process that triggers an ER stress response driven by increased 
peripheral insulin resistance.  This mechanism, in combination with 
hyperglycaemia, is suggested to drive a glucolipotoxic environment believed to 
ultimately culminate in the pancreatic β-cell demise (Gregor and Hotamisligil, 
2007; Hotamisligil, 2010; Cnop et al., 2011).  Evidence now suggests that 
metabolism, the immune inflammatory response and the ERS are tightly 
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regulated adaptive mechanisms that collectively respond to changes in energy 
flux, making these mechanisms intricately related to, and essential for cell 
survival (Hotamisligil, 2010; Cao et al., 2008).  However, this could also lead to 
eventual dysfunctional responses due to chronic toxic stimuli such as excess 
glucose or SFA levels (Hummasti and Hotamisligil, 2012; Wellen and Hotamisligil, 
2005; Kaufman et al., 2002; Hotamisligil and Erbay, 2008).   
 
Activation of NLRs, in particular the NLRP3 inflammasome is proposed to occur 
via a two signal activation step, triggered by both exogenous and endogenous 
danger signals.  The activation of NLR links the activation of proinflammatory 
caspase-1 and increased secretion of IL-1β levels, suggested to have an integral 
role in pancreatic β-cell apoptosis (Franchi et al., 2012; Mankan et al., 2012; 
Tannahill and O’Neill, 2011; Harder et al., 2009; Muňoz-Planillo et al., 2009).  
Recent studies have demonstrated that TXNIP interacts directly with NLRP3 in a 
ROS-sensitive manner (Zhou et al., 2010), suggesting a role for TXNIP as a 
NLRP3 inflammasome ligand.  This suggests a pathway where glucolipotoxic 
conditions may activate the inflammasome, leading to increased IL-1β levels that 
are of particular interest in obesity and T2D as a cytotoxic pro-inflammatory 
trigger.   
 
The aims of the present studies were to investigate the role of TXNIP in 
pancreatic β-cell apoptosis during experimental conditions of glucotoxicity and 
glucolipotoxicity.  Experiments were conducted using an INS-1 cell line with a 
TET-inducible stable-INS-1 TXNIP overexpression vector created by our group.  
An INS-1-empty vector (EV) cell line with endogenous TXNIP expression was 
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also created as a control cell line.  The involvement of IL-1β in pancreatic β-cells 
subjected to glucotoxicity and glucolipotoxicity was also investigated.  
 
5.2 Materials and methods 
5.2.1 Chemicals and reagents 
Chemicals, reagents and antibiotics were purchased from Sigma Aldrich.  
Hygromycin B was obtained from PAA laboratories.   
 
5.2.2 Cell culture conditions 
The culture of rodent pancreatic β-cell lines were performed as described in 
Section 2.2.  The stably transfected INS-1 cells with the TXNIP transgene under 
the control of a TET-inducible promoter (denoted as INS-TXNIP) and the empty 
vector control cells (denoted as INS-EV) were generated by our group (Kansikas, 
2012).  Cells were cultured as described in Section 2.2 in culture medium 
maintained with hygromycin B.  For experiments, the cells were cultured 
overnight in low glucose conditions (5 mM), then 1 μg/ml TET or doxycycline 
(DOX) was added to culture medium with various glucose concentrations and 
incubated for 48 h.   
 
Fatty acid solutions were prepared and experiments conducted using serum free 
culture medium as previously detailed in Section 2.3.  Cell viability was assessed 
using PI staining via flow cytometry as previously described in Section 2.4.2.  
Western blotting was performed as described in Section 2.5.  PCR to detect the 
presence of IL-1β in rat and 1.1B4 human pancreatic β-cells was conducted as 
detailed in Section 2.7.  Immunoassay using competitive ELISA was carried out 
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according to the protocol described in Section 2.8.  Immunocytochemistry to 
probe for IL-1β and NLRP3 was conducted as detailed in Section 2.9.   
 
5.3 Results  
5.3.1 Tetracycline induces TXNIP protein overexpression in 
INS-TXNIP cells but not in INS-EV cells 
To investigate the proposed proapoptotic role of TXNIP, a TET-inducible 
overexpression of TXNIP in the rat cell model INS-1 was used.  Initial experiments 
were conducted to verify that TET induced expression of TXNIP in the INS-TXNIP 
cells but not the INS-EV cells, as demonstrated previously by our group.  
 
Western blotting of whole cell lysates probed with TXNIP antibody showed that 
increasing concentrations of TET induced a clear dose-dependent upregulation 
of TXNIP.  There was no detectable expression of TXNIP when the INS-EV 
control cells were incubated with any concentrations of TET (Fig. 5.1).  These 
results were found to be significant at all TET concentrations compared to the 
TET-free control group (p=<0.001).  The fold increases compared to the control 
were: 25 ng/ml TET, 2.1-fold increase; 50 ng/ml TET, 2.5-fold increase, 100 ng/ml 
TET, 2.8-fold increase; 500 ng/ml TET, 3.2-fold increase and 1000 ng/ml TET, 
3.9-fold increase.  There was no detectable level of TXNIP expression in the INS-
EV cells ± TET compared to the TET-free INS-TXNIP control group.   
  
225 
 
 
 
 
  
Fig. 5.1 Tetracycline-inducible overexpression of TXNIP in INS-
TXNIP and INS-EV pancreatic β-cells 
INS-TXNIP pancreatic β-cells and their empty vector control cells INS-
EV were incubated overnight in 5 mM glucose culture conditions. Cells 
were treated with increasing concentrations of tetracycline and incubated 
for 48 h. Whole cell lysates were probed using TXNIP antibody. Results 
represent blots from experiments performed in triplicate (N=3). 
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5.3.2 Hyperglycaemia induces TXNIP overexpression in INS-
TXNIP cells but not in INS-EV cells 
Our group (Kansikas, 2012) and others (Minn et al., 2005) demonstrated that 
TXNIP overexpression could also be induced by hyperglycaemia.  Therefore, 
Western blotting was conducted to ascertain whether this was reproducible.  Cells 
were pre-incubated overnight in 5 mM glucose concentrations, to ensure that 
basal TXNIP expression was established before the cell lines were subjected to 
11 and 31 mM glucose concentrations.  Western blotting of whole cell lysates 
from these treatments were probed using a TXNIP antibody.  There was a 2.4-
fold increase between the 11 mM glucose group and the 5 mM glucose control 
(p=<0.001), and significant 7.6-fold increase in TXNIP expression was observed 
in the INS-TXNIP cells at 31 mM glucose compared to the 5 mM glucose control 
(p=<0.001) (Fig. 5.2).  By comparison, a 1.7-fold expression of TXNIP was 
detected in the INS-EV cell line under 31 mM glucose culture conditions when 
compared to the 5 mM INS-TXNIP glucose control (p=<0.01).   
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Fig. 5.2 Glucose-inducible overexpression of TXNIP in INS-
TXNIP and INS-EV pancreatic β-cells 
INS-TXNIP pancreatic β-cells and control cells INS-EV were 
incubated overnight in 5 mM glucose culture conditions. They were 
incubated with various concentrations of glucose for 48 h. Whole 
cell lysates were probed using TXNIP antibody. Results represent 
blots from experiments performed in triplicate (N=3). 
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5.3.3 The effects of tetracycline-induced TXNIP overexpression 
on cell death in INS-TXNIP and INS-EV pancreatic β-cells 
Having established in Sections 5.3.1 and 5.3.2 that both TET and high glucose 
incubation conditions can induce TXNIP expression, cell viability assays were 
conducted to investigate whether over-expression of TXNIP affected cell death in 
our model.   
 
INS-TXNIP rodent pancreatic β-cells and INS-EV control cells were pre-
incubated overnight with 5 mM glucose, then treated with 11 or 31 mM 
concentrations of glucose ± 1000 ng/ml TET.  The percentage cell death 
observed between the various glucose concentrations alone, or the various 
glucose concentrations co-incubated with TET were compared.  In the INS-
TXNIP cells incubated with only glucose, percentage cell death was as follows: 5 
mM glucose control, 6.4%; 11 mM glucose, 7% and 31 mM glucose, 7.2% (Fig. 
5.3 a)).  There was no significant difference between the 11 or 31 mM glucose 
treatments when compared with the 5 mM glucose control.   
 
In the INS-TXNIP cells cultured with TET, percentage cell death was found to be: 
5 mM glucose, 6.4%; 11 mM glucose, 11.7% and 31 mM glucose, 21.1%.  There 
was a 3.3-fold increase in percentage cell death seen when comparing the 31 
mM glucose group to the 5 mM glucose control (p=<0.001).  Furthermore, our 
results showed that there was a 2.9-fold increase in percentage cell death when 
comparing the 31 mM glucose group in the absence of TET with the 31 mM group 
in the presence of TET (p=<0.001).   
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In the INS-EV cells incubated with only glucose, percentage cell death was found 
to be: 5 mM glucose control, 4.5%; 11 mM glucose, 4% and 31 mM glucose, 4.7%.  
There was no significant difference observed between the 11 or 31 mM glucose 
treatments compared to the 5 mM control.   
 
In the INS-EV cell cultured in the presence of TET (Fig. 5.3b)), percentage cell 
death was: 5 mM glucose, 6.4%; 11 mM glucose, 5.5% and 31 mM glucose, 
19.6%.  There was a 3.1-fold increase in percentage cell death seen when 
comparing the 31 mM glucose to the 5 mM glucose control (p=<0.001).  In 
addition to this, our results showed a 4.1-fold increase in percentage cell death 
when comparing the 31 mM glucose group in the absence of TET with the 31 mM 
group treated with TET (p=<0.001).   
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Fig. 5.3 Tetracycline- and glucose-induced TXNIP overexpression 
on cell death in INS-TXNIP and INS-EV pancreatic β-cells 
INS-TXNIP (a) and INS-EV (b) cells were incubated overnight in 5 mM 
glucose culture conditions, then treated with 11 or 31 mM glucose 
concentrations. Cells were incubated for 48 h with or without tetracycline 
(1 μg/ml). Cell death was assessed by flow cytometry using propidium 
iodide staining. Results represent mean ± SEM from experiments 
performed in triplicate (N=3). *** p=˂ 0.001 vs. 5 mM glucose, ### p=˂ 
0.001 vs. no tetracycline  
231 
 
5.3.4 The effects of high glucose and palmitate concentrations 
on cell death in INS-TXNIP and INS-EV pancreatic β-cells 
The mechanism of glucolipotoxicity has been shown to exert a detrimental effect 
on cell viability, as demonstrated by others (El-Assaad et al., 2003; Poitout and 
Robertson, 2008), and by our results reported in rodent cell models earlier in 
these studies.  Therefore, we sought to investigate the effect of glucolipotoxic 
conditions in this cell model, to compare variability between the INS-TXNIP and 
the INS-EV cells.  This would also allow comparisons to be made between results 
seen in this cell model with results from other rodent cell models under 
glucolipotoxic conditions that we have reported in earlier studies.  Therefore, 
these next assays were designed so each cell line was co-incubated with 11 or 
31 mM glucose and 250 μM palmitate.   
 
Our results for the INS-EV cells showed a 3.7-fold increase in percentage cell 
death, when comparing the co-incubation of 11 mM glucose and 250 μM 
palmitate with the 11 mM glucose control (17.3±1.3% vs. 4.7±0.3% respectively, 
p=<0.001).  A 9.4-fold increase in percentage cell death was seen when 
comparing the co-incubation of 31 mM glucose and 250 μM palmitate to the 
control (44.1±1.9% vs. 4.7±0.3% respectively, p=<0.001).   
 
Results for the INS-TXNIP cells demonstrated a 3.7-fold increase in percentage 
cell death when comparing the co-incubation of 11 mM glucose and 250 μM 
palmitate with the control (14.3±0.4% vs. 3.9±1.2%, p=<0.001).  This was 
followed by a 9.7-fold increase in percentage cell death which was evident when 
comparing the co-incubation of 31 mM glucose and 250 μM palmitate to the 
control (37.7±2% vs. 3.9±1.2%, p=<0.001).  There was however, no significant 
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difference in the percentage cell death observed in any treatment group when 
comparing the INS-TXNIP cells with the INS-EV cells (Fig. 5.4).  The typical 
percentage cell death we report here in this cell model correlates with results that 
we have shown in earlier sections in other rodent pancreatic β-cell models.   
 
 
  
Fig. 5.4 The effect of high glucose and palmitate on cell death in INS-
TXNIP and INS-EV pancreatic β-cells 
INS-TXNIP pancreatic β-cells and INS-EV control cells were incubated 
overnight in 5 mM glucose culture conditions. Cells were treated with 11 mM 
glucose (control), or co-incubated with 250 μM palmitate and 11 or 31 mM 
glucose concentrations for 48 h. Cell death was assessed by flow cytometry 
using propidium iodide staining. Results represent mean ± SEM from 
experiments performed in triplicate (N=3). *** p=˂0.001 vs. control, ### 
p=˂0.001 vs. control 
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5.3.5 The effect of tetracycline vs. doxycycline on cell death in 
INS-TXNIP pancreatic β-cells 
Tetracycline is a commonly used antibiotic in TET-regulatory systems.  
Doxycycline is a TET analogue, and is suggested to be more stable than TET in 
cell culture conditions, and can also be used in TET-on inducible cell model 
systems as used here.  Both antibiotics were used here at the same concentration 
for comparison purposes, to consider whether the antibiotic itself was responsible 
for alterations to percentage cell death seen.  The aim of these studies was to 
further define experimental conditions whereby culture with these antibiotics may 
induce changes in cell death in this β-cell model.  Results of percentage cell death 
in the INS-TXNIP control cells, i.e. cells cultured without TET or DOX, were found 
to be: 5 mM glucose, 7.9%, 11 mM glucose, 8.6% and 31 mM, 9.4%.  There was 
no significant difference between the 11 or 31 mM glucose groups compared to 
the 5 mM glucose control.   
 
The percentage cell death observed when INS-TXNIP cells were incubated with 
TET were as follows: 5 mM glucose, 7.5%; 11 mM glucose, 10.3% and 31 mM, 
17.3%.  There was a 1.7-fold increase in percentage cell death seen between 31 
mM glucose and the 5 mM glucose (p=<0.001) and this is in line with our previous 
findings in Section 5.3.3.  Furthermore, a 1.6-fold increase in percentage cell 
death was seen when comparing the 31 mM glucose group incubated with TET 
and the 31 mM glucose control group (p=<0.001).   
 
Finally, we report the percentage cell death seen when INS-TXNIP cells were 
incubated with DOX: 5 mM glucose, 7.1%; 11 mM glucose, 9.86% and 31 mM, 
16.8%.  There was a 1.5-fold increase in percentage cell death observed between 
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31 mM glucose when compared to the 5 mM glucose group (p=<0.001).  This 
was coupled with a 1.6-fold increase in percentage cell death seen when 
comparing the 31 mM glucose group incubated with DOX and the 31 mM glucose 
control group (p=<0.001) (Fig. 5.5).  These fold increases in percentage cell death 
were comparable to findings in the TET-treated groups.  Indeed, there was no 
observable difference between the TET and DOX groups at any glucose 
concentration.  It was only at the highest 31 mM glucose concentration that an 
increase in percentage cell death was observed when cells were co-incubated 
with each antibiotic.   
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Fig. 5.5 The effect of tetracycline vs. doxycycline on cell death in 
INS-TXNIP pancreatic β-cells 
INS-TXNIP cells were incubated overnight in 5 mM glucose culture 
conditions, then treated with 11 or 31 mM glucose, or with tetracycline 
(1 μg/ml) or doxycycline (1 μg/ml), and incubated for 48 h. Cell death 
was assessed by flow cytometry using propidium iodide staining. 
Results represent mean ± SEM from experiments performed in 
triplicate (N=3). *** p=˂0.001 vs. 5 mM glucose, ### p=˂0.001 vs. 5 
mM glucose, ††† p=˂0.001 vs. 31 mM glucose 
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5.3.6. The effect of L-glucose and D-mannitol osmotic controls 
on cell death in INS-TXNIP pancreatic β-cells 
L-glucose and mannitol are commonly used as osmotic control ‘sugars’ for high-
glucose experiments, to determine whether increased percentage cell death 
observed under chronic hyperglycaemic conditions is due to osmotic stress.  L-
glucose is a glucose stereoisomer and mannitol is a sugar alcohol.  Neither sugar 
can enter cells, thus remain within the extracellular compartment (Boland and 
Garland, 1993) although both sugars exert the same osmotic effect as D-glucose.  
Our results here demonstrated for the first time in this cell model that there was 
a 5.9-fold increase (p=<0.001) in INS-TXNIP percentage cell death seen when 
the 11 mM L-glucose group (41±1.2%) was compared with 11 mM D-glucose 
(7±0.6%) (Fig. 5.6a)).  Additionally, our results demonstrated a 2.5-fold increase 
in percentage cell death (p=<0.01) when comparing INS-TXNIP cells incubated 
with D-mannitol (17.8±1.3%) with D-glucose (Fig. 5.6b)).   
  
237 
 
 
  
Fig. 5.6 The effect of L-glucose and D-mannitol osmotic controls 
on cell death in INS-TXNIP pancreatic β-cells 
INS-TXNIP cells were incubated overnight in 11 mM glucose culture 
conditions, then replaced with 11 mM L-glucose (a) or D-mannitol (b) 
as osmotic controls and incubated for 48 h. Cell death was assessed 
by flow cytometry using propidium iodide staining. Results represent 
mean ± SEM from experiments performed in triplicate (N=3). 
***p=˂0.001 vs. D-glucose, ** p=<0.01 vs. D-glucose 
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5.3.7 The effect of succinate on cell death in INS-TXNIP rat 
pancreatic β-cells 
We earlier proposed that succinate may act as a cytoprotective agent against 
high glucose and high FA conditions, through its ability to potently stimulate 
insulin release, thereby potentially inhibiting ROS production and mitochondrial 
dysfunction.  To date, there is very limited data regarding the use of succinate as 
a protective compound in relation to T2D, and certainly we are not aware of any 
reports regarding its action in this cell model.  Therefore, in the next series of 
experiments, we sought to define experimental conditions whereby succinate 
may be cytoprotective in the INS-TXNIP β-cell model.   
 
INS-TXNIP cells were initially incubated in normal culture conditions with 11 mM 
glucose, and increasing concentrations of succinate were tested.  Our results 
show that succinate was well-tolerated up to 10 mM; there was no difference in 
the percentage cell death seen at 1, 5 or 10 mM succinate compared to the 
control group.  However, at the higher succinate concentrations tested (15 and 
20 mM), there was a significant increase in percentage cell death compared to 
the control (p=<0.001) (Fig. 5.7a)).  Overall, our results showed percentage cell 
death to be: control, 1.6%; 1 mM succinate, 2.2%; 5 mM succinate, 1.6%; 10 mM 
succinate, 2.6%; 15 mM succinate, 7.2% and 20 mM succinate, 85.8%.   
 
In a parallel treatment group, cells were co-incubated with 250 μM palmitate and 
11 mM glucose, and increasing concentrations of succinate.  The addition of 
succinate did not confer any protection at all when palmitate was present (Fig. 
5.7b)).  Indeed, the addition of succinate greatly increased the percentage cell 
death seen across all concentrations tested in this culture condition.  The results 
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in percentage cell death for this study were: control (no palmitate or succinate), 
6.2%; 250 μM palmitate, 18.9%, 1 mM succinate, 29.8%; 5 mM succinate, 47.5%; 
10 mM succinate, 53.5%; 15 mM succinate, 69.4% and 20 mM succinate, 96.4%.   
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Fig. 5.7 The effect of succinate on cell death in INS-TXNIP 
pancreatic β-cells: 11 mM glucose ± palmitate  
INS-TXNIP pancreatic β-cells were incubated overnight in 5 mM 
glucose, then treated with succinate in 11 mM glucose (a) or co-
incubated with 250 μM palmitate and 11 mM glucose, and succinate 
(b). Cells were incubated for 48 h. Cell death was assessed by flow 
cytometry using propidium iodide staining. Results represent mean ± 
SEM from experiments performed in triplicate (N=3). *** p=˂0.001 vs. 
control 
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These experiments were repeated using 31 mM glucose culture conditions (Fig. 
5.8a)).  In this instance, succinate was well-tolerated up to 15 mM, but showed a 
6.7-fold increase in percentage cell death of INS-TXNIP cells at 20 mM 
(p=<0.001).  The results for percentage cell death were: control, 4.2%; 1 mM 
succinate, 3.6%; 5 mM succinate, 2.3%; 10 mM succinate, 2.2%; 15 mM 
succinate, 2.9% and 20 mM succinate, 28%.   
 
In a parallel study, INS-TXNIP cells were co-incubated with 250 μM palmitate and 
31 mM glucose, and increasing concentrations of succinate.  Again, in line with 
our findings reported above, the addition of succinate significantly exacerbated 
the percentage cell death seen in the INS-TXNIP cells at all concentrations tested 
(Fig. 5.8b)).  Results for percentage cell death from this experiment were: control 
(no palmitate or succinate), 4.2%; 250 μM palmitate, 52.6%, 1 mM succinate, 
52%; 5 mM succinate, 58.6%; 10 mM succinate, 59.3%; 15 mM succinate, 80.3% 
and 20 mM succinate, 82.8%.   
 
Interestingly, the percentage cell death seen in the INS-TXNIP cells at 11 mM 
glucose was significantly higher than compared to 31 mM glucose conditions 
when 20 mM succinate was added (85.8±0.4% vs. 28±0.3% respectively, 
p=<0.001) (Fig. 5.9a)).  The addition of succinate did not ameliorate the 
cytotoxicity caused by co-incubation with palmitate: significantly higher cell death 
was observed with all succinate concentrations except 20 mM (p=<0.001), when 
comparing the 31 mM glucose group to the 11 mM glucose group (Fig. 5.9b)).   
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Fig. 5.8 The effect of succinate on cell death in INS-TXNIP 
pancreatic β-cells: 31 mM glucose ± palmitate 
INS-TXNIP pancreatic β-cells were incubated overnight in 5 mM 
glucose, then treated with succinate in 31 mM glucose (a), or co-
incubated with 250 μM palmitate and 31 mM glucose, and succinate 
(b). Cells were incubated for 48 h. Cell death was assessed by flow 
cytometry using propidium iodide staining. Results represent mean ± 
SEM from experiments performed in triplicate (N=3). *** p=˂0.001 vs. 
control 
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Fig. 5.9 Comparison of the effect of succinate on cell death in INS-
TXNIP pancreatic β-cells: 11 vs. 31 mM glucose ± palmitate 
INS-TXNIP pancreatic β-cells were incubated overnight in 5 mM 
glucose, then treated with succinate in 11 or 31 mM glucose conditions 
(a), or co-incubated with 250 μM palmitate and 11 or 31 mM glucose and 
succinate (b). Cells were incubated for 48 h. Cell death was assessed 
by flow cytometry using propidium iodide staining. Results represent 
mean ± SEM from experiments performed in triplicate (N=3). *** 
p=˂0.001 vs. control 
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Following on from this, these studies were again replicated, but with the addition 
of TET (1000 ng/ml) to investigate whether TXNIP overexpression in this cell line 
would affect the percentage cell death observed under these experimental 
conditions (Fig. 5.10a)).  Cells were co-incubated with 250 μM palmitate and 11 
mM glucose, and increasing concentrations of succinate.  In line with our previous 
findings, succinate was not shown to be cytoprotective.  The percentage cell 
death seen at each succinate concentration was significantly greater than when 
compared to the control.  Results for percentage cell death were: control (no 
palmitate, TET or succinate), 6.3%; 250 μM palmitate, 23.6%; 250 μM palmitate 
and 1 mM succinate, 30.3%; 250 μM palmitate and 5 mM succinate, 40.3%; 250 
μM palmitate and 10 mM succinate, 56.7%; 250 μM palmitate and 15 mM 
succinate, 79.9% and finally, 250 μM palmitate and 20 mM succinate, 97.7%.   
 
For comparison purposes, results for percentage cell death between cells 
incubated in the presence of TET were compared to those incubated in the 
absence of TET.  There was no significant difference between any treatment 
combinations (Fig. 5.10b)).   
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Fig. 5.10 The effect of succinate on cell death in INS-TXNIP 
pancreatic β-cells: 11 mM glucose, 250 μM palmitate ± tetracycline  
 
INS-TXNIP pancreatic β-cells were incubated overnight in 5 mM glucose, 
then treated with succinate in 11 mM glucose, 250 μM palmitate and 
tetracycline at 1000 ng/ml (a). Cells were incubated for 48 h. Comparison 
of cells treated with or without tetracycline (b). Cell death was assessed 
by flow cytometry using propidium iodide staining. Results represent 
mean ± SEM from experiments performed in triplicate (N=3). *** p=˂0.001 
vs. control 
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In the final set of experiments in this series, INS-TXNIP cells were co-incubated 
with a higher 31 mM glucose concentration and 250 μM palmitate, and increasing 
concentrations of succinate (Fig.5.11a)).  Again, similar to our reported findings 
earlier, succinate was not shown to be cytoprotective when palmitate was present.  
The percentage of cell death observed at each succinate concentration was 
significantly greater than when compared to the control.  Results for percentage 
cell death here were: control (no palmitate, TET or succinate), 8.6%; 250 μM 
palmitate, 46.8%; 250 μM palmitate and 1 mM succinate, 51.5%; 250 μM 
palmitate and 5 mM succinate, 57.5%; 250 μM palmitate and 10 mM succinate, 
72.2%; 250 μM palmitate and 15 mM succinate, 90.5% and finally, 250 μM 
palmitate and 20 mM succinate, 100%.   
 
The percentage cell death seen in cells incubated in the presence of TET were 
compared to those incubated in the absence of TET at the 31 mM glucose 
concentration (Fig. 5.11b)).  There was no significant difference between any 
treatment combinations.   
 
A final comparison of the percentage cell death was made between cells that 
were co-incubated with palmitate, TET and either 11 or 31 mM two glucose 
concentrations.  These results showed that the percentage of cell death was 
significantly higher in the cells incubated with 31 mM glucose (Fig. 5.12).  This 
was the case for 250 μM palmitate treatment, which is consistent with all our 
pervious evidence (p=<0.001), however with the addition of succinate, the 
percentage cell death was significantly higher in 1, 5 and 10 mM (p=<0.001) 
concentrations, and in the 15 mM succinate group (p=<0.01).   
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Fig. 5.11 The effect of succinate on cell death in INS-TXNIP 
pancreatic β-cells: 31 mM glucose, 250 μM palmitate ±tetracycline  
INS-TXNIP pancreatic β-cells were incubated overnight in 5 mM glucose, 
then treated with succinate in 31 mM glucose, 250 μM palmitate and 
tetracycline (1000 ng/ml) (a). Cells were incubated for 48 h. Comparison 
of cells treated with or without tetracycline (b). Cell death was assessed 
by flow cytometry using propidium iodide staining. Results represent 
mean ± SEM from experiments performed in triplicate (N=3). *** 
p=˂0.001 vs. control 
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Fig. 5.12 Comparison of the effect of succinate on cell death in INS-
TXNIP pancreatic β-cells: 11 vs. 31 mM glucose, 250 μM palmitate ± 
tetracycline  
INS-TXNIP pancreatic β-cells were incubated overnight in 5 mM glucose 
culture conditions. They were co-incubated with succinate in 11 mM or 
31 mM glucose conditions, 250 μM palmitate and tetracycline (1000 
ng/ml). Cells were incubated for 48 h. Cell death was assessed by flow 
cytometry using propidium iodide staining. Results represent mean ± 
SEM from experiments performed in triplicate (N=3). *** p=˂0.001, ** 
p=<0.01 vs. 11 mM treatment groups  
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5.3.8 The effect of succinate on cell death in 1.1B4 human 
pancreatic β-cells 
We have previously mentioned the paucity of data with regard to the functional 
responses of 1.1B4 human pancreatic β-cells to FA in vitro.  Furthermore, to the 
best of our knowledge, the use of succinate as a cytoprotective agent in this cell 
model has not been reported.  Therefore, for the first time we provide results from 
experiments that investigated the response of 1.1B4 cells to succinate, in 
experimental conditions of glucolipotoxicity.  Studies were conducted as 
described in Section 5.3.7.  Our results here show that when the 1.1B4 human 
pancreatic β-cells were incubated with 11 mM glucose (Fig. 5.13a)), succinate 
was well tolerated up to 15 mM as no significant change in percentage cell death 
was seen.  However, at 20 mM, succinate caused a significant increase in 
percentage cell death compared to the control (94.6±3.5% vs. 21±0.6% 
respectively, p=<0.001).  This was in line with our findings in the INX-TXNIP 
rodent pancreatic β-cells.  To quantify our results, the following percentage cell 
deaths were observed when succinate concentrations were compared to the 
control: 1 mM succinate, 14.6%; 5 mM succinate, 12.8%; 10 mM succinate, 
13.2%; 15 mM succinate, 18.2% and finally, 20 mM succinate, 94.6%.   
 
Co-incubation of the 1.1B4 cells with 11 mM glucose and 250 μM palmitate (Fig. 
5.13b) showed a significant increase in percentage cell death vs. the control 
(89.6±4.5% vs. 20.5±0.6% respectively, p=<0.001).  However, the addition of 
succinate led to a dose-dependent decrease in percentage cell death, found to 
be significant at both 10 and 15 mM concentrations (p=<0.001) when compared 
to the palmitate and glucose control group.  This was in contrast to our results 
reported in the INS-TXNIP cells.  At 20 mM, succinate did not afford any 
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protection against palmitate-induced apoptosis, and was 1.4-fold higher than 
compared to the palmitate and glucose control.  To fully quantify our results, 
changes in percentage cell death were as follows: control (no palmitate or 
succinate), 20.5% cell death; 250 μM palmitate, 71.5% cell death; 1 mM succinate, 
67.7% cell death; 5 mM succinate, 63% cell death; 10 mM succinate, 46% cell 
death; 15 mM succinate, 26.8% cell death and finally, 20 mM succinate, 89.6% 
cell death.   
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Fig. 5.13 The effect of succinate on cell death in 1.1B4 human 
pancreatic β-cells: 11 mM glucose ±palmitate 
1.1B4 human pancreatic β-cells were co-incubated with succinate in 11 
mM glucose (a) or co-incubated with 250 μM palmitate (b) for 48 h. Cell 
death was assessed by flow cytometry using propidium iodide staining. 
Results represent mean ± SEM from experiments performed in triplicate 
(N=3). *** p=˂0.001 vs. control, ### p=<0.001 vs. no succinate  
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In the next set of experiments, 1.1B4 cells were co-incubated with a higher 31 
mM glucose concentration and increasing concentrations of succinate (Fig. 
5.14a)).  The results from this experiment showed that at 31 mM glucose, 
succinate was again found to be well-tolerated up to 15 mM, and percentage cell 
death was significantly less than the control group (p=<0.001 for 1, 5, 10 and 15 
mM succinate concentrations).  Similar to our findings in the 11 mM glucose 
concentrations, no protection was seen using 20 mM succinate, where the 
percentage cell death was found to be 1.2-fold higher than the control group 
(p=<0.001).  Detailed results from this experiment were as follows: control, 23.7% 
cell death; 1 mM succinate, 11.5% cell death, 5 mM succinate, 14.9% cell death; 
10 mM succinate, 13.6% cell death; 15 mM succinate, 13% cell death and 20 mM 
succinate, 29.6% cell death.   
 
The co-incubation of cells with 31 mM glucose and 250 μM palmitate led to a 3.8-
fold increase in percentage cell death vs. the control group (89.5±4.3% vs. 
23.7±0.4% cell death respectively, p=<0.001).  However, the addition of succinate 
led to a dose-dependent decrease in percentage cell death when compared to 
the succinate-free group (significant at 5 mM succinate, p=<0.01, and both 10 
and 15 mM succinate, p=<0.001).  Again, 20 mM succinate did not confer any 
protection against high concentrations of glucose and palmitate (Fig. 5.14b)), and 
was 1.2-fold higher than the palmitate and glucose control (p=<0.001).  To further 
quantify these results, percentage cell deaths were as follows: control (no 
palmitate or succinate), 23.7% cell death; 250 μM palmitate, 76.5% cell death; 1 
mM succinate, 73.5% cell death; 5 mM succinate, 63.8% cell death; 10 mM 
succinate, 49.2% cell death; 15 mM succinate, 28.3% cell death and finally, 20 
mM succinate, 89.5% cell death.    
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Fig. 5.14 The effect of succinate on cell death in 1.1B4 human 
pancreatic β-cells: 31 mM glucose ±palmitate 
1.1B4 human pancreatic β-cells were co-incubated with succinate in 31 
mM glucose (a) or co-incubated with 250 μM palmitate (b) for 48 h. Cell 
death was assessed by flow cytometry using propidium iodide staining. 
Results represent mean ± SEM from experiments performed in triplicate 
(N=3). *** p=˂0.001 vs. control, ### p=<0.001, ## p=<0.01 vs. succinate  
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When comparing the glucose concentrations, there was a 3.2-fold reduction in 
percentage cell death (p=<0.001) seen in the 20 mM succinate group in the 31 
mM vs. the 11 mM glucose group, and this is in line with our findings previously 
noted in the INS-TXNIP cells (Fig. 5.15a)).  There was no statistically significant 
difference in the percentage of cell death seen between groups co-incubated with 
palmitate at either glucose concentration (Fig. 5.15b)).   
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Fig. 5.15 The effect of succinate on cell death in 1.1B human 
pancreatic β-cells: 11 mM vs. 31 mM glucose ±palmitate 
1.1B4 human pancreatic β-cells treated with succinate in 11 mM or 31 mM 
glucose conditions (a). A second treatment group was co-incubated with 
250 μM palmitate (b). Cells were incubated for 48 h. Cell death was 
assessed by flow cytometry using propidium iodide staining. Results 
represent mean ± SEM from experiments performed in triplicate (N=3). *** 
p=˂0.001 vs. 11 mM glucose 
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5.3.9 Detecting the expression of IL-1β mRNA in rodent INS-
TXNIP pancreatic β-cells by RT-PCR 
We have previously described the link between chronic inflammation, 
upregulation of the NLRP3 inflammasome, activation of pro-inflammatory 
caspase-1 and the subsequent secretion of IL-1β as an underlying mechanism 
observed in T2D, which may drive pancreatic β-cell apoptosis.  However, the 
expression of IL-1β mRNA has not yet been reported in the INS-TXNIP cells to 
our knowledge, therefore the expression of IL-1β mRNA in INS-TXNIP cells under 
experimental conditions of lipotoxicity and glucolipotoxicity was investigated 
using RT-PCR.   
 
Amplicons equivalent to the size expected for IL-1β were obtained when RNA 
from the INS-TXNIP cells was amplified by RT-PCR.  A qualitative assessment 
and densitometric analysis revealed that the INS-TXNIP cells exhibited a 3.2-fold 
higher level of IL-1β mRNA expression induced by incubation with the 31 mM 
glucose concentration compared to the 11 mM glucose concentration when co-
incubated with palmitate (Fig. 5.16).   
 
DNA sequencing of the amplicon products returned only a partial read (Fig. 5.17).  
Nonetheless, this suggested that IL-1β expression was induced by the INS-
TXNIP pancreatic β-cells under incubation conditions of glucolipotoxicity.  
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Fig. 5.16 IL-1β mRNA expression in rodent INS-TXNIP pancreatic 
β-cells determined by RT-PCR 
RT-PCR was carried out where cDNA was generated from mRNA 
extracted from INS-TXNIP cells. Bands were viewed under UV light 
after staining of the agarose gel with Gel-Red.  
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Fig. 5.17 IL-1β amplicon identity in INS-TXNIP pancreatic β-
cells 
Amplicon identity was confirmed by direct sequencing of the 
excised and purified DNA product by Eurofins MWG Operon 
(Germany). Primers are indicated in green.  
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5.3.10 Detecting the expression of IL-1β mRNA in human 1.1B4 
pancreatic β-cells by RT-PCR 
The expression of IL-1β in 1.1B4 human pancreatic β-cells under experimental 
conditions of glucolipotoxicity was also investigated using RT-PCR.  Again, a 
qualitative assessment and densitometry of the gel suggested that the 1.1B4 
human pancreatic β-cells exhibited a 1.6-fold higher level of IL-1β mRNA 
expression upon co-incubation with 11 mM glucose and 250 μM palmitate, and a 
1.8-fold higher level of IL-1β expression upon co-incubation with 11 mM glucose 
and 250 μM palmitate than when incubated with 11 mM glucose alone (Fig. 5.18).  
DNA sequencing of the amplicons again returned only a partial read, but 
nonetheless suggested that IL-1β was expressed by the 1.1B4 pancreatic β-cells 
(Fig. 5.19) under incubation conditions of glucolipotoxicity.   
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Fig. 5.18 IL-1β mRNA expression in human 1.1B4 pancreatic 
β-cells determined by RT-PCR 
RT-PCR was carried out where cDNA was generated from mRNA 
extracted from 1.1B4 human pancreatic β-cells. Bands were 
viewed under UV light after staining of the agarose gel with Gel-
Red. 
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Fig. 5.19 IL-1β amplicon identity in human 1.1B4 pancreatic β-cells 
Amplicon identity from primer set 1 was confirmed by direct sequencing 
of the excised and purified DNA product by Eurofins MWG Operon 
(Germany). Primers are indicated in green. 
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5.3.11 Detecting the secretion of IL-1β by INS-TXNIP and 1.1B4 
pancreatic β-cells by ELISA 
As an additional method to detect the expression of the pro-inflammatory cytokine 
IL-1β in both INS-TXNIP and 1.1B4 human pancreatic β-cells, a commercially 
available ELISA kit was used to assess IL-1β secretion.  The cells were treated 
with concentrations of glucose and palmitate previously demonstrated to 
consistently induce cytotoxicity.  However, our results did not detect secretion of 
IL-1β from either rodent or human pancreatic β-cell lines at any of the 
combinations of hyperglycaemia and hyperlipidaemia tested.  
 
5.3.12 Detecting the secretion of IL-1β and NLRP3 proteins in 
INS-TXNIP and 1.1B4 pancreatic β-cells by ICC 
The mechanism between the expression of the pro-inflammatory cytokine IL-1β, 
and TXNIP expression driving upregulation of the NRLP3 inflammasome is 
currently still unclear, although IL-1β has been demonstrated to be secreted by 
both rodent cell models and human subjects with T2D.  However, the secretion 
of IL-1β and NLRP3 has not yet been reported in INS-TXNIP or 1.1B4 cells, so 
this was investigated for the first time in these next set of experiments.  
Immunocytochemistry was carried out using anti-IL-1β and anti-NLRP3 
antibodies on cultured INS-TXNIP rodent pancreatic β-cells and 1.1B4 human 
pancreatic β-cells.  Both cell models were subjected to treatment conditions 
known to consistently induce cytotoxicity.   
 
In the INS-TXNIP cells, when comparing the control cells subjected to normal 
culture conditions (Fig. 5.20a)) with the glucolipotoxic conditions (Fig. 5.20b)), the 
IL-1β expression appeared to have undergone a change in distribution, from 
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ubiquitous cytoplasmic expression to punctate expression localised to areas of 
the cell.  This also appeared to be the case for the 1.1B4 human pancreatic β-
cells (Fig. 5.21a) control vs. Fig. 5.21b) the treatment group).   
 
Probing with the NLRP3 antibody did not show any apparent difference in 
distribution or expression between the control group (Fig. 5.22a)) or the 
glucolipotoxic conditions in INS-TXNIP cells (Fig. 5.22b)), or in 1.1B4 human 
pancreatic β-cells (Fig. 5.23a) and b)).   
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Fig. 5.20 IL-1β secretion by INS-TXNIP rodent pancreatic β-cells 
Secretion of IL-1β (green) using immunocytochemistry in cultured 
INS-TXNIP pancreatic β-cells in a) control treatment group and b) 
31 mM glucose and 250μM palmitate conditions for 48 h. Cell nuclei 
were stained using DAPI (blue).  
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Fig. 5.21 IL-1β secretion by 1.1B4 human pancreatic β-cells 
Secretion of IL-1β (green) using immunocytochemistry in cultured 
1.1B4 human pancreatic β-cells in a) control treatment group and 
b) 31 mM glucose and 250μM palmitate conditions for 24 h. Cell 
nuclei were stained using DAPI (blue).  
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Fig. 5.22 NLRP3 secretion by in INS-TXNIP rodent pancreatic β-
cells 
Secretion of NLRP3 (green) using immunocytochemistry in cultured 
INS-TXNIP pancreatic β-cells in a) control treatment group and b) 
31 mM glucose and 250μM palmitate conditions for 48 h. Cell nuclei 
were stained using DAPI (blue).  
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Fig. 5.23 NLRP3 secretion by 1.1B4 human pancreatic β-cells 
Secretion of NLRP3 (green) using immunocytochemistry in 
cultured 1.1B4 human pancreatic β-cells in a) control treatment 
group and b) 31 mM glucose and 250μM palmitate conditions for 
24 h. Cell nuclei were stained using DAPI (blue).  
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5.3.13 The effect of pro-inflammatory cytokines on cell death in 
1.1B4 human pancreatic β-cells 
It has been shown in rodent models and human islets that chronic exposure to 
pro-inflammatory cytokines such as IL-1β can have a detrimental effect on 
pancreatic β-cell viability.  However, the effect of pro-inflammatory cytokines on 
cell death has not yet been reported in the 1.1B4 human pancreatic β-cells.  
Therefore, from our final set of experiments, we report novel data from 1.1B4 β-
cells subjected to exogenous pro-inflammatory cytokines.   
 
Our results demonstrated that the incubation of 1.1B4 cells with IL-1β alone (Fig. 
5.24), although slightly increased compared to the control, did not significantly 
increase percentage cell death.  There was a significant 2.3-fold increase in 
percentage cell death when the 1.1B4 cells were subjected to TNF-α compared 
to the control (p=<0.01), but again, there was no statistically significant effect on 
percentage cell death when comparing cells incubated with IFN-γ to the control.  
The co-incubation of cells with IL-1β and TNF-α, or TNF-α and IFN-γ, increased 
percentage cell death by 2.1-fold and 2-fold respectively (p=<0.05) compared to 
the control.  Interestingly, the co-incubation of IL-1β and IFN-γ did not affect cell 
percentage death, as there was no statistically significant difference between the 
treatment group and control, although perhaps not unduly surprising given the 
results of the 1.1B4 cells being incubated with these two cytokines alone.  Finally, 
the incubation of 1.1B4 cells with all three pro-inflammatory cytokines significantly 
increased the percentage cell death by 2.4-fold.  To fully quantify our results, 
percentage cell death were as follows: control, 9.6%; IL-1β, 13.7%; TNF-α, 21.9%; 
IFN-γ, 9.5%; IL-1β and TNF-α, 20.2%; IL-1β and IFN-γ, 11.9%, TNF-α and IFN-
γ, 19% and all pro-inflammatory cytokines, 23%.   
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Fig. 5.24 The effect of pro-inflammatory cytokines on cell death in 1.1B4 
human pancreatic β-cells  
1.1B4 human pancreatic β-cells were treated with various combinations of pro-
inflammatory cytokines at 20ng/ml, and incubated for 48 h. Cell death was 
assessed by flow cytometry using propidium iodide staining. Results represent 
mean ± SEM from experiments (N=5). *** p=<0.001, ** p=<0.01,* p=<0.05 vs. 
control 
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5.4 Summary of novel results 
 The overexpression of TXNIP in the TET-induced INS-TXNIP cell model 
under experimental conditions of glucotoxicity, leads to a significant increase 
in percentage cell death (p=<0.001) (Fig. 5.3), but not in conditions of 
glucolipotoxicity (Fig. 5.10 and 5.11).   
 Succinate up to 15 mM is well-tolerated during glucotoxicity, but not 
glucolipotoxicity in INS-TXNIP cells (Fig. 5.8).   
 Succinate up to 15 mM is significantly cytoprotective (p=<0.001) against 
glucotoxicity and glucolipotoxicity in 1.1B4 human pancreatic β-cells (Fig. 5.13 
– 5.15).   
 The pro-inflammatory cytokine IL-1β is expressed by INS-TXNIP and 1.1B4 
cells under experimental conditions of glucolipotoxicity (Fig. 5.16 – 5.19).   
 The pro-inflammatory cytokine TNF-α significantly increases percentage cell 
death (p=<0.05) in 1.1B4 human β-cells under chronic incubation conditions 
(Fig. 5.24).  Co-incubation of 1.1B4 β-cells with IL-1β and TNF-α, and TNF-α 
and IFN-γ significantly increases percentage cell death (p=<0.05).  The 
combined treatment of 1.1B4 cells with IL-1β, TNF-α and IFN-γ significantly 
increases percentage cell death (p=<0.01).   
 The sole incubation of 1.1B4 cells with the endogenous pro-inflammatory 
cytokine IL-1β does not significantly affect percentage cell death.  
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5.5 Discussion 
The detrimental effect of glucolipotoxicity on the pancreatic β-cell has been well 
established (El-Assaad et al., 2003; Poitout and Robertson, 2008; Gregor and 
Hotamisligil, 2007; Hotamisligil, 2010; Cnop et al., 2011).  It has also been well 
recognised that chronic exposure to pro-inflammatory cytokines such as IL-1β 
has a damaging effect on pancreatic β-cell viability (Böni-Schnetzler et al., 2009; 
Dinarello et al., 2010; Donath et al., 2009; Maedler et al., 2002; Masters et al., 
2010; Masters et al., 2011).  Glucolipotoxicity has been shown to stimulate the 
secretion of both IL-1β-dependent and IL-1β-independent proinflammatory 
cytokines in cultured human islets and rodent models (Wen et al., 2012; 
Vandanmagsar et al., 2011; Wen et al., 2011; Masters et al., 2012; Zhou et al., 
2010; Westermark et al., 2011).  This suggests a likely pathway by which an 
inflammatory response may drive recruitment and activation of the inflammasome 
(Donath et al., 2010).  More recently, a link has been made between the activation 
of metabolic stress due to chronic nutrient overload, and the recruitment of pro-
inflammatory mediators suggested to underlie progressive metabolic dysfunction 
such as seen in obesity and T2D (Donath, 2011).  However, the exact underlying 
mechanisms are still not well understood, and we sought to investigate the role 
of potential mediators involved in inflammatory activation and progression due to 
glucolipotoxicity.   
 
In the first instance, we sought to establish that the INS-TXNIP/INS-EV cell model 
used in our investigations responded appropriately to TET, as it has been 
suggested that TET-on systems may be prone to leakage (Pham et al., 2008).  
Increasing TET concentrations resulted in a clear dose-dependent increase in 
expression of TXNIP in the INS-TXNIP cells, and there was no TXNIP expression 
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when cells were incubated in the absence of TET.  The INS-EV cells did not 
exhibit any expression of TXNIP, even when incubated with the highest TET 
concentration, thus our Western blots confirmed that there is no leakage in this 
model and were in line with results reported by our group previously.   
 
High glucose concentrations have been reported to induce TXNIP 
overexpression in the EV cell model by our group (Kansikas, 2012).  This 
phenomenon has also been shown by Minn and colleagues (2005) in INS-1 cells 
and rodent islets.  Results from Western blots from our present studies confirmed 
that indeed, TXNIP overexpression was induced in INS-TXNIP cells incubated in 
high glucose concentrations.  Furthermore, significant endogenous expression of 
TXNIP in the INS-EV cells was apparent under high glucose conditions, thus 
confirming that our results are in line with previous findings from our group.   
 
The TXNIP protein inhibits thioredoxin activity, and inhibiting TXNIP action has 
been shown to protect against glucotoxicity in the isolated islets of a diabetic 
mouse model (Shalev, 2008).  This implies that TXNIP overexpression may 
exacerbate cell death during hyperglycaemic conditions, and indeed, TXNIP has 
been demonstrated to be a proapoptotic mediator under hyperglycaemic 
conditions in mouse and rat cell models (Junn et al., 2000; Wang et al., 2002; 
Chen et al., 2008; Shalev, 2008; Chen et al., 2010).  The addition of TET when 
INS-TXNIP cells were incubated with 31 mM glucose led to a significant increase 
in the percentage cell death seen compared to the 5 and 11 mM groups treated 
with TET, and this correlated with significantly increased levels of TXNIP 
expression as seen from our Western blot results.  However, in our study, 
glucose-induced TXNIP overexpression in the INS-TXNIP cells without TET did 
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not result in increased percentage cell death over and above the control despite 
an increase in TXNIP expression.  These results support evidence previously 
reported by our group (Kansikas, 2012), and suggest that the extent of TXNIP 
induction achieved by TET is far higher than the TXNIP level achieved by high 
glucose conditions alone.  Interestingly, results from our group previously showed 
that TET-overexpression of TXNIP does not lead to increased percentage cell 
death when cells are incubated with palmitate (Kansikas, 2012), and our results 
also corroborate this.   
 
Results gleaned from the INS-EV cells showed that again, high glucose 
conditions do not result in increased percentage cell death over and above the 
control, even though our Western blot results demonstrated an increase in 
endogenous TXNIP expression in this cell-line at 31 mM glucose concentrations.  
It was unexpected however, that the addition of TET in the 31 mM glucose 
experimental conditions resulted in a significant increase in percentage cell death 
in the INS-EV cells.  The Western blot results clearly showed that incubation with 
TET does not induce TXNIP expression in the empty vector cells, so increased 
TNXIP expression cannot be an explanation for the increased cell death observed.  
Nevertheless, the endogenous expression of TXNIP in the empty vector under 
conditions of high glucose does question whether it is appropriate to utilise this 
cell line as a control in high glucose treatment conditions.  Therefore, given the 
unusual findings reported here, it was deemed practical to exclude the INS-EV 
cell line from future studies.  The INS-TXNIP cells incubated at 5 mM glucose 
conditions, where basal expression of TXNIP was not detectable by Western blot, 
and no detrimental effect on cell death was observed upon incubation with TET, 
served as a more appropriate control for future experiments in this cell model.   
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This unusual finding in the INS-EV cells does raise the question whether TET 
may be responsible for the increased percentage cell death seen in this cell 
model.  It is well-reported in the literature that TET is well-tolerated under normal 
cell culture conditions.  Indeed, our group demonstrated previously that TET was 
not toxic to this cell model at the concentrations used in our experimental 
conditions (Kansikas, 2012).  Our results reported in Section 5.3.5 show that at 5 
and 11 mM glucose conditions TET was well tolerated, and hence, also support 
the principle that TET is not toxic to our cell model.  However, clearly under 31 
mM glucose conditions, the addition of TET does appear to significantly increase 
percentage cell death compared to cells incubated at the same glucose 
concentration without TET, so is this cytotoxicity due to TXNIP overexpression, 
or from TET itself?  The use of DOX as an alternative to TET in TET-on systems 
is becoming more commonplace due to the stability of DOX, and because DOX 
can be used at lower concentrations than TET.  Under our experimental 
conditions, results demonstrated that DOX was also well-tolerated at 5 and 11 
mM glucose concentrations, but a significant increase in percentage cell death 
was seen at 31 mM glucose concentrations just as seen with TET.  It could be 
inferred from these results that it is the antibiotics per se that are responsible for 
the increased cell death seen, but clearly at lower glucose concentrations they 
do not affect cell viability, irrespective of increased TXNIP expression as 
demonstrated by our Western blot results.  Furthermore, an extensive search of 
the literature does not suggest that the use of either TET or its analogue DOX, 
induces cytotoxicity in TET-regulated systems.  Therefore, this supports the 
likelihood that the over-expression of TXNIP induced by the presence of either 
antibiotic in combination with a high glucose concentration, is the cause of 
increased cell death rather than antibiotic-toxicity alone.   
275 
 
Taken together, our results support a role for TXNIP as a proapoptotic factor in 
the TET-induced INS-TXNIP cell model under experimental conditions of 
glucotoxicity. It is interesting that under glucolipotoxic conditions, TET-induced 
TXNIP overexpression does not exacerbate cell death over and above the 
percentage cell death seen when cells are incubated with high glucose and high 
palmitate conditions in the absence of TET.  This does not rule out TXNIP as a 
proapoptotic intermediary, but may suggest that ultimately, the role of TXNIP may 
only be relevant in glucotoxic conditions, rather than glucolipotoxic conditions.   
 
To consider whether osmotic stress due to high glucose concentrations was the 
cause of elevated cell death in our model, cells were also incubated with L-
glucose and D-mannitol osmotic controls, which exert the same osmotic effect as 
D-glucose.  These sugars are not metabolised because of their inability to be 
phosphorylated by glucokinase, the first enzyme in the glycolysis pathway.  It is 
also thought that these sugars are unable to enter cells during incubation 
conditions, thus remaining strictly within the extracellular compartments (Boland 
and Garland, 1993).  L-glucose may still be able to participate in extracellular 
glycation reactions contributing to osmotic effects, but D-mannitol cannot thus 
acts as a true osmotic control (Yu et al., 2007).  The percentage cell death seen 
when cells were incubated with these sugar analogues was much higher than the 
percentage of death seen when cells were incubated with D-glucose.  This 
suggests that the ability of cells to metabolise D-glucose during chronic 
incubation conditions thereby reducing glucose concentrations over time, may 
afford a compensatory mechanism against glucotoxicity.  It further suggests that 
cell death observed during hyperglycaemic conditions is not entirely due to 
osmotic effects.  Our group also reported that the glucose-induced upregulation 
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of TXNIP was not an osmotic effect of high glucose incubation, as no increase in 
TXNIP expression was seen when cells were incubated with L-glucose (Kansikas, 
2012).   
 
There has been some limited evidence to suggest a role for succinate as a 
cytoprotective agent, by way of reduced ROS production due to the ability of 
succinate to potently stimulate insulin release (Fahien and MacDonald, 2002; 
Vengerovskii et al., 2007; Zavodnik et al., 2011).  It has been suggested that 
supplementation of the TCA cycle with intermediate metabolites enhances 
anaplerotic reactions and protects against glucolipotoxic conditions (Choi et al., 
2011).  We sought to investigate whether succinate afforded any cytoprotection 
in pancreatic β-cells incubated in glucotoxic or glucolipotoxic conditions.  Our 
results suggested that succinate is protective against glucotoxic conditions in the 
INS-TXNIP cell line up to concentrations of 15 mM.  However, succinate was not 
cytoprotective in our experiments at any concentration when the INS-TXNIP cells 
were subjected to glucolipotoxic conditions.  The addition of palmitate clearly 
antagonised the protective effect of succinate in this cell model.  This is in contrast 
to results reported in glucolipotoxicity studies by Choi and colleagues who 
reported that succinate afforded a protective effect in INS-1 cells under 
experimental conditions of glucolipotoxicity (2011).  Taken together, our results 
support a cytoprotective role for succinate under glucotoxic conditions in the INS-
TXNIP cells, but not in conditions of glucolipotoxicity.   
 
In the 1.1 B4 human pancreatic β-cells, our results showed that succinate was 
cytoprotective up to concentrations of 15 mM in experimental conditions of 
hyperglycaemia.  Interestingly, at higher glucose conditions, the cytoprotective 
277 
 
effect of succinate was greatly amplified, as percentage cell death was 
significantly less than the control in these conditions.  Furthermore, and in 
contrast to results gleaned from the INS-TXNIP cell line, succinate was shown to 
be dose-dependently cytoprotective up to concentrations of 15 mM in the 1.1B4 
cells under high glucose and high palmitate conditions.  Quite why there was such 
a difference between the cell lines is unclear, and would need further investigation 
into the molecular and functional responses of each cell line, to be able to 
understand and compare the mechanisms responsible for the variations seen.  
Nonetheless, our results do support a cytoprotective role for succinate in the 
1.1B4 human pancreatic β-cells under both glucotoxic and glucolipotoxic 
conditions.   
 
Emerging links between activation of the NLRP3 inflammasome and upregulation 
of the pro-inflammatory cytokine IL-1β have been established in glucolipotoxic 
conditions.  Furthermore, recent evidence from animal studies, in vitro work and 
clinical trials have shown persuasive evidence that a primary cause of pancreatic 
β-cell loss in T2D is due to IL-1β (Dinarello et al., 2010).  We sought to investigate 
IL-1β expression in our cell models.  Results confirmed that both INS-TXNIP cells 
and the 1.1B4 human pancreatic β-cells expressed IL-1β mRNA under 
glucolipotoxic incubation conditions, and furthermore mRNA expression was 
increased in the higher glucose conditions.  Although only partial reads were 
obtained from amplicon sequencing, they did strongly support the expression of 
IL-1β upon alignment of the partial sequence with the predicted IL-1β nucleotide 
sequence.  These findings are in line with other groups who have found a pro-
inflammatory response due to nutrient excess in other β-cell lines (Donath et al., 
2010; Böni-Schnetzler et al., 2008; Dinarello, 2010; Maedler et al., 2009).  
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However, it must be emphasised that these results do not necessarily prove that 
IL-1β is expressed at the protein level.   
 
Moreover, the ELISA for IL-1β did not detect expression of the pro-inflammatory 
cytokine IL-1β during glucolipotoxic incubation conditions in either INS-TXNIP or 
1.1B4 pancreatic β-cells.  However, very high percentage of cell death is 
observed in cells subjected to high glucose and high palmitate treatments as we 
have previously shown in our in vitro studies.  Therefore, it is possible that the 
level of IL-1β secretion in the supernatant from the limited number of surviving 
cells was below the limit of detection of the assay, rather than due to little or no 
IL-1β expression at a protein level per se.   
 
The ICC data was somewhat unusual, in that the subcellular distribution of IL-1β 
appeared to be ubiquitous in the control cells, whereas cells subjected to high 
levels of glucose and palmitate appeared to demonstrate punctate and localised 
IL-1β expression.  This result was observed in both the INS-TXNIP and 1.1B4 
human pancreatic β-cell models when probing for IL-1β.  This could of course 
mean that IL-1β was not expressed under conditions of glucolipotoxicity, however 
positive ICC for IL-1β has been previously demonstrated in both animal models 
of diabetes and in humans with T2D (Maedler et al., 2002).  It is more likely 
however, that this localisation of was due to pro-IL-1β associating with the 
inflammasome for cleavage into mature IL-1β for secretion, explaining the pattern 
of IL-1β staining.  Attempts to determine IL-1β expression by Western blot using 
whole cell lysates from parallel treatments were unsuccessful and did not show 
any detectable expression (data not shown).  This was initially assumed to be 
due to very low levels of IL-1β secretion as a consequence of greatly elevated 
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cell death as outlined above.  However, in light of the additional ICC data, it is 
more likely that the antibody was of poor quality or poor specificity.   
 
Although the mechanism of action is unclear, there is little doubt of the role of the 
NLRP3 inflammasome in chronic inflammatory conditions.  Therefore, it was 
unexpected that ICC failed to show any NLRP3 expression in either INS-TXNIP 
or 1.1B4 cells subjected to glucolipotoxic conditions.  Our parallel experiments to 
determine NLRP3 expression by Western blot using whole cell lysates were 
unsuccessful using the same antibody (data not shown).  This was almost 
certainly for the same reasons as outlined above for IL-1β, which was likely poor 
quality or poor specificity antibody. Furthermore, we looked to determine ASC 
expression by Western blot using whole cell lysates, and through ICC, but again 
failed to determine any detectable expression. 
 
While the role of pro-inflammatory cytokines such as IL-1β, TNF-α and IFN-γ 
have been well established over the last few decades in T1D, but it has only been 
recently that pancreatic β-cell dysfunction in T2D has been suggested as a result 
of pro-inflammatory cytokine influence (Wang et al., 2010).  We sought to 
investigate the effect of pro-inflammatory cytokines on the novel 1.1B4 human 
pancreatic β-cell, and to our knowledge, no other work has yet been reported on 
these findings in this cell-line.   
 
Incubation with TNF-α, but not any other cytokine, significantly increased 
percentage cell death compared to the control.  Previous evidence of the effects 
of incubation with pro-inflammatory cytokines either alone or in combination have 
been greatly varied, and have been dependent on factors such as glucose 
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concentration, cytokine concentration and cell model used.  Although it may have 
been reasonable to expect to observe increased percentage cell death during 
chronic incubation with human recombinant IL-1β, evidence so far suggests that 
the effects on viability due to incubation with IL-1β have only been reported in rat 
islets.  Indeed, a combination of pro-inflammatory cytokines has been necessary 
to induce the same effect in mouse or human islets (Mandrup-Poulsen, 1996; Suk 
et al., 2001; Donath et al., 2010).   
 
The cellular origin of IL-1β, at least in human islets, is still not fully understood, 
and may be from the β-cell itself, or from recruited macrophages or T-cells during 
an ongoing inflammatory state (Böni-Schnetzler et al., 2008; Donath et al., 2005; 
Donath et al., 2008).  Often, synergism between combinations of pro-
inflammatory cytokines has been required to elicit significant cell death (Suk et 
al., 2001; Wang et al., 2010), and indeed, with the exception of TNF-α, this was 
seen in the 1.1B4 cells.  Interestingly, is has been shown that pro-inflammatory 
cytokine-induced cell death in pancreatic β-cells does not involve the p-
eIF2α/ATF4/CHOP10 apoptotic pathway, eliminating ER stress in apoptosis 
under these conditions (Åkerfeldt et al., 2008).  Clearly, much additional work is 
required to more fully elucidate cytokine influence and expression in the human 
pancreatic β-cell line.  However, taken together, our evidence presented offers 
persuasive argument that IL-1β expression in the INS-TXNIP and 1.1B4 human 
pancreatic β-cells is likely.   
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Chapter 6 Discussion 
Obesity is a key risk factor for developing T2D (Vernochet et al., 2009; Ford et 
al., 1997; Gwiazda et al., 2009).  Hyperlipidaemia is often associated with obesity, 
and can lead to elevated plasma levels of FFAs (Newsholme et al., 2007; Wei et 
al., 2006).  Chronic elevations of FFAs are suggested to have a detrimental effect 
on β-cell viability and drive the progression of T2D in a process termed lipotoxicity 
(Butler et al., 2003; Eizirik et al., 2008; Cnop et al., 2005; Maedler, 2008; Eitel et 
al., 2003; El-Assaad et al., 2003).   
 
Important information regarding the molecular mechanisms of FAs has been 
gleaned from in vitro studies using various pancreatic β-cell models.  These 
studies have demonstrated that FAs exert differential responses in β-cells under 
chronic incubation conditions.  The degree of toxicity or protection exerted by a 
FA species varies markedly according to the carbon chain length, degree of 
saturation or configuration of the individual FA species being studied.  Long-
chain-SFAs (≥C16:0) exert a detrimental effect on β-cell viability, whereas 
medium and shorter-chain SFAs (≤C14:0) or LC-MUFAs (≥C16:1) are well 
tolerated by β-cells.  A further critical finding is that the in vitro co-incubation of 
LC-MUFAs with LC-SFAs, attenuates the cytotoxic effects observed in β-cells 
when they are incubated solely with a LC-SFA species (Newsholme et al., 2007; 
Karaskov et al., 2006; Welters et al., 2004; Eitel et al., 2003; Dhayal et al., 2008; 
Diakogiannaki et al., 2007; Diakogiannaki et al., 2008; Morgan et al., 2008).   
 
The molecular mechanisms that mediate cytotoxic or cytoprotective responses of 
β-cells to FA species remain unclear.  However, increasing evidence implicates 
a role for ER stress in mediating β-cell death associated with chronic lipotoxicity-
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induced stress (Qu et al., 2009; Breckenridge et al., 2003; Laybutt et al., 2007).  
The primary aim of the ER stress response is to restore cellular homeostasis, but 
if ER stress is persistent, it may induce β-cell apoptosis (Araki et al., 2003; Laybutt 
et al., 2007; Karaskov et al., 2006; Breckenridge et al., 2003; Wei et al., 2009; Qu 
et al., 2009; Fonseca et al., 2009; Scheuner and Kaufman, 2008).   
 
A critical early step in the ER stress pathway is the phosphorylation of eIF2α (Qu 
et al., 2009; Fonseca et al., 2009; Cnop et al., 2008; Araki et al., 2003; Herbert, 
2007).  It is generally accepted that this eIF2α phosphorylation step is mediated 
by PERK (Kapoor and Sanyal, 2009; Cunha et al., 2008; Eizirik et al., 2008; Qu 
et al., 2009; Harding et al., 2000; Herbert, 2007).  However, evidence from a more 
recent study suggests that PERK may adopt a more cytoprotective role, while 
another eIF2α kinase, PKR, may assume a role in regulating proapoptotic 
responses in β-cells (Morgan, 2009; Lee et al., 2007).   
 
The primary aim of this thesis was to investigate whether cell death induced in 
pancreatic β-cells during lipotoxic incubation conditions, was due to activation of 
an ER stress response centred on alterations to PKR activation.   
 
Chapter 3: The role of PKR in pancreatic β-cell apoptosis  
This chapter focussed on the use of a putative small molecule inhibitor 
Compound-16, transient PKR KD using adenoviral DN vectors and the creation 
of stable PKR KD BRIN-BD11 clones using shRNA to manipulate PKR activity.  
Studies were predominantly viability studies and Western blotting to correlate 
with ER stress markers.   
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Key findings 
The key findings from this chapter were that Compound-16 (5 – 25 μM) 
significantly protected BRIN-BD11 cells against palmitate-induced cell death.  
Furthermore, Compound-16 significantly protected BRIN-BD11 cells against 
serum-starvation for up to a 30 h incubation period before significant protection 
was lost.  Western blot analyses of lysates from BRIN-BD11 cells incubated with 
5 μM Compound-16 showed a significant increase in the ER stress marker 
phospho-eIF2α despite improving cell viability during chronic palmitate exposure.  
However, Compound-16 is potently cytotoxic to INS-1 cells and MIN6 cells.   
 
The use of PERK and PKR DN adenoviral vectors demonstrated that transient 
KD of these kinases individually, or together, significantly reduced the 
phosphorylation of eIF2α, thereby confirming a role for both kinases within ER 
stress pathways in BRIN-BD11 cells.  Stable PKR KD clones using BRIN-BD11 
parental cells show that the loss of PKR function significantly protects against 
palmitate-induced cell death in BRIN-BD11 cells and potentiates the 
cytoprotective action of palmitoleate.   
 
Taken together, our results provide novel evidence that in BRIN-BD11 rodent 
pancreatic β-cells, PKR has a clear role in mediating cytotoxic and cytoprotective 
responses during exposure to various FA species.  This supports recent evidence 
that identifies PKR as a central player within nutrient sensing pathways in mouse 
cell models (Nakamura et al., 2010).  Other recent works have shown that PKR 
is required for inflammasome activation in response to certain PAMPs such as 
ATP.  PKR interacts with the NLRP3 inflammasome to mediate assembly and 
activation, linking this nutrient sensing protein with chronic inflammation and 
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inflammasome-dependent IL-1β secretion (Lu et al., 2012; So et al., 2013).  This 
establishes a central role for PKR within multiple immune and metabolic 
responses.  Taken together, PKR represents a critical target for the design of 
therapeutic agents aimed to reduce β-cell loss in the progression of T2D.   
 
Limitations of study 
The potent toxicity of Compound-16 to INS-1 and MIN6 cells raises questions 
regarding the suitability of this compound for use with in vitro pancreatic β-cell 
models.  The lack of a commercially available rat phospho-PKR antibody, and 
poor specificity of human and mouse phospho-PKR antibodies prevented critical 
Western blot corroboration of results obtained from viability studies.  Additional 
challenges with upstream and downstream ER stress marker antibodies made it 
difficult to make conclusive statements regarding the involvement of potential 
mediators of the p-eIF2α/ATF4/CHOP10 apoptotic pathway in lipotoxic conditions.   
 
Areas for future research 
A primary aim to further this research would be to commission a custom-made 
rat phospho-PKR antibody, to allow the opportunity to obtain conclusive evidence 
of alterations to PKR activity in glucotoxic, lipotoxic and glucolipotoxic culture 
conditions.  Western blot and PCR studies to fully delineate all proteins involved 
along the ER stress pathway from activating ligands to effector molecules, would 
provide important information for effective targeted therapeutic intervention of 
critical pathway mediators.  Furthermore, these mechanisms need to be 
investigated in human pancreatic β-cells and human islets, to complement 
existing knowledge in rodent models.  An additional line of study would be to 
utilise the islet cells from patients with T2D, recovered post mortem, to look for 
285 
 
evidence of ER stress and apoptosis.  Further experiments using Compound-16 
are necessary to explore the involvement of related kinases that can 
phosphorylate eIF2α to quantify redundant kinase activity, as this was not 
conducted in the original Jammi work.   
 
Chapter 4: Characterisation of 1.1B4 human pancreatic β-cells 
The use of in vitro cell models in diabetes research represents a convenient 
approach to study physiological and pathophysiological mechanisms, and can be 
advantageous in the development of novel pharmacological agents.  Studies 
using rodent pancreatic β-cell lines have contributed valuable observations 
regarding the molecular and functional responses of β-cells to experimental 
conditions that are suggested to drive the progression of T2D in vivo (Asfari et 
al., 1992; Gazdar et al., 1980; Santerre et al., 1981; McClenaghan et al., 1996; 
Efrat et al., 1988; Miyazaki et al., 1990).   
 
However, despite the usefulness of rodent cell models, there are differences 
between rodent and human pancreatic β-cell responses to glucotoxicity and 
lipotoxicity, and it is critical that any findings in rodent cells are verified in human 
β-cells.  Furthermore, aberrant functional responses, such as poor insulin 
secretion in response to secretagogues or cell dedifferentiation over time, have 
limited the usefulness of human pancreatic β-cell models in T2D studies (Ulrich 
et al., 2002; Skelin et al., 2010; Newgard and McGarry et al., 1995; Dufayet de la 
Tour et al., 2001; Demeterco et al., 2002; Gueli et al., 1987; Levine et al., 1995; 
Beattie et al., 1999; Russ et al., 2008).  Due to the restricted availability of primary 
human islets, and their poor response to culture conditions, considerable effort 
has been made into the development of human pancreatic β-cell lines from 
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human pancreatic sources over the last few decades (Negi et al., 2012; Hohmeier 
and Newgard, 2004).   
 
The development of a novel human insulin-secreting β-cell line 1.1B4 was 
described in 2011.  These cells were reported to be stable in culture conditions 
and to display typical characteristics of human pancreatic β-cells.  This provided 
the opportunity to undertake functional studies to characterise the effects of FA 
species, which have not yet been reported in this β-cell line.  Therefore, in these 
studies, we employed the use of 1.1B4 human pancreatic β-cells to investigate 
for the first time, their in vitro responses to different FA species.   
 
Key findings 
The key findings from this chapter showed that medium-chain SFAs are well-
tolerated in 1.1B4 human pancreatic β-cells under chronic incubation conditions.  
In contrast, the LC-SFAs palmitate (C16:0) and stearate (C18:0) induce a dose-
dependent increase in percentage cell death under chronic incubation conditions.  
The longer-chain SFA stearate does not exert a greater cytotoxic effect than 
palmitate as shown in rodent β-cells.  Co-incubation of 1.1B4 cells with palmitate, 
and the MUFAs palmitoleate (C16:1) or oleate (C18:1), induces a dose-
dependent decrease in percentage cell death under chronic incubation conditions.  
However, the longer-chain MUFA oleate does not exert a greater cytoprotective 
effect than palmitoleate as demonstrated in rodent β-cells.   
 
In consideration of the primary aim of this thesis, Compound-16 was used in 
preliminary experiments to investigate the role of PKR KD in mediating cytotoxic 
or cytoprotective responses in lipotoxic conditions.  However, similar to our 
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findings in both INS-1 and MIN6 cells, Compound-16 is potently cytotoxic to 
1.1B4 cells.   
 
The incubation of 1.1B4 cells with methyl-SFA species does not affect cell viability.  
Moreover, the incubation of 1.1B4 cells with the MUFAs methyl-palmitoleate and 
methyl-oleate exerts a dose-dependent cytoprotective effect against palmitate-
induced cell death.  However, the longer-chain methyl-oleate species does not 
exert a greater cytoprotective effect than methyl-palmitoleate.   
 
These studies establish 1.1B4 responses to various FA species in novel data not 
shown before in this cell line, suggesting these cells are a suitable model to study 
β-cell dysfunction during lipotoxic conditions.  Our data corroborates previously 
reported well-tolerated effects of methyl-palmitate and cytoprotective effects of 
methyl-palmitoleate in BRIN-BD11 cells (Briaud et al., 2001; Cunha et al., 2008).  
Furthermore, our results using methyl-stearate and methyl-oleate in the 1.1B4 
cells adds to the currently limited knowledge regarding the impact of methylated 
FAs on β-cell viability (Diakogiannaki et al., 2007; Dhayal et al., 2008).  
 
Limitations of study 
The main limitation of this study is the method of creation of the 1.1B4 cell line, 
which were created using an in vitro cell line with tumoral origin (McCluskey et 
al., 2011).  The development of in vitro cell line typically focusses on cell survival 
and proliferation, rather than maintaining long-term viability (Alderman et al., 
1985).  This can impact on secretory capacity, and it has been reported that this 
cell line does have poor secretory response to secretagogues (McCluskey et al., 
2011).  The induced pseudo-islet formation of these cells was reported to improve 
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secretory capacity, suggesting that cell-cell interactions are critical to retain 
normal physiological responses of β-cells.  This highlights the importance of 
confirmatory work in islets in addition to in vitro monolayer cell culture models 
(Guo-Parke et al., 2012).   
 
Future work 
The use of RT-PCR and Western blotting to investigate the activation of ER stress 
markers would be useful to determine molecular mechanisms of lipotoxicity in this 
cell line, as these have not yet been studied.  Furthermore, the use of next 
generation sequencing would provide rapid and comprehensive results of gene 
expression within this cell line.  This would afford valuable information to enable 
comparisons to be made between 1.1B4 cell and human β-cell gene expression.  
This would also allow the opportunity to investigate whether erroneous gene 
expression exists due to the tumoral origin of the cell model.  
 
Chapter 5 The role of TXNIP and inflammatory mediators in 
pancreatic β-cell apoptosis  
Thioredoxins have a predominant role as intracellular antioxidant enzymes (Arner 
& Holmgren, 2000; Hirota et al., 1997; Hirota et al., 1999; Martin & Dean, 1991).  
Their predominant role is to maintain an intracellular reducing environment, 
through reduction of thiol groups within protein cysteine side chains (Gilbert, 1990; 
Berndt et al., 2007).  Thioredoxin activity is regulated by TXNIP, a highly inducible 
gene, expressed in human islets cultured in hyperglycaemic conditions (Shalev 
et al., 2002).  TXNIP initiates oxidative stress within β-cells by a converse 
mechanism to thioredoxin (Nishiyama et al., 1999; Nishiyama et al., 2001).  
TXNIP has been shown as a pro-apoptotic mediator in pancreatic β-cells and is 
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suggested to drive apoptosis in T2D (Shalev, 2008; Minn et al., 2005, Junn et al., 
2000). 
 
The use of succinate as a potential cytoprotective compound in T2D has been 
recently suggested.  Succinate stimulates insulin release, which is suggested to 
inhibit ROS production and mitochondrial oxidative phosphorylation dysfunction 
in conditions of nutrient excess (Fahien and MacDonald, 2002; Vengerovskii et 
al., 2007; Zavodnik et al., 2011).   
 
The activation of NLRs by glucolipotoxic conditions links the upregulation of 
proinflammatory caspase-1 and increased secretion of IL-1β levels.  The 
production of pro-inflammatory IL-1β is a commonly accepted mechanism 
thought to drive apoptotic pathways seen in chronic metabolic conditions such 
T2D (Maedler & Donath, 2004).  TXNIP has been shown to interact with NLRP3, 
thereby linking activation of the inflammasome with glucolipotoxicity.  This 
mechanism is suggested to drive increased IL-1β production, which is thought to 
have an integral role in pancreatic β-cell apoptosis (Franchi et al., 2012; Mankan 
et al., 2012; Tannahill and O’Neill, 2011; Harder et al., 2009; Muňoz-Planillo et 
al., 2009).   
 
Key findings 
The key findings from this chapter are that TXNIP overexpression in the TET-
induced INS-TXNIP cell model leads to a significant increase in percentage cell 
death in glucotoxic conditions, but not in conditions of glucolipotoxicity.  Succinate 
(≥5 ≤15 mM) is cytoprotective against glucotoxicity, but not glucolipotoxicity in 
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INS-TXNIP cells.  However, succinate (≥1 ≤15 mM) is cytoprotective against both 
glucotoxicity and glucolipotoxicity in 1.1B4 human pancreatic β-cells.   
 
The pro-inflammatory cytokine IL-1β is expressed by INS-TXNIP and 1.1B4 cells 
under experimental conditions of glucolipotoxicity.  Incubation with endogenous 
TNF-α increases percentage cell death in 1.1B4 human β-cells during chronic 
incubation conditions, as does co-incubation with IL-1β and TNF-α, TNF-α and 
IFN-γ or combined treatment with IL-1β, TNF-α and IFN-γ.  However, the 
incubation of 1.1B4 cells with endogenous IL-1β alone does not significantly 
affect percentage cell death.  
 
Our results from this chapter suggest that the role of TXNIP in β-cells is apoptotic 
only under conditions of glucotoxicity, and this corroborated findings by Chen and 
colleagues (2008; 2010), and Shalev (2008) in INS-1 cells and mouse islets.  
There is little data on the cytoprotective role of succinate in T2D.  Choi et al., 
(2010) used succinate in INS-1 cells, and demonstrated that it can act as a 
cytoprotective agent in conditions of glucotoxicity and glucolipotoxicity.  We have 
shown here in INS-TXNIP cells, that succinate is only cytoprotective in conditions 
of glucotoxicity.  In contrast however, we established that succinate is protective 
against cell death induced by glucotoxicity and glucolipotoxicity in 1.1B4 human 
cells.  Clearly, the variable efficacy of succinate within these studies, particularly 
under different stress-inducing conditions, highlights the importance of further 
work required to clarify molecular mediators and signalling pathways more fully.  
However, it does suggest that succinate may have a therapeutic use in protecting 
β-cell viability.   
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The cellular origin and mechanism of cell death induced in pancreatic β-cells by 
IL-1β is not well understood and studies to date have been limited.  The PCR and 
ICC studies from this chapter suggest that IL-1β is secreted from INS-TXNIP and 
1.1B4 pancreatic β-cells, contributing towards a paucity of information in this area.  
Interestingly, we have shown that the action of IL-1β alone does not induce 
apoptosis in 1.1B4 β-cells under normal glucose concentrations.  Previous 
studies have invariably used conditions of glucolipotoxicity, and/or a combination 
of proinflammatory cytokines to demonstrate cytotoxic effects on β-cell viability 
(Maedler et al., 2002).  As such, this suggests that although IL-1β clearly does 
have a role in the progression of β-cell dysfunction, it requires additional 
synergistic effect from other mediators to lead to eventual β-cell demise. 
 
Limitations of studies 
The results returned from IL-1β mRNA expression would have been more 
compelling if full reads had been returned from amplicon sequencing.  
Furthermore, corroborating Western blot and ELISA detection of IL-1β protein 
expression from cell lysates would have provided definitive proof of pancreatic β-
cell IL-1β secretion.  By virtue of experimental design, chronic glucotoxicity and 
glucolipotoxicity usually results in very high percentage β-cell death, highlighting 
a limitation of using in vitro cell culture models to study β-cell dysfunction and 
apoptosis in experimental conditions of T2D.  Poor specificity of NRLP3 and ASC 
antibodies meant mediators of inflammasome activation could not be 
corroborated in these studies.  
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Areas for future research 
To strengthen results from these studies, and to potentiate targeting of mediators 
of inflammasome activation, further work is needed to detect and characterise 
ligands and integral proteins within the chronic inflammatory pathway, in both in 
vitro human pancreatic β-cells and human islets in T2D experimental conditions.  
This would mean locating and validating good quality antibodies with which to 
conduct further Western blotting, ICC and precipitation studies.    
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